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"Ever tried. Ever failed. No matter. Try Again. Fail again. Fail better."
- Samuel Beckett

Abstract
The advent of the big data era poses major challenges to the biomedical domain.
First, it is necessary to adopt strategies that integrate and link the heterogeneous
resources that contain multiscale and multimodal data in order to fill the existing
knowledge gaps. Further, there is a need for developing methods designed not
only to interrogate the data but also to interpret and decode the complex world of
biology.
In this work, we address the two aforementioned challenges in the domain
of pathway knowledge. This thesis presents two ecosystems devised to harmo-
nize and consolidate knowledge from disparate pathway databases, ultimately
providing a holistic view of the pathway landscape. Leveraging this integrative
effort, we designed a benchmarking study that demonstrates significant impact of
database selection in functional enrichment methods and prediction modeling. The
results of this work advocate for integrative approaches since our unifying schema
has been shown to yield more robust and interpretable results than individual
databases and to improve the predictability in modeling tasks. Tangential to these
pathway-driven approaches, this work also presents two frameworks devised to
identify mechanisms and biomarkers in the neurodegenerative and psychiatric
field. The first resource, NeuroMMSig, is the largest inventory of candidate mech-
anisms for Alzheimer’s and Parkinson’s disease. This manually-curated collection
of over 200 computable mechanistic networks emerged as a novel knowledge-
based paradigm by laying the ground for the first draft of a mechanism-based
taxonomy in both conditions. The second resource, PTSDDB, is a database cat-
aloging biomarker information in the context of post-traumatic stress disorder
that opens the door for a future systematic meta-analysis of results reported in
literature. Finally, we conclude the thesis with a novel approach that bridges the
gap between mechanistic knowledge and patient-level data, paving the way for a
mechanism-based stratification of dementia patients.
In summary, this thesis presents novel methodologies for the integration of
pathway knowledge. In addition, it introduces new resources and strategies in
the context of neurodegenerative and psychiatric disorders. These advances have
numerous applications in translational research, ranging from drug discovery to
patient stratification.
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1 Introduction
The advent of big biodata, machine learning, and artificial intelligence brings high
hopes that these state of the art technologies will lead to great advances in the
biomedical field [1]. However, the structural and functional complexity of living
organisms pose unique challenges for these approaches because they were not
originally designed to interpret nor understand the mechanisms underlying biol-
ogy. Living organisms are comprised of specialized and variable cellular and tissue
structures comprised of molecules, which are essentially sets of atomic structures.
Each of these can be considered biological levels of organization, that are not only
regulated by their underlying changes but also by their interactions with other
levels in this multi-scale hierarchy (Figure 1) [2]. As an illustration, an imbalance
in the concentration of a given transcription factor can dysregulate the expression
of multiple proteins, ultimately resulting in cell death and organ dysfunction.
Furthermore, not only are particular species distinct, but each individual organism
has a unique composition of different tissue and cellular types that are themselves
constituted by millions of disparate biological entities. Hence, understanding
biology involves revealing the causal interactions occurring between these entities,
both in each of the mentioned scales and across them [3, 4].
1.1 Pathways: the functional units of biology
Because cells are the basic structural and functional units of living organisms,
studying the interactions occurring at this level is essential to enhance our un-
derstanding of biology. However, though every cell in an individual organism
typically contains identical genetic information, the context in which they reside
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Figure 1: Multi-scale biology of a given organism in a bottom–up approach. Any biological
organism can be subdivided in multiple scales depending on the level of granularity we
want to study its structure or function. Here, this organizational representation of biology
is depicted in terms of distinct scales of increasing complexity, from the atomic level to the
tissue and the organ level. The growing need to understand the interactions across these
different scales was what gave rise to the field of systems biology. This interdisciplinary
field of study attempts to understand biology by modeling and analyzing these complex
interactions using computational and mathematical methods.
makes them well adapted for disparate specialized tasks [5]. In order to help us
in deconvoluting the numerous processes that take place on both cellular and
sub-cellular levels, humans conceived the notion of a pathway, which corresponds
to a series of molecular interactions that leads to a particular event. This concept
facilitates the representation, formalization, and interpretation of biological events
by abstracting these series of interactions from a vast and complicated biologi-
cal universe [6]. In other words, cataloging biological knowledge into pathways
reduces complexity from all possible interacting molecular entities to sets of well-
studied and validated functional relationships between entities that culminate in
specific biological processes.
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Pathways are usually represented as networks or mathematical models 1. How-
ever, simplifying biology into any human-fabricated representation inevitably
results in a loss of information, such as spatio-temporal information, or even
ignores certain biological entity types altogether [7]. Nonetheless, a network ab-
straction can facilitate pathway visualization and interpretation on account of
its concordance with biological systems: nodes correspond to molecular entities
(e.g., genes, proteins, chemicals, etc.) and edges to types of interactions occurring
between them (e.g., inhibition, phosphorylation, etc.) (Figure 2). Although net-
works can comprise a broad range of molecular types (e.g., proteins, chemicals,
small molecules, etc.), they are generally reduced to the most direct outcome of
our genetic makeup (i.e., the genetic and protein levels) such that we can garner
mechanistic insights on how they operate. Thus, pathways are frequently viewed
and simplified to “gene sets”, the collection of all genes/proteins that constitute a
pathway, due to the major challenges of incorporating complex network topology
and translating the variety of relationships they comprise into pathway analysis
methods. Although pathway network representations offer a comprehensive pic-
ture of the interactions occurring in a given pathway, limitations still exist such as
incorporating kinetic or time information in biological reactions. To address these
shortcomings, various algorithms and techniques have been developed to model
and simulate the dynamic changes of a pathway both qualitatively and over time
[8–12].
While pathways have been introduced as powerful resources to store knowl-
edge, their capabilities extend far beyond data warehousing. During the last
decades, pathway networks have also been extensively used to complement and
assist in the generation of new hypotheses and the interpretation of biomedical
data. They have now become one of the cornerstones of data-driven analyses
in systems biology. There are several reasons that explain the extensive use of
pathway-driven analysis [14]. First, pathways are often associated with familiar
biological and medical concepts (e.g., inflammation, cell death, etc.), thereby sim-
plifying and facilitating the interpretation and comparison of results. Second, they
support drug identification and development by elucidating their downstream
mechanistic effects. Third, they reduce complexity in a field involving millions of
molecular entities (e.g., genes, chemicals, (SNPs), protein variants, etc.). Thus, they
indirectly act as a dimensionality reduction technique by projecting results onto a
smaller shared feature space. Finally, due to their inherent multi-scale nature, they
enable the integration of multiple -omics data (e.g., metabolomics, genomics, and
proteomics). Taken together, the use of pathway constructs opens the door to not
only better understanding of biology, but also to novel approaches aimed at drug
1Hereafter, the term “network” will be used interchangeably with the term "graph”.
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Figure 2: A) MERTK signaling pathway. MERTK is a receptor tyrosine kinase that trans-
duces signals into the cytoplasm after the binding of several ligands such as GAS6, Protein
S, Tubby (TUB), TULP1 and LGALS3. The downstream effects of MERTK activation range
from regulating processes such as cell survival or migration to cell differentiation and
apoptosis. This figure was adapted from [13]. B) Pathway representation as a network.
Biological entities are represented as nodes, and their interactions as edges.
identification, precision medicine, and disease modeling.
One of the current challenges in systems biology is in defining the boundaries
of these modular units that we call pathways. It is difficult not only to identify the
set of interactions comprising a pathway, but also to demarcate the limits of where
a pathway starts and/or where it ends. Answering this question is not a trivial task
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due to pathway crosstalk (i.e., pathways with up- or down-stream effects on each
other, such as feedback loops) and the involvement of genes in multiple pathways
(i.e., pleiotropic genes). Although this question leads to philosophical discussions
around the nature of "what really is a pathway?", these questions are often ig-
nored because pathways are inherently abstract concepts defined by researchers
based on current scientific knowledge. Accordingly, pathway demarcations are
dynamic and change over time in parallel with scientific developments. Further,
investigating the boundaries of a particular pathway is a time- and labor-intensive
task. First, a researcher must manually investigate the literature to formulate a
pathway. Next, in order to prove her hypotheses, she must conduct dedicated
experiments varying from classical knock-out to advanced gene editing techniques
such as CRISPR/Cas9 that aim at elucidating the downstream effects of a pathway.
In summary, characterizing new pathways and establishing their borders is a
challenging task that requires significant amounts of resources. These resources
must nonetheless be invested in order to gain a comprehensive overview of the
pathway landscape.
1.2 Pathway databases
From the end of the last century, several efforts from various research groups,
institutions, and private companies have focused on capturing disparate facets
of pathway knowledge (e.g., signaling cascades, metabolic routes, and regulatory
networks) and storing them in databases aimed at organizing information from this
domain. According to PathGuide, there exist about a thousand pathway databases
available 2 [15, 16]. One of the reasons explaining their rapid growth was through
a need to formalize and store information generated by the explosive growth of
the biomedical literature. However, this large number of databases also implies
that these databases have been independently implemented and are currently
isolated in so-called "data silos", thus hampering centralization approaches that
seek to consolidate their knowledge.
While there exist hundreds of databases, only a handful of them are highly
cited and employed (Table 1). There are several reasons that could explain this.
First, the majority of databases are limited in scope with regard to the number
of pathways they cover or they present outdated pathway representations since
2Note that this is an approximation intended to provide a rough estimate on the current number
of databases. Moreover, it is important to mention that the last update in PathGuide was conducted
in September of 2017, while this thesis was written in 2019.
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Type Pathway Resource Publications
Primary
KEGG 27.713
Reactome 3.765
WikiPathways 651
Integrative
MSigDB 2.892
Pathway Commons 1.640
ConsensusPathDB 339
Table 1: Number of publications citing major pathway resources for pathway enrichment
in PubMed Central (PMC), 2019. It is important to note the difference between primary
(i.e., resources containing their own pathway information) and integrative databases
(i.e., resources that integrative information from multiple databases). The latter are
also referred as meta databases in literature. To develop an estimate on the number
of publications using several pathway databases for pathway enrichment, SCAIView
(http://academia.scaiview.com/academia; indexed on 01/03/2019) was used to con-
duct the following query using the PMC corpus: “<pathway resource>” AND “pathway
enrichment”.
these resources can demand extensive manual curation. Second, the recognition of
certain resources as reference databases as well as the preference of the researcher
conducting the study introduces a bias towards the use of certain databases.
Third, the funding body of each database (i.e., academic institutions vs. private
companies) directly influences whether the access is public or not and thus, its
usage. Below, a survey of the major resources in the field is presented.
• Kyoto Encyclopedia of Genes and Genomes (KEGG). As one of the old-
est databases in the field, KEGG comprises a collection of pathway-related
materials including networks, genomic information, and schematic represen-
tations for hundreds of pathways and metabolic routes in different species
[17]. This resource has been maintained since 1995 by Kanehisa’s laboratory
at Kyoto University in Japan. The main asset of KEGG is in its set of manually
drawn pathway maps, representing molecular interaction and reaction net-
works. These are divided into several sections depending on their function
or nature: metabolism, genetic information processing, environmental infor-
mation processing, cellular processes, organismal systems, human diseases,
and drug development [17].
• Reactome. This database is one of the largest public resources for biological
pathways [18, 19]. Reactome is curated and maintained by an international
multidisciplinary team by institutions from Canada, the United States, and
6
Europe since 2003. As its name suggests, Reactome’s modeling unit is a
biological reaction where each reactant and product is linked to its corre-
sponding reaction. Thus, the aggregate of reactions constitute a network of
biological interactions that are then grouped into pathways. The latest release
of the database contains several thousand pathways for 79 species, including
two thousand pathways for Homo sapiens alone 3. Furthermore, its powerful
tools, like its pathway browser, enable the scientific community to exploit
the information in this resource by exploring pathway networks, overlay-
ing data, and conducting pathway enrichment analysis, among other tasks.
These tools are complemented by a dedicated Application Programming
Interface (API) that offers downloading the database content in disparate
formats as well as making complex queries to the database. Additionally, it
is important to remark that the content of this database is not only highly cu-
rated but also cross-referenced and linked to other databases using controlled
ontologies.
• WikiPathways. This resource is a community-driven database for contribut-
ing and maintaining content dedicated to biological pathways [20–22]. While
the core of WikiPathways is comprised of peer-reviewed pathways, any
registered user can curate and submit pathways to this resource, thus facil-
itating both outreach and its maintenance. Furthermore, it contains large
amounts of Reactome content thanks to a recently implemented converter
[23]. Although WikiPathways contains pathways for multiple species, its
main asset is the collection of approximately 500 human pathways that have
been made public to the community through its open access web application.
• Gene Ontology (GO). Despite the fact that it is not technically a pathway
database, this resource provides a hierarchically organized set of thousands
of standardized terms for biological processes, molecular functions and
cellular components, as well as curated and predicted gene annotations based
on these terms for multiple species. Its annotations can be used to interpret
genomic information by asking questions such as how, where, and in which
context a gene or protein operates. Additionally, GO is complemented by
other databases such as PANTHER [24]. Therefore, GO is also commonly
used for functional enrichment analysis. Although this resource does not
yet contain pathway networks as the previously mentioned resources, it
is important to remark that GO has proposed a new syntax for joining its
annotations into larger models of biological function that could represent
pathways, as will be discussed in the next section. In summary, GO can be
3Statistics based on Reactome’s release number 68.
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used for pathway enrichment analysis for a comprehensive representation
of multi-scale relationships across biological entities.
While pathway databases cover a variety of scopes (e.g., metabolic or signaling)
and contexts (e.g., cellular- and species-specific databases), the majority of studies
thus far only employ a single database (Table 1). There could be two reasons that
might explain this. First, researchers usually do not require specialized databases
but rather generalized ones that cover as much pathway knowledge as possible.
Second, running an analysis on a different database essentially means duplicating
the workload, as analytic tools can be run with just one format. Further, this limited
interoperability across tools and databases has been magnified by the adoption of
multiple standards. Consequently, integrative efforts have continuously attempted
to consolidate disparate databases, aiming to centralize pathway information.
Consolidating the knowledge contained in various databases is typically con-
ducted by a so-called meta database (i.e., a database of databases). One of the
most well-known meta databases is Molecular Signatures Database (MSigDB).
This resource is a collection of publicly available gene sets annotated to their corre-
sponding pathways. Other popular meta databases such as Pathway Commons
[25] or ConsensusPathDB [26, 27] go one step further by accommodating path-
way networks from multiple resources. Furthermore, to enable the exploration of
pathway topology, they are complemented by corresponding web applications.
Nevertheless, despite the use of these meta databases being especially suited for
analyzing consolidated pathway information, their underlying merged data is
not completely harmonized nor linked. For instance, because Pathway Commons
does not harmonize the interactions from original resources, it is not possible to
investigate the consensus or crosstalk of two overlaid networks from disparate
resources. Additionally, because related pathways across resources have never
been annotated and linked together, a typical pathway enrichment analysis could
yield duplicate pathways (e.g., Pathway A from resource X and Pathway A’ from
resource Y).
1.3 Interoperability and integration of pathway databases
While semantic web technologies have paved the way for integrative approaches
to manage, retrieve, represent, and harmonize knowledge, there exist two fun-
damental challenges that have impeded the path to make pathway knowledge
fully interoperable across databases. The first barrier, as previously mentioned,
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is related to the abstract nature of pathway delineations. This, together with the
absence of a dedicated pathway controlled vocabulary until recently [28, 29], ex-
plains why there are no pathway cross-references and mappings across databases.
Similar to the lack of controlled vocabularies during the first decades of database
development, the absence of a golden standard to formalize pathway knowledge
led to the advent of multiple formats and schemata. However, all these novel
formats share a fundamental principle: they are all computable formats which
prioritize human readability in order to facilitate the work of curators. While the
existence of heterogeneous standards offer researchers numerous alternatives to
implement databases depending on their purpose or the underlying data to be
stored, they also pose a technical obstacle when harmonizing data across distinct
resources. The following section presents a survey of standard formats used to
formalize pathway data.
Figure 3: Diversity in formats used by the four pathway databases reviewed in this thesis.
Although the majority of these resources export to more than one standard, a limited
number of them are shared across resources.
• Resource Description Framework (RDF). This format is a standard format
for storing, managing, and modeling knowledge and it originated in the
semantic web domain. It was designed to describe resources and the relation-
ships that link them. RDF is comprised of triples, each formed by a subject, a
predicate, and an object, in which the subject is the acting resource, the predi-
cate is a linking relationship, and the object is the resource that is acted upon.
Both subject and object can be represented as a Uniform Resource Identifier
(URI), the base of its vocabulary. This flexibility permits the merging of data,
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though the schemas which form their basis may differ in contrast to other
formats such as Extensible Markup Language (XML). Further, the use of
triples as semantic units supports linking data across distint resources, as
illustrated by Bio2RDF [30], WikiPathways [31], and Scholia [32].
• Biological Pathway Exchange (BioPAX). This format was initially designed
to drive the exchange of biological pathway data, thereby facilitating its
integration, visualization, and analysis [33]. Further, it is highly effective in
handling ontologies and exporting its content to other data types since it
is derived from two semantic web standards, RDF and Web Ontology Lan-
guage (OWL). BioPAX 3.0, its latest version, defines five top level classes (i.e.,
entities, genes, physical entities, interactions and pathways) to support the
representation of pathways. The ontology defines discrete physical entities,
interactions as sets of physical entities and pathways as sets of interactions.
In a graph representation, this would be analogous to nodes, hyperedges
and graphs, respectively. Numerous databases use BioPAX to store path-
way knowledge, including Reactome, WikiPathways as well as Pathway
Commons (Figure 3).
• Systems Biology Markup Language (SBML). This format, which is based
on XML, was designed to represent computational models of systems biology
[34]. Although SBML was originally designed to serve as a lingua franca in
the field of biochemical network modeling, it has evolved to represent other
biological processes. Due to its origins, this language offers users the option
to include quantitative information in the form of equations such as chemical
reactions. This promotes the exchange of quantitative models of biochemical
networks between different simulation tools. Physical entities are denoted
species and processes are called reactions. They can be encoded as models,
that when decomposed, closely resemble chemical reaction equations. Finally,
SBML is used or can be exported by various databases such as Reactome
(Figure 3) and HumanCyc [35].
• Biological Expression Language (BEL). Conceived in the private sector, this
language is specially suited to represent biomedical knowledge in a com-
putable form by capturing causal and correlative relationships [36]. BEL
allows for the inclusion of a minimal set of information for each triple or
BEL statement (i.e., a reference, evidence text, and defining entities accord-
ing to the functions or relationships allowed in the language). This set of
triples of the form subject, predicate, and object are then combined into a
network. Furthermore, entities are formalized by using external vocabu-
laries and ontologies, thus easing their normalization and cross-reference
to domain-specific databases (e.g., Chemical Entities of Biological Interest
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(CHEBI) [37], HUGO Gene Nomenclature Committee (HGNC) [38], etc.).
Additionally, its inherent flexibility supports annotating triples with contex-
tual information as well as encoding entities spanning multiple scales (e.g.,
molecules, cellular processes, phenotypes, etc.). BEL is now open source
and it is being developed by a consortium of institutions [39] that provide
tools and resources to visualize and analyze the resulting networks (e.g., BEL
Editor, Knowledge Assembly Model (KAM) navigator, PyBEL [40]). Similar
to Bio2RDF, the Bio2BEL framework [41] demonstrates how BEL can drive
semantic integration and harmonization in networks and systems biology.
• Other standards. Although the aforementioned standards are backed by
larger communities, other formats extensively used in the field also exist.
For instance, Systems Biology Graphical Notation (SBGN), is suited for the
storage and exchange of signalling pathway, metabolic network and gene
regulatory network information [42]. Further, Proteomics Standards Initiative
- Molecular Interaction (PSI-MI) is a data exchange format for molecular
interactions maintained by the Human Proteome Organization (HUPO)
[43], and Simple Interaction Format (SIF) is an elegant format designed to
build graphs from lists of molecular interaction units. Two other XML-based
languages, CellML [44] and KGML, are respectively designed to describe
mathematical models and pathway maps in KEGG. Lastly, GO has recently
developed a new format called Causal Activity Models (CAM) designed to
give more expressibility to its annotations and convert them to networks
(Figure 3).
While most of the standard languages described in this survey share capa-
bilities and have been proven to effectively model biological knowledge, each
language is best suited for a particular application depending on both the goal and
domain of study. For example, SBML specializes in modeling quantitative aspects
of molecular processes, including chemical kinetics. On the other hand, both BEL
and BioPAX have a strong focus on capturing interactions across biological entities.
However, their structural differences influence how flexible curators can be in
representing biological entities and their interconnections. Since the structure of
BEL more closely resembles a generic network, it allows for more freedom in defin-
ing relationships and entities. This enables assembling contextualized knowledge
from multiple scales (e.g., molecular, phenotypic, and genetic level), thus, making
it particularly well-suited for clinical applications and disease modeling. However,
this may cause harmonization issues if two curators represent entities differently.
BioPAX, on the other hand, has a more complex structure that encourages curators
to define entities using standard biological paradigms that can make it highly
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verbose. Moreover, some formats offer curators a predefined vocabulary to ex-
press relationships (e.g., BEL) while others such as BioPAX let curators decide
their own. In terms of usage by the bioinformatics community, BioPAX and SBML
are supported by a larger number of software tools and databases than BEL and
RDF. Ultimately, all languages mentioned in this thesis have been designed to
connect entities or relationships to external vocabularies in order to facilitate the
cross-linking and transforming of knowledge from one language to another. This
eases the burden of pathway knowledge exchange by integrating resources that
use different formats, thus, connecting data silos.
The properties and characteristics of a particular database format, alongside
the complementary software tools that support it, play an important role for the
adoption and application of a given pathway resource. We can divide these tools
into three different categories depending on their purpose: (i) curation workflows,
(ii) analytical tools, and (iii) parsers and converters. Among the noteworthy in the
first category are Payao for SBML [45], MINERVA or the SBGN editor for SBGN
[46, 47] and NaviCell for any XML-based format [48]. Thanks to the compatibility
across formats, the second category is broader and offers numerous visualization
and distribution tools, such as NDEx or PathVisio [49–56]. Finally, the latter group
accounts for tools designed to convert from one format to the other such as [23, 51,
57–60]. These tools are ultimately responsible for enabling interoperability across
resources. Converters operate by applying a set of inference rules to map two
distinct data models, which effectively transforms one format to another. However,
conducting this mapping task often leads to the inclusion of ambiguities, redun-
dancies, or even information loss. Summarizing, this harmonization challenge
necessitates converting each of the database formats into a consensus schema that
integrate their heterogeneous information.
The wide range of both databases and formats complicates evaluating the po-
tential overlap across pathway databases. Furthermore, the presence of database-
specific terminologies and formats compels manual intervention in order to assess
the consensus of a particular across databases as outlined by [61]. To integrate mul-
tiple databases into centralized repositories, different approaches have attempted
to consolidate disparate databases by converting each of their individual formats
to a common structure.
Pathway Commons, one of the meta databases previously mentioned, has
undertaken this tremendous effort of uniting databases together with the help of
BioPAX [25]. OmniPath, on the other hand, combines multimodal information
from heterogeneous databases (e.g., transcription factors, protein-protein interac-
tions, etc.) and assembles it to a simplified triple-based format [62]. Furthermore,
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this resource is complemented with a Python package that facilitates its usage
for other applications. Similar to OmniPath, the graphite R package integrates
multiple sources and enables users to manipulate the resulting networks [63].
However, as previously mentioned, there are some limitations of these integrative
approaches. First, the fact that OmniPath and graphite do not follow a systems
biology standard, but rather implement generic network schemata, leads to an
over-simplification of relationships present in the resources they integrate. For
example, OmniPath does not include directionality, though this information is
present in most of its original resources. Furthermore, their underlying networks
exclusively contain signed information (i.e., activation and inhibition) and lose
contextual information such as differentiating between biological classes (e.g., gene
versus protein) or how activation is mediated (e.g., phosphorylation, biochemical
reaction, etc.).
While integrative resources facilitate the generation of multi-scale knowledge
graphs, data integration has to be conducted with a minimal loss of information.
Capturing contextual information is essential for analyzing -omics data with the
support of the knowledge embedded in the network structure. This, together with
the rapid development of novel machine and deep learning techniques [64–66]
calls for sophisticated approaches that adequately harmonize both biological enti-
ties and relationships, while permitting the contextualization of the information
comprised in the knowledge graph. The next chapter introduces the concept of
disease maps (i.e., a knowledge graph of a given disease) and how they can be
employed to represent the mechanisms around human disorders.
1.4 Disease maps
Canonical pathways formalize sets of "biological snapshots" that correspond to the
chains of causation occurring in normal cellular physiology. However, pathway
interactions can be altered by their environment and context [5]. In other words,
the same pathway in the same organism can effectively yield two completely
opposite outcomes in two different cellular types (e.g., neuron, adipocyte, etc.) or
states (e.g., age, signaling from neighbouring cells, nutrition, cell cycle stage, etc.).
Therefore, establishing clear and delineated pathway boundaries based on contex-
tualized information is crucial to better comprehend and interpret the inherently
dynamic nature of biology. Accordingly, classical pathway-centric approaches
must be extended to incorporate contextual information in order to shape and
adapt pathway knowledge depending on the context given in the studied model.
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Contextualization might explain the success of pathway resources to decipher
and unravel the underlying pathophysiological mechanisms in certain diseases,
especially in those where research has been abundant (e.g., cancer and metabolic
disorders), and the lack of success in others (e.g., neurodegenerative or psychiatric
conditions). The latter diseases tend to be especially complicated due to their still
unknown multifactorial nature. This, in turn, has translated into a limited number
of treatments for them (if any).
Capturing disease-specific information is essential because pathways can have
different behaviours depending on one or the other scenario. For this reason,
roadmaps were launched to build disease maps for various conditions organized
by the Disease Maps Project [67]. The goal of disease maps is to formalize the
knowledge around signaling, metabolic, and gene regulatory pathway networks
that are involved in the disease of study in order to reveal underlying crosstalk
and interplays across disease mechanisms. This task requires both clinicians and
biologists to curate relevant literature in order to ensure that key molecular play-
ers involved in the disease pathophysiology are present. Moreover, as novel hy-
potheses or mechanisms are proposed, the content has to be adequately updated,
ensuring that the new pieces are coherently integrated in the "disease map puzzle".
As opposed to standard pathway resources, disease maps not only contextualize
disease-specific information but often add several other biological aspects and
scales such as Single Nucleotide Polymorphism (SNP)s, gene variants, and clinical
phenotypes associated with the condition [68, 69]. Therefore, disease maps go be-
yond classical pathway representations by integrating novel biological scales and
mechanistic information to provide a more comprehensive overview of the disease
landscape. In summary, disease maps are computable assemblies of expert-curated
and contextualized knowledge that can not only be used to store this information
but also to model disorders and generate new hypotheses.
Over the last few years, several initiatives were launched to build disease maps
in conditions such as Alzheimer’s disease (AD) (AlzPathway), Parkinson’s disease
(PD) (PDMap), asthma (AsthmaMap), cancer (Atlas of Cancer Signalling Network),
rheumatoid arthritis, and influenza [70–76]. Apart from the continuous updates of
these existing resources, other disease maps are also currently under development
in areas such as acute kidney injury, spinal cord injury, Meniere’s disease, lung
cancer, and cystic fibrosis, among others [77]. Of the above mentioned disease
maps, among the largest are AlzPathway (Figure 4) and PDMap, developed by two
particular efforts in the field of neurology. Although mechanistic information is
lacking in this challenging area, both resources emerged as comprehensive catalogs
of their respective conditions by incorporating information from over a hundred
review articles in the case of AlzPathway, and over thousand research articles
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Figure 4: Overview of AlzPathway overlaid with canonical pathway annotations. Most of
the pathways identified in this work overlap with NeuroMMSig. This figure was taken
from [70].
in the case of PDMap. Further, PDMap is complemented by MINERVA, a web
application that supports the curation, annotation and visualization of biological
networks [46]. On the other hand, AlzPathway cannot be directly explored on its
website but rather must be visualized with the help of auxiliary software (Figure
4). Although both maps can be explored through user-friendly interfaces that
even show cell compartmentalization, the format chosen (i.e, SBML), constrains
scientists to analyze and investigate network crosstalk since an entity can be
present multiple times in the map. In other words, because the map layout is
compartmentalized and enables presenting multiple representations of the same
molecule in different mechanistic or pathway networks, these networks cannot be
later overlaid without processing the original networks. This duplication issue at
the node level can only be overcome with substantial manual effort (i.e., manually
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linking entities in a post-processing step) or by converting such formats to other
graph-generic formats.
Concluding, contextualizing and formalizing knowledge in the form of disease
maps enables cataloging crosstalk across molecular players and pathways in a
particular disease. By doing so, the analysis of disease modeling supports investi-
gating disease aetiology by generating novel mechanistic hypotheses. However,
the expansion and maintenance of disease maps is crucial in order to continue
integrating the knowledge coming from novel literature. Furthermore, in the
particular case of neurological disorders, disease maps could incorporate other
aspects and biological scales related to the condition such as imaging readouts
(e.g., volume of region brains), biomarkers, and clinical features (e.g., psychologi-
cal tests). Finally, future overarching approaches that connect these computable
knowledge templates to real multi-scale and multimodal cohorts could shed some
light on the mechanisms underlying aetiology of these complex disorders.
1.5 Neurodegenerative and psychiatric disorders
Neurological disorders group together a series of conditions, such as Alzheimer’s
disease, Parkinson’s disease, epilepsy, or multiple sclerosis, where there exist ner-
vous system malfunctions or damage. On the other hand, psychiatric disorders,
such as anxiety, schizophrenia, or post-traumatic stress disorder manifest through
disturbed behaviour and emotional states. These two groups of disorders impose
a major economic and social burden. Not only the patient, but also the family and
caretakers of the patient are profoundly impacted by the decline of the patient,
and the accompanying emotional burden. On the other hand, in economic terms,
dementia alone has a global impact larger than one trillion dollars in the United
States alone [78]. Furthermore, the population growth expectations suggest that
the economic costs associated with mental illnesses will grow exponentially over
the next 30 years [79]. The following subsections introduce the three neurodegen-
erative and psychiatric conditions (i.e., PD, AD, Post-traumatic stress disorder
(PTSD)) that this thesis focuses on.
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1.5.1 Alzheimer’s disease
Alzheimer’s disease (AD) is a neurodegenerative disease that progressively affects
memory, thinking, and behavior by inducing neuronal dysfunction. This condition
is the most predominant form of dementia and is the neurological disorder with
the highest prevalence in the population [80, 81]. Although multiple hypotheses
have been proposed [82–86], little is known about its multifactorial aetiology.
The variety of mechanisms implicated (or thought to be) and the vast number of
possible chemicals to target them can explain why, despite the billions invested
by pharmaceutical companies, there still is no cure for AD, only treatments that
relieve patients from their symptoms [87]. Other reasons could be attributed to
the fact that patients are treated in advanced stages of the disease (i.e., treatment
comes too late) [88] or trials are conducted in highly heterogeneous patient groups
(i.e., drugs might work exclusively in a subpopulation).
Today, it is estimated that about 50 million people live with some form of
dementia. The majority of the cases exist in developed countries where patients
can be diagnosed and have access to health care. By 2050, when the population
pyramids of developing countries evolve from their current expansive shapes (i.e.,
bell-curved) to stationary ones (i.e., rectangular shape), this number is expected to
be tripled [89]. However, the number of scientific publications related to dementia
is ten times smaller than the cancer field [89]. The combination of this under-
representation together with the future demographic outlooks could explain why
western countries have set dementia as a public health priority and have launched
numerous projects addressing this issue.
Although there exist multiple types of dementia, there tends to be agreement
in the literature on the subdivision of AD into two main subtypes [90–92]:
• Familial AD. This subtype is related to mutations involved in AD-related
genes, such as APP, PSEN1 and PSEN2. New insights on these etiological
agents are essential for a better understanding of the pathogenesis of AD.
• Sporadic AD. Accounting for about 95% of all cases, sporadic AD presents
the same symptoms as the previous subtype though it cannot be distin-
guished from the familial form since the etiology of this form has yet to be
fully elucidated. It is believed that it is caused by environmental factors as
well as a genetic component.
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1.5.2 Parkinson’s disease
Parkinson’s disease (PD), the second most common neurodegenerative disease, is
characterized by a series of unknown detrimental changes in the central nervous
system that lead to dysfunction in the motor system. PD pathophysiology is
associated with a deterioration of the dopamine release system that ultimately
disrupts motor system skills, translating into unstable and unplanned movements.
Hence, trembling movements are the most common symptom at early stages. Later
stages, however, develop into cognitive decline and behavioral issues as the areas
of the brain become affected [93]. Unfortunately, although some of the symptoms
can be alleviated, as of yet there is no cure for PD.
Epidemiologically, PD is a highly prevalent condition as studies indicate ap-
proximately ten million patients are affected worldwide [94]. However, this num-
ber is expected to double in the next decades due to an increase in aging popula-
tions, longer disease durations, and environmental as well as social risk factors
[95]. Conversely to AD, this condition is more prevalent in men with a 1.6 to 1
ratio [96]. This difference is believed to be attributed to the neuroprotective effect
of estrogen in women [97–99].
Since PD is a multifactorial condition and its pathophysiology has yet to
be fully understood, various studies have been conducted and found numerous
mechanisms to be associated with PD (Figure 5). According to the possible etiology
and clinical implications, two subtypes of PD can be characterized [102]:
• Familial or monogenic PD. Accounting for approximately 5% of the diag-
nosed cases of PD, this subtype is caused by inheritable monogenic genetic
variants, such as SNCA, PINK1, and LRRK2 [103]. Typical traits of this PD
subtype are both early onset (around forty years) and accelerated disease
progression.
• Idiopathic or sporadic PD. Idiopathic PD constitutes roughly 90% of diag-
nosed PD cases. Men of age 80 years represent the majority of the cases and
the average age of diagnosis is 55 years old. In contrast to familial PD, the
pathogenesis of this type is gradual and its pathophysiology is associated
with epigenetic and environmental factors [104].
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Figure 5: Schematic representation of the crosstalk between different mechanisms impli-
cated in PD pathophysiology. Both Mitochondrial dysfunction (A) and neuroinflammation
(B) result in a cascade of cellular events that lead to apoptosis such as generation of Reac-
tive Oxygen Species (ROS) (E), mitochondrial fission/fragmentation (C) or ATP depletion.
Cellular responses to these changes include alteration in gene expression (H) or autophagy
and mitophagy (D). These processes are related with the aggregation of proteins such as
synuclein and activation of the ubiquitin system, both of which are disease hallmarks.
Finally, excitotoxicity (I) caused by a dysregulation in the influx of Ca 2+ is also related to
mitochondrial dysfunction through the depolarization of its membrane. This figure has
been adapted from [100, 101].
1.5.3 Post-traumatic stress disorder
PTSD is a common psychiatric disorder that can occur in individuals after a
traumatic event [105]. This condition is diagnosed by psychologists based on
the presentation of four characteristic symptom: intrusions, avoidance, negative
19
cognitions/mood, and hyperarousal [106]. While PTSD pathophysiology is not
yet fully understood, research suggests that numerous neurological systems that
regulate mental and physical health functions are implicated [107]. Furthermore,
PTSD symptoms complicate its diagnosis. In fact, it was not officially recognized
as a condition until 1980 by the American Psychiatric Association [108].
From the epidemiological point of view, [105] has a prevalence around 3.5%
in the United States [106]. Globally, although trauma exposure is unequally dis-
tributed due to cultural differences and the presence of local conflicts, this condi-
tion is present in around 10% of the total population at some point of their lives
[109]. Finally, it is important to note these figures can be considered conservative
as epidemiological studies indicate that over 70% of the population experiences a
traumatic event [109, 110].
Besides the epidemiological figures, PTSD has a significant impact on our
economy and society. Economically, the costs derived from this condition are
related to the health resources used, such as medication, and resources lost in terms
of productivity and presenteeism. Due to the difficulty in estimating economic
cost-of-illness, there have been no studies focusing on the global economic impact
of PTSD. However, a local study based in Northern Ireland reported surprisingly
large figures for such a small region [111]. Similarly to neurodegenerative diseases,
the social impact is not restricted to patients but also to families, relatives, and the
care staff who suffer from prolonged stress, depression and other psychological
disorders.
The principal treatments for PTSD patients are psychotherapy and medica-
tion. The most common prescriptions are antidepressants that act as a Selective
Serotonin Re-uptake Inhibitors (SSRIs) (e.g., Zoloft and Paxil). However, the mech-
anism of action of these drugs is still unknown, and such generic medication is
prescribed for multiple other psychiatric disorders. Furthermore, the benefits of
these drugs may be outweighed by their numerous side effects [112]. Since we
still lack the mechanistic understanding about the pathophysiological changes
occurring in the brain that lead to this disorder, it is critical to start by analyz-
ing biomarker data in order to pinpoint endophenotypic traits implicated in this
disorder. In addition, biomarker discovery, as in neurodegenerative diseases, is
essential for detecting symptomatic patients at an early stage of the disease so
they can be immediately treated at a early stage of the disease for more timely
treatments.
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1.6 Translational research: applying knowledge-derived
hypotheses to the clinic
The previous section illustrates the necessity to elucidate the pathophysiology
underlying these disorders. While knowledge-driven approaches can be used
to exploit pathway and mechanistic information and model the disease, such
tasks have to be complemented with data-driven approaches. One of the classical
examples on how the crosstalk between the two is essential for driving science is
the drug development process. In this domain, data-driven approaches are applied
to validate a candidate drug by analyzing data from a clinical- or cohort-based
study. However, to be successful, a study needs to be designed in a way that
takes into account prior knowledge (e.g., reflecting patient heterogeneity and
conducting a meta-analysis of the literature).
Disease have a time dimension that also needs to be modelled by knowledge-
driven approaches. This aspect is well-characterized in longitudinal studies whose
data can be analyzed to study patient-specific progression. Using this information,
we can stratify the patients that present similar patterns during disease progres-
sion and analyze the pathways or mechanisms that differentiate these patient
subgroups. This, in turn, can support us understanding how their mechanistic
characteristics lead to disparate clinical phenotypes. Building such a "mechanism-
based taxonomy" is crucial to reveal the mechanistic underpinnings of highly
heterogeneous patient populations in conditions whose pathophysiology is yet
unknown.
Stratification approaches are especially relevant for the idiopathic subtypes of
AD and PD since the majority of the disease population falls into heterogeneous
groups, as previously discussed. Specific patient subtypes must be properly charac-
terized in order to correctly identify the disease mechanisms at work. Without this
crucial first step, clinical trials will fail. This illustrates the power of a combined
data- and knowledge-driven approach for knowledge discovery and its broad
applicability to precision medicine and translational research.
Crossing the translational divide between knowledge-driven discovery and
clinical implementation first requires linking information from the biomarkers
and endpoints measured in a clinical study with knowledge-derived models. This
crucial step involves curating and organizing this information in order to facilitate
the harmonization and integration of results from multiple studies. Therefore, nu-
merous initiatives currently aim to catalogue biomarker information on particular
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conditions, such as colorectal cancer [113], Alzheimer’s disease [114], tuberculosis
[115], and liver cancer [116].
While the value of these integrative efforts is often underestimated and is
associated with demanding tasks such as data preprocessing and harmonization,
these resources foster research by providing a more comprehensive view of the
information available. For instance, making large studies such as Alzheimer’s
Disease Neuroimaging Initiative (ADNI) and Parkinson’s Progression Markers Ini-
tiative (PPMI) interoperable allow for replicating and validating previous studies.
In addition, the considerable amount of data generated by merging studies that
share significant overlap enables developing more robust models and drawing
and validating new conclusions and hypotheses.
1.7 Outline of the thesis
This thesis first focuses on the development of novel software tools and web
applications designed to better interlink, consolidate, and harmonize knowledge
across different pathway databases. Chapter 2 presents ComPath, an ecosystem
that supports curation of pathway mappings between databases and fosters the
exploration of pathway information through several novel visualizations. By
using this ecosystem, we curated a novel dataset of pathway mappings that
provides a comprehensive view on pathway relationships across three major
databases (i.e., KEGG, Reactome, and WikiPathways). Chapter 3 presents PathMe,
the first framework which successfully harmonizes pathway networks across
the previously mentioned databases, at both entity and relationship level. Both
tools are complemented with their corresponding web applications facilitating
the exploration and analysis of the knowledge they consolidate. Finally, chapter
4 presents a comprehensive benchmarking of individual pathway databases on
statistical enrichment analysis and predictive modeling methods. Furthermore,
with the help of the former two tools (i.e., ComPath and PathMe), we establish
an approach to integrate pathway knowledge from different resources into a
merged dataset to demonstrate that integrative approaches outperform individual
databases. This study illustrates how database choice has a significant impact
on results and highlights the importance of integrative approaches as a way to
mitigate this bias.
The following chapters outline knowledge- and data-driven approaches aiming
to unravel the underlying pathophysiological mechanisms involved in psychiatric
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and neurodegenerative disorders. Chapter 5 presents an innovative enrichment
paradigm, NeuroMMSig, supported by over 200 disease-specific mechanistic net-
works for three neurodegenerative disorders, as opposed to canonical pathways,
to offer the scientific community a novel resource for knowledge discovery in the
context of three conditions (AD, PD, and epilepsy). Chapter 6 introduces the first
biomarker database in the context of PTSD. This resource, the first of its kind, cata-
logs biomarker information in a comprehensive database complemented by a web
application aiming to facilitate future analysis and research in the field. Finally,
chapter 7 illustrates how the crosstalk between machine learning predictive mod-
els derived from the major AD clinical study like ADNI, and knowledge-driven
approaches such as NeuroMMSig can reveal promising mechanistic links in this
condition.
The final chapter outlines the main topics, discusses the limitations and presents
possible future directions of this work, serving as a conclusion of the thesis.
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2 ComPath: an ecosystem for
exploring, analyzing, and curating
mappings across pathway databases
Introduction
The growth of pathway knowledge that has accompanied the recent explosion of
high-throughput biological data has led to the development of dozens of databases.
However, the lack of interoperability between them hampers an integrative ap-
proach that can synergistically exploit these resources in a coordinated fashion.
Due to the lack of a gold standard in the field of systems biology to represent path-
ways, various formats were adopted to improve reproducibility and facilitate the
exchange of pathway knowledge [117]. Though several efforts have successfully
accommodated multiple pathway databases, the absence of a unified pathway
ontology [29] and the lack of inter-database mappings which impede the ability to
assess the knowledge gaps and biases that may be present in pathway databases.
This chapter presents a flexible software that is able to integrate gene-centric and
chemical pathway data from multiple databases in order to explore, analyze, and
curate pathway knowledge. Using this software, we established the first mappings
across three of the major pathway databases (i.e., KEGG, Reactome, WikiPathways)
[17, 20, 118].
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ComPath: an ecosystem for exploring, analyzing, and curating
mappings across pathway databases
Daniel Domingo-Fernández 1,2, Charles Tapley Hoyt 1,2, Carlos Bobis-Álvarez3, Josep Marín-Llaó1,4 and Martin Hofmann-Apitius 1,2
Although pathways are widely used for the analysis and representation of biological systems, their lack of clear boundaries, their
dispersion across numerous databases, and the lack of interoperability impedes the evaluation of the coverage, agreements, and
discrepancies between them. Here, we present ComPath, an ecosystem that supports curation of pathway mappings between
databases and fosters the exploration of pathway knowledge through several novel visualizations. We have curated mappings
between three of the major pathway databases and present a case study focusing on Parkinson’s disease that illustrates how
ComPath can generate new biological insights by identifying pathway modules, clusters, and cross-talks with these mappings. The
ComPath source code and resources are available at https://github.com/ComPath and the web application can be accessed at
https://compath.scai.fraunhofer.de/.
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INTRODUCTION
The notion of pathways enables the representation, formalization,
and interpretation of biological events or series of interactions.
Cataloging biological knowledge into pathways reduces complex-
ity from all possible interacting molecular entities to a set of well-
studied and validated functional relationships between molecular
entities culminating in biological processes. Several efforts have
generated databases of pathways with varying specificity and
granularity that comprise signaling cascades, metabolic routes,
and regulatory networks from precise signatures with no more
than a couple of acting players to general pathways involving
thousands of molecular players.1–4
Simplifying biology into pathways and representation as
network models or mathematical models inevitably results in a
loss of information such as spatiotemporal information or even
entire biological entity types. The network abstraction facilitates
pathway visualization and interpretation thanks to the harmony
between biological networks and systems: nodes correspond to
molecular entities and edges to types of interactions occurring
between them (e.g., inhibition, phosphorylation, etc.). Although
networks can comprise a broad range of molecular types (e.g.,
proteins, chemicals, small molecules, etc.), they are generally
reduced to the most direct outcome of our genetic makeup - the
genetic and protein levels - so that we can mechanistically
understand their functionality. Thus, they are frequently viewed
and simplified to “gene sets”, the collection of all genes/proteins
that constitute the pathway, due to the major challenges of
incorporating network topology and translating the variety of
relationships into pathway analysis methods.
While dedicated research groups and commercial entities with
experienced curators have lead a majority of the efforts to
compile, delineate, and store biological knowledge into pathway
databases,2,5 community and crowdsourced efforts have recently
gained traction.3,6 Further, the variability in curation team
composition, database scope (e.g., signaling pathways, gene
regulatory networks, and metabolic processes), and curation
guidelines led to the adoption of different (and in many ways
incompatible) schemata and formalisms such as Biological Path-
way Exchange (BioPAX;7) and Systems Biology Markup Language
(SBML;8). These incompatibilities motivated the integration and
harmonization of resources into pathway meta-databases such as
Pathway Commons9 and PathCards,10 which focus on integrating
databases; iPath,11 which focuses on pathway visualization; and
SIGNOR, which focuses on signaling pathways.12
Even after integrating multiple pathway databases into a
pathway meta-database, it is difficult to assess the agreements,
discrepancies, redundancy, and the complementarity of their
contents because of the lack of availability of pathway mappings
(e.g., pathway A from resource X is equivalent to pathway B from
resource Y) in the original databases. These mappings are difficult
to establish because of the arbitrary and overlapping nature of
pathway boundaries as well as the absence of a common pathway
nomenclature. Several controlled vocabularies have been gener-
ated as initial attempts to standardize pathway nomenclature,13,14
but most pathway databases had already been established by the
time these ontologies were published. Therefore, consolidating
pathway knowledge is a persisting issue and it is still required to
map pathways from different resources together to improve
database interoperability.
Hierarchical clustering approaches have been presented as a
way of grouping similar pathways based on their corresponding
gene sets in order to propose pathway mappings.10,15 Though
these approaches can systematically cluster pathways from
multiple resources, there are some limitations to consider: first,
the usual tradeoff between over/under-clustering,16 and second,
pathway nomenclature and biological context are not considered
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by the clustering algorithm; it often leaves out equivalent
pathways with low similarity and ignores the context of the
pathway (e.g., cell/disease specificity). Nevertheless, these limita-
tions can be overcome by following clustering and prioritization
methods with the manual curation required to interpret the
abstract concepts that inherent to pathway definitions (e.g.,
biological process, cellular location, condition, etc.).
Though numerous algorithms17 and tools4,18 have been
successfully applied to interpret experimental data through the
context of pathway databases,19,20 there has not yet been a
systematic comparison between the contents of various pathway
databases, an assessment of their overlaps and gaps, or an
establishment of mappings. Previous studies have only focused on
comparing a single or small set of well-established pathways
across multiple resources.21,22 For example, a comparison focused
on metabolic pathways revealed how a set of five databases only
agreed in a minimum core of the biochemistry knowledge.23
These studies demonstrate the need to connect insights
provided by each pathway database to foster a greater under-
standing of the underlying biology. Here, we present ComPath, a
web application that integrates content from publicly accessible
pathway databases, generates comparisons, enables exploration,
and facilitates curation of inter-database mappings.
RESULTS
We developed an interactive web application that enables users to
explore, analyze, and curate pathway knowledge. Below, we
present three case studies illustrating how it can be used for each
of these purposes. The figures for each were generated by
interactive, dynamic views in the ComPath web application based
on three major public pathway databases: KEGG, Reactome, and
WikiPathways (Fig. 1).
Case study I: comparison of pathway databases
Assessment of gene coverage . Analysis of the overlaps between
Kyoto Encyclopedia of Genes and Genomes (KEGG), Reactome,
and WikiPathways revealed that there are ~3800 common human
genes shared between the three databases (Fig. 2a). While at least
one common human gene was present in almost every pathway
across each database, the number of pathways with more
common human genes diminishes much more quickly in
WikiPathways and Reactome (Supplementary Figure S1). This
may be due to database properties such as pathway size (e.g., on
average, pathways contain 90 genes in KEGG, 50 in Reactome, and
42 in WikiPathways) or gene promiscuity (i.e. genes functionally
linked to many pathways) that might influence the results of
analyses using pathway resources (Supplementary Table 2). For
further investigation, the ComPath web application generates
summary tables and creates several visualizations to enable
exploration of the distributions of pathway size and gene
memberships for each database, visualizations that present an
overview of the database properties to help identify effects such
as gene promiscuity or differences the distribution of gene set
sizes (Fig. 2b).
Exploration of pathways. While the previous views produced
gene-centric summaries of the contents of pathway databases,
ComPath also enables the exploration of pathway similarity
landscape using Clustergrammer.js.24 Figure 2C illustrates how
this view can identify clusters of pathways based on their similarity
and then elucidate the hierarchical relationships between the
Metabolic pathway, the largest KEGG pathway, and other more
high-granular KEGG metabolic pathways (e.g., alpha-Linolenic acid
metabolism, Lipoic acid metabolism, and ether lipid metabolism).
Case study II: identification of pathway modules, overlaps, and
interplays using pathway enrichment
ComPath couples classic pathway enrichment analysis18,25–27 with
pathway-centric visualizations to identify modules, investigate
overlaps, and cluster pathways. This case study demonstrates their
use to investigate the roles of the pathways related to established
genetic associations in the context of Parkinson's disease (PD).
Pathway enrichment with Fisher's exact test using a gene panel
associated with PD reviewed by Brás et al.28 (the gene set will be
referenced as PDgset) yielded over 300 pathways containing at
least one of the panel's genes (Fig. 3a). We discarded pathways
with fewer than two genes from PDgset, that were larger than 300
genes, or that were not found to be statistically significant (false
discovery rate >5%) after applying multiple hypothesis testing
correction with the Benjamini–Yekutieli method under
dependency.29
Three views were used to assist in the interpretation of the
remaining 29 enriched pathways: a pathway network view was
used to identify pathway modules, a pathway overlap view was
used to explore the intersections and cross-talks between
pathways, and a pathway dendrogram view was used for
clustering.
The pathway network view renders a pathway-to-pathway
network in which nodes represent pathways and weighted edges
represent their corresponding gene set similarities in a similar
fashion to PathwayConnector.30 For the PDgset, this visualization
helped us to define six different modules (i.e., groups of pathways)
by removing edges with a weight lower than 0.2 (Fig. 3b). The
largest module (labeled as M1) contained pathways related to the
processes of endocytosis and vesicle transport, both of which are
putatively disrupted in PD.31 M2 comprised pathways related to
PTK6 signaling such as the Reactome pathway, PTK6 promotes
HIF1A stabilization, whose high pathway enrichment significance
(q-value= 0.0005), as well as its role in regulating another PDgset
gene, ATP13A2,32 suggests that it may be linked to PD. ATP13A2 is
directly responsible for Kufor-Rakeb syndrome,33 a rare juvenile
form of PD, and participates in two other PD mechanisms:
lysosomal iron storage and mitochondrial stress. Because path-
ways related to these two mechanisms (i.e., Lysosome pathway
Fig. 1 The ComPath ecosystem has three main components: the
pathway database plugins, the ComPath framework, and the
ComPath web application. The ComPath framework mediates the
communication between the plugins containing the pathway
database information and the web application
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from KEGG, Pink/Parkin mediated mitophagy from Reactome, and
Mitophagy pathway from both KEGG and Reactome; M4) were also
enriched by pathway enrichment analysis, we investigated the
role of ATP13A2 in PD further.
ATP13A2 is activated by phosphatidylinositol(3,5)bisphosphate,
a particular phosphatidylinositol involved in M3 pathways
(phosphatidylinositol metabolism and signaling pathways).
Because this activation leads to a reduction in mitochondrial
stress and α-synuclein toxicity, two hallmarks of PD, ATP13A2 has
been proposed as a therapeutic target.34 Ultimately, the explora-
tion of the similarities and cross-talks between these three
modules suggests further investigation of the candidate PD gene
ATP13A2. Ultimately, this view complements pathway enrichment
in the identification of pathway modules, exploration pathway
cross-talks, and prioritization of genes for further study.
While the pathway network viewer provides an overview of the
different modules and their cross-talks, it does not reveal
information about their contained pathways' boundaries and
intersections. Therefore, we implemented the pathway overlap
view; an interactive Euler diagram that allows exploration of
pathway demarcations (Fig. 3c). We employed this view to identify
the set of genes common to all pathways in M5, a module
comprising the two Alzheimer's disease (AD) and two PD
pathways from KEGG and WikiPathways. Subsequently, we used
the ComPath pathway enrichment wizard to investigate in which
pathways the common five genes identified (APAF1, CASP3,
CASP9, CYCS, and SNCA) participate. The analysis revealed that
they are predominantly involved in apoptosis, an important
process in both AD and PD pathophysiology.35,36
The third visualization renders the results of the hierarchical
clustering approach described in Chen et al. in the form of a
dendrogram, enabling deterministic pathway grouping based on
gene set similarity. We used this view in the PDgset example to
assign the pathways without module membership to the closest
module (Supplementary Figure S2). The dendrogram proposed
merging three previously unassigned pathways into M2 (i.e.,
Allograft Rejection, MAPK Signaling pathway, and Rasp1 signaling
pathway). Additionally, the resulting dendrogram from clustering
revealed hierarchical relationships between pathways (e.g., Pink/
Parkin Mediated Mitophagy is a subset of the Reactome
Mitophagy pathway), information that can be used to establish
pathway mappings, as we show in the following case study.
Case study III: establishing mappings between pathway databases
ComPath, as well as other tools, have demonstrated the benefits
of integrating pathway knowledge from diverse resources to
improve biological functional analysis.9,10,18 However, even after
overcoming the technical hurdle of harmonizing different formats
used by different databases, these integrative approaches must be
complemented by mappings at a pathway level in order to have
cross references between databases; thus, improving their
interoperability. Such information could then be used to first link
related pathways and then investigate their interplays, explore the
consistency of their boundaries, calculate their discrepancies and
agreements, or simply contextualize the knowledge around a
certain biological process.
In order to address this, ComPath introduces a curation
environment in which users from the scientific community can
propose and maintain a collection of established mappings
between pathways from various databases. This laborious task is
facilitated by the interactive visualizations (i.e., a dendrogram view
and a similarity landscape heatmap) presented in the previous
case studies as well as dedicated pathway pages where the
content, descriptions, references, and the established mappings
can be examined (Fig. 4a). Furthermore, ComPath suggests the
most similar pathways based on this information so users can
propose new mappings. This new mappings are included into the
mapping catalog that serves as a search interface as well as a
distribution platform for mappings (Fig. 4b). In addition, the
mapping catalog promotes community engaging incorporating a
voting system where authenticated users can agree or disagree on
mappings; this way, proposed mappings with a net sum of votes
>3 are automatically registered as accepted.
After an exhaustive investigation of all possible mappings
between pathways in KEGG, Reactome, and WikiPathways (see
Methods), we identified 58 equivalencies between KEGG and
Reactome, 64 between Reactome and WikiPathways, and 55
between KEGG and WikiPathways. Of these equivalent pathways,
21 are shared between the three resources (Fig. 5 and
Supplementary Table 4). We also identified 247 hierarchical
relationships between KEGG and Reactome, 597 between KEGG
and WikiPathways, and 564 between Reactome and WikiPathways.
After considering these, approximately 26% of KEGG, 70% of
Reactome, and 35% of WikiPathways did not share any mappings
with any other database (Supplementary Figure S4). The high
uniqueness observed in Reactome could be attributed to several
factors: its small pathway sizes, its high granularity, and its high
coverage of HGNC (Fig. 2a).
The results of this curation effort are distributed at
https://github.com/ComPath/resources and https://compath.scai.
fraunhofer.de/ so they can be revised, updated, and exploited by
the research community hoping that this work serves as a first
endeavor towards unifying pathway knowledge.
DISCUSSION
The lack of a lingua franca in systems biology hampers the
harmonization that would enable the exploration of the coverage,
agreements, or discrepancies in the pathway knowledge. Harmo-
nizing this information is an important step to better comprehend
and model biology as well as improve the bioinformatics pipelines
Fig. 2 a An Euler diagram summarizing the human gene-centric coverage of KEGG, Reactome, and WikiPathways compared to the universe of
all genes from HGNC (more details in Supplementary Table 1). b Histogram views present gene promiscuity or pathway size distributions. c
The pathway similarity landscape of KEGG visualized as a heatmap
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Fig. 3 a Results of pathway enrichment using the PDgset as input using the ComPath pathway enrichment wizard. We would like to remark
that enrichment results might change over time since ComPath regularly updates their underlying pathway databases. In order to promote
reproducibility, the current version of the databases is displayed in the ComPath overview page and older versions can be provided upon
request. b The Pathway Network Viewer displays the similarity around a selection of pathways. c The Pathway Overlap View depicts the
overlaps and intersection of pathways enriched from the PDgset
D. Domingo-Fernández et al.
4
npj Systems Biology and Applications (2018)    43  Published in partnership with the Systems Biology Institute
Fig. 4 a The pathway info view introduces basic pathway information such as its participating molecular entities, references, or mappings and
enables automatic mapping suggestions based on different similarity metrics. Furthermore, the mappings of the selected pathway can be
visualized with a dynamic view that enables exploration of multiple levels of its hierarchy (Supplementary Figure S3). b The mappings view
allows users to browse established mappings, propose new mappings, and give feedback on putative mappings
D. Domingo-Fernández et al.
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that utilize this knowledge to elucidate biological insights. As a
first step towards closing this gap, we have implemented an
environment capable of accommodating the pathway knowledge
from multiple databases in order to facilitate its exploration and
analysis through a web application. The flexibility of ComPath
enables the incorporation of additional databases as well as
dynamic update of its resources; the latter of which is often
neglected, but can have a significant effect on derived analyses.37
Additionally, an embedded curation interface allow users to curate
and establish mappings between pathways. Accordingly, we used
ComPath to conduct extensive curation work to link the pathways
from three major pathway databases in order to evaluate their
similarities and differences. This mapping catalog serves as a first
effort towards unifying and linking pathway information across
databases that can later be adopted by the original databases or
to create ontologies that store these mappings. Because
databases regularly add new pathways and update gene
identifiers, we plan to update ComPath biannually as well as
curate mappings for these newly added pathways – current
mappings do not have to be updated since the focus of the
pathway does not change.
The common genes between KEGG, Reactome, and WikiPath-
ways covered the majority of pathways, indicating that their
pathway knowledge is partially biased towards this shared gene
set, even while there are still thousands of genes that have not yet
been functionally annotated to pathways. Furthermore, our
curation effort revealed that a surprisingly low number of
pathways (21) were equivalent between KEGG, Reactome, and
WikiPathways. On the other hand, the number of mapped
pathways increased significantly when the hierarchical mappings
were considered, revealing the inconsistent granularity employed
to delineate pathway boundaries.
Although the absence of topological pathway information in
ComPath is an irrefutable limitation in this study, gene-centric
approaches enable a reduction of complexity in pathway
comparison as well as integration of resources which do not
provide topology information.10 Furthermore, recent studies
revealed significant differences across a large sample of
topology-based pathway analysis methods,38 and highlighted
that gene sets alone might be sufficient to detect an enriched
pathway under realistic circumstances.39 Hence, even if the
abstraction of pathways as gene sets might not exploit all the
existing pathway information, it is sufficient to drive an investiga-
tion of the pathway knowledge.
The established inter-database mappings allowed to link
pathways from three major databases, opening the door towards
a better integration of the pathway knowledge. In the future,
these links can be used to complement and fill pathway
knowledge as well as to conduct a precise evaluation of
equivalent or related pathways by exploiting the available format
converters such as the converter from Reactome to WikiPath-
ways.40 Furthermore, ComPath have been designed to accom-
modate multiple types of molecular entities participating in
pathways (i.e. Reactome chemical information); thus, enabling to
replicate the analyses presented with lipid or metabolite
databases such as LIPEA41 or HMDB.42
In summary, we demonstrated that ComPath serves as an
exploratory, analytic, and curation framework for pathway
databases. Furthermore, we showed how the ComPath web
application can complement enrichment approaches to elucidate
and prioritize pathways and genes related to interesting biological
phenomenon. Finally, we hope that the implementation of a
curation ecosystem and the first mapping efforts conducted in
this work pave the way towards unifying the pathway knowledge.
METHODS
ComPath framework
At its core, ComPath is a framework for integrating pathway and gene set
databases. We defined a set of guidelines for implementing wrappers
around the processes of downloading data, transforming it into a common
data model, and making queries. These guidelines are encoded in an
abstract class with the Python programming language such that new
plugins can be quickly implemented for new resources. Each implementa-
tion must have a mapping between genes and pathways as well as
functions for exporting pathways as gene sets, performing pathway
enrichment analysis, and performing reasoning/inference over pathway
hierarchies.
Compath plugins
We implemented plugins for four major public pathway databases: KEGG,
Reactome, WikiPathways, and MSigDB.1–4 They can be used individually as
a way of extracting, updating, and exploring the pathways contained
within the database. Additionally, they can be used jointly in the ComPath
web application where the pathways from multiple databases are
integrated for their exploration, analysis, and curation.
ComPath web application
The web application was implemented in the Python programming
language using the Flask microframework and a suite of its extensions. The
compatibility between Flask and the data models defined in all pathway
plugins allows the integration and harmonization of the pathway
knowledge in an extensible manner. To illustrate the flexibility of ComPath,
we have included plugins for the Alzheimer’s disease and Parkinson’s
disease gene sets associated with disease-specific mechanisms from
NeuroMMSig43 in the public version of the ComPath web (https://compath.
scai.fraunhofer.de/).
ComPath leverages a variety of state-of-the-art libraries for visualization
and exploration of pathway knowledge. We chose Bootstrap for the design
of the website since its responsive design retains full compatibility across
all devices. Interactive visualizations are generated using several Javascript
libraries, including D3.js, Clustergrammer.js,24 and Cytoscape.js.44
We implemented a RESTful API documented with an OpenAPI
specification that can be accessed through the ComPath instance released
at https://compath.scai.fraunhofer.de/apidocs. The API enables users to
programmatically extract mapping information and perform queries using
different genes or pathways identifiers.
Code availability
The source code for ComPath and its plugins can be found on GitHub
(https://github.com/ComPath and https://github.com/Bio2BEL) under the
MIT license. Both the plugins and the web application can be installed with
Fig. 5 Venn diagram illustrating the overlaps of equivalent path-
ways between KEGG, Reactome, WikiPathways resulting from the
curation exercise. Note: the number of overlapping pathways in the
Venn diagram do not exactly match the number of equivalent
mappings since there are equivalent pathways within WikiPathways
that, when mapped to another database, could have more than one
equivalent pathway. For example, there are two equivalent Wnt
signaling pathways in WikiPathways that are both mapped to their
corresponding Reactome pathway. This is resolved to a unique in
the Venn diagram. A list of intra-database equivalent pathways is
presented in the Supplementary Table 3
D. Domingo-Fernández et al.
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PyPI (https://pypi.org), the main packaging system for Python. Further-
more, we have included a Dockerfile to enable reproducing the ComPath
environment with Docker (https://www.docker.com/). Finally, documenta-
tion is included in each GitHub repository and it is also accessible at Read
the Docs (https://readthedocs.org).
Estimating pathway similarity
While a variety of indices (e.g., Jaccard, Sørensen–Dice, Tversky) have been
used to assess the similarity between sets, the Szymkiewicz-Simpson
coefficient (Eq. 1) is most appropriate for comparing sets widely varying in
size. Similarly to previous studies, we have chosen this index to not only
calculate pathway similarity but also reveal contained pathways (i.e., when
most of the nodes from a small pathway are in a larger pathway) to
indicate potential hierarchical relationships.10,45–47
S X;Yð Þ ¼ X \ Yj jmin Xj j; Yj jð Þ
Equation 1. The Szymkiewicz-Simpson coefficient calculates the similarity
between two sets (X and Y) where 0 ≤ S ≤ 1. The similarity is the size of the
intersection of the two sets divided by the size of the smaller.
Curation of pathway mappings
Here, we describe a semi-automatic curation procedure we used in order
to systematically generate equivalency and hierarchical mappings
between the human pathways originating from KEGG, Reactome, and
WikiPathways. Here, it is important to note that we have only focused on
generating mappings for the pathways originating from each of the three
resources, not their imported pathways from other databases (e.g.,
WikiPathways imported Reactome pathways that are evidently equivalent
to the ones in Reactome). First, we define two types of mappings:
1. equivalentTo. An undirected relationship denoting both pathways
refer to the same biological process. The requirements for this
relationship are:
● Scope: both pathways represent the same biological pathway
information.
● Similarity: both pathways must share at minimum of one
overlapping gene.
● Context: both pathways should take place in the same context
(e.g., cell line, physiology).
2. isPartOf. A directed relationship denoting the hierarchical relation-
ship between the pathway 1 (child) and 2 (parent). The require-
ments are:
● Subset scope: the subject (pathway 1) is a subset of pathway 2
(e.g., reactome pathway hierarchy).
● Similarity: same as above.
● Context: same as above.
We generated all possible mappings between pathways in each
database (KEGG-WikiPathways, KEGG-Reactome, and WikiPathways-Reac-
tome) and prioritized them based on the follow two independent metrics
that have been proposed to calculate pathway similarity:10
1. Lexical similarity between each pair of pathways' names was
calculated using the Levenshtein distance.48
2. Content similarity between each pair of pathways' genes was
calculated using the previously described Szymkiewicz-Simpson
coefficient.
After prioritization, our three curators from different areas of expertize
(neuroscience, medicine, and biology) independently evaluated both
similarities and the scope and context included in the pathway
descriptions to assign the mapping types and to remove false positives.
Furthermore, we investigated possible intra-database mappings within
KEGG and WikiPathways since these resources do not yet contain
hierarchical relationships. Finally, our curators combined the results and
re-evaluated them to generate a consensus mapping file. It is available at
https://github.com/ComPath/resources under the MIT License.
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Conclusions
We have developed ComPath, a flexible framework for harmonizing and integrat-
ing key molecular players such as gene and chemical sets curated in pathway
databases. ComPath is complemented with a web application [119] that accom-
modates heterogeneous data to enable the exploration, analysis, and curation of
pathway knowledge. The web application offers i) analytical functionalities to
conduct pathway enrichment, ii) novel visualizations to investigate overlap and
crosstalk, both at the database and pathway level, and iii) a community-driven
interface to curate inter-database pathway mappings. We illustrate the utility of
ComPath by analyzing pathway crosstalk using PD hallmark genes and by curat-
ing the first mappings across three of the major pathway databases (i.e., KEGG,
Reactome, and WikiPathways) [17, 20, 118].
While related pathways can be found in disparate resources, the biomedical
community can greatly benefit from a pathway catalogue which establishes the
degree to which pathways in one resource are related to those in another. The
dataset curated in this work fills this void by connecting three of the major pathway
databases and enables systematic approaches to compare and investigate similarity
across specific pathways or databases. Finally, it provides the first overview of
the diversity in the pathway representations captured across the three databases.
Thus, highlighting the importance of connecting pathway resources to provide a
global and comprehensive picture of pathway knowledge.
35
36
3 PathMe: Merging and exploring
mechanistic pathway knowledge
Introduction
In parallel to the development of pathway databases during the last decades,
numerous formats have been proposed to formalize pathway knowledge. This
variety of formats enables curators to represent pathways optimally for their spe-
cific research questions. However, this presents a major roadblock to integrative
approaches. Though frameworks such as Pathway Commons [25], graphite [63],
and OmniPath [62] have integrated information from multiple pathway databases,
they do not harmonize their heterogeneity in multi-scale biological entities and
relationships. Accommodating this complementary information into a common
schema is instrumental to provide a comprehensive view of the pathway land-
scape. This becomes even more evident when existing databases contain largely
non-overlapping set of pathways, as we have shown in the previous chapter.
This challenge prompted us to develop PathMe, a sophisticated software that
harmonizes pathway knowledge using BEL as an overarching and integrative
schema.
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Abstract
Background: The complexity of representing biological systems is compounded by an ever-expanding body of
knowledge emerging from multi-omics experiments. A number of pathway databases have facilitated pathway-centric
approaches that assist in the interpretation of molecular signatures yielded by these experiments. However, the lack of
interoperability between pathway databases has hindered the ability to harmonize these resources and to exploit their
consolidated knowledge. Such a unification of pathway knowledge is imperative in enhancing the comprehension and
modeling of biological abstractions.
Results: Here, we present PathMe, a Python package that transforms pathway knowledge from three major pathway
databases into a unified abstraction using Biological Expression Language as the pivotal, integrative schema. PathMe is
complemented by a novel web application (freely available at https://pathme.scai.fraunhofer.de/) which allows users to
comprehensively explore pathway crosstalk and compare areas of consensus and discrepancies.
Conclusions: This work has harmonized three major pathway databases and transformed them into a unified schema
in order to gain a holistic picture of pathway knowledge. We demonstrate the utility of the PathMe framework in: i)
integrating pathway landscapes at the database level, ii) comparing the degree of consensus at the pathway level, and
iii) exploring pathway crosstalk and investigating consensus at the molecular level.
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Background
The interpretations of molecular signatures that are typic-
ally yielded by genome-scale experiments are often sup-
ported by pathway-centric approaches through which
mechanistic insights can be gained by pointing at a set of
biological processes. Thus, parallel to the development of
novel data-driven approaches, pathway databases emerged
as comprehensive resources that could be used to comple-
ment analyses with prior knowledge. These resources have
embraced standard file formats and schemata in order to
facilitate the exchange of pathway knowledge. However,
each resource has chosen a different one and though these
formats possess overlapping capabilities to produce com-
putational models of biology, their intended purposes and
applications are somewhat distinct. For instance, Systems
Biology Markup Language (SBML) is a standard for the
representation of computational models of systems biol-
ogy, Systems Biology Graphical Notation (SBGN) facili-
tates the storage and exchange of signaling pathways,
metabolic networks and gene regulatory network informa-
tion, and Biological Pathway Exchange (BioPAX) has been
designed with the purpose of establishing a common ex-
change format for biological pathway data [12, 25, 31]. A
variety of formats offer the scientific community multiple
approaches to curate pathway knowledge. However, a
multitude of diverse formats and a lack of interoperability
between them tends to hamper efforts to collate the
knowledge contained in pathway databases. In practice,
this has led to the generation of data silos derived from
the gradual detachment of complementary work from
different research groups which use distinct modeling lan-
guages. Therefore, metadatabases such as Pathway Com-
mons [9] and ConsensusPathDB [26], which incorporate
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several different primary resources in their data ware-
houses, and integrative software applications such as
graphite [37] and OmniPath [41] have been created with
the primary intention to integrate pathway knowledge
from multiple databases. Beyond these, other approaches
such as those taken in PathCards [4], RaMP [45], and
ComPath [14], have focused on integrating gene sets and
chemical knowledge related to pathways, but without in-
cluding their topological information (i.e, relationships
were excluded from the network). For instance, ComPath,
the precursor of this work, harmonized pathway informa-
tion at the gene level in order to conduct extensive man-
ual curation that mapped and cross-referenced pathway
representations across databases. This mapping catalog re-
veals which pathways are covered by which database (e.g.,
pathway in resource X is equivalent to pathway in re-
source Y) and facilitates comparing the results of pathway
enrichment methods.
The representation of pathway knowledge can span sev-
eral scales including molecular events, cellular processes
and/or phenotypes, which are captured in varying degrees
by integrative resources. For example, ConsensusPathDB
and graphite effectively account for and harmonize metab-
olites, genes, and proteins when integrating pathways
from multiple databases, but exclude biological types at
higher order scales, such as biological processes, and other
entities, such as miRNAs. On the other hand, Pathway
Commons can incorporate multiple scales of biology by
retaining original entity identifiers; however, it does not
directly harmonize biological entities.
An ongoing challenge in harmonizing pathway re-
sources is the use of distinct nomenclatures by individual
databases. For example, for gene and gene products there
exist several standard terminologies such as ENTREZ
[32], UniProt [2], Ensembl [24], and HGNC [35], or for
chemicals, ChEBI [21], ChEMBL [18], and PubChem [6].
Despite the availability of standard terminologies, some
resources still assign biological entities and concepts to in-
ternal database identifiers. Therefore, mappers are neces-
sary to normalize identifiers and facilitate resource
harmonization (van [42]). Similarly, the harmonization of
biological relationships is required to unify heterogenous
networks. While several format translators can convert in-
teractions across formats [5, 7, 13, 20, 44], the process of
harmonizing relationships, or edges in pathway networks,
is not trivial; thus, hampering an integrative approach
comprising several databases.
Just as pathway databases should be regularly updated to
incorporate continual changes in pathway definitions, path-
way metadatabases should also be updated in parallel to re-
flect such changes; it has been shown that by using
outdated resources, results of studies are strongly influ-
enced, and follow-up studies are negatively impacted [43].
Correspondingly, approaches to harmonize pathway data
also require these considerations or they too would be sub-
ject to similar liabilities. Moreover, pathway analysis soft-
ware have been recently complemented with user-friendly
exploratory tools and applications such as Pathway Com-
mons, PathVisio [29], Cytoscape.js [17], or NDEx [36],
which have been specifically designed for the visualization
of individuals pathways and biological networks, including
at a finer, more granular level. While the scientific commu-
nity has greatly benefited from the development of these
tools, there is still the need to develop applications that
focus on visualizing the consensus and crosstalk between
multiple, disparate pathway representations. While previ-
ously mentioned attempts have succeeded in accumulating
and increasing the availability of database content, there
has not yet been a systematic evaluation that investigates
the degree of overlap or the amount of agreements/discrep-
ancies in related or equivalent pathways from different da-
tabases. Previous comprehensive comparisons of database
content were restricted to single or small sets of pathways
because of the considerable amount of manual intervention
(e.g., entity/relationship normalization, image reconstruc-
tion, etc.) required to shed light on the degree of overlap of
equivalent pathways [11, 39]. Conversely, conducting a sys-
tematic comparison requires harmonization of entities and
biological interactions across databases and minimizing
pathway information loss whilst accommodating databases
into an interoperable schema (i.e., retain most of the differ-
ent biological abstractions that each database offers in the
transformation process). Finally, connecting and integrating
pathway knowledge can enhance pathway enrichment ana-
lyses, as has already been demonstrated in a more simplistic
approach by Minadakis et al., as well as drive curation and
new experimentation by highlighting the consensus,
discrepancies, and unexplored areas of the pathway
landscape.
Here, we introduce PathMe, an extensible package that
harmonizes multiple databases using Biological Expression
Language (BEL) as a common interoperable schema and
enables pathway knowledge evaluation and exploration
powered by a stand-alone web application with a special
focus on highlighting pathway crosstalks and consensus.
Implementation
PathMe framework is comprised of two parts: the open-
source Python package that converts the different database
formats into BEL and the web application that allows for
the exploration of the resulting networks (Fig. 1).
The PathMe Python package
Integrating knowledge across pathway databases
Integrating pathway knowledge from multiple databases
first requires transforming the content of each database
into a common underlying schema. While multiple
triple-based formats can be used to formalize pathways
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in system biology, we adopted BEL as the pivotal unify-
ing schema since it provides a reasonable trade-off be-
tween expressivity and standardized organization. Until
now, we have implemented parsers for three major data-
bases (i.e., KEGG, Reactome, and WikiPathways [15, 27,
38]) that extract pathway information and serialize it to
BEL. As the principal goals of PathMe are to enable dir-
ect comparisons and explorations of pathways from dif-
ferent databases, cross-database mappings of identifiers
and relation types are required. Accordingly, the parsers
harmonize molecular entities to identifiers from stand-
ard nomenclatures as well as interaction types into their
corresponding BEL relationships.
In order to harmonize entities, we prioritized standard
nomenclatures for each of the modalities (e.g., genes, pro-
teins, metabolites, etc.) included in the three studied data-
bases (Additional file 1: Tables S1, S4, and S6). HGNC was
the top-level priority namespace for genes and gene prod-
ucts [35]. HGNC was selected as it is recognized as an au-
thority for standard nomenclature assignments and
annotations for human genes and because the software is
primarily concerned with converting human pathways. In
the absence of HGNC identifiers, lower level priority name-
spaces were used to derive the top level HGNC identifier
assignment. For instance, we aimed to use intermediate
level UniProt identifiers [2] to map back to HGNC identi-
fiers. If mappings to the prioritized namespaces were not
available, genes and gene products retained their database-
specific identifiers and were assigned to namespaces desig-
nated by their respective databases in order to maximize
the retrieval of entities from each resource. Similarly,
metabolites were prioritized to preferentially obtain ChEBI
identifiers because of ChEBI’s wide usage as a source of
manually curated stable identifiers and annotations for
small chemical compounds [21]. In their absence, either
PubChem identifiers were assigned or, once again, they
retained their database-specific identifiers. Once entities
were assigned to standardized identifiers, the modalities de-
fined by the source databases were mapped to their corre-
sponding BEL node classes (e.g., gene, protein, metabolite,
biological process, etc.). Efforts were made to accommodate
entities not readily mappable to BEL nodes by using BEL
node classes which can incorporate flexibility in their defi-
nitions. For instance, unspecified physical entities in Wiki-
Pathways are given the abstract class label, ‘DataNode’;
these ‘DataNodes’ were mapped to BEL abundances, a cat-
egory that represents the abundance of a biological entity
such as a chemical or an unspecified molecule. Entity class
mappings from the source databases to BEL are summa-
rized in Additional file 1: Tables S2, S5, and S7.
Similar to the normalization of biological entities into
a standardized nomenclature and their translation into
corresponding BEL entity classes, distinct relationships
utilized in the biological networks of different databases
must too be normalized. While the versatility of BEL
permitted the successful transformation of all relation-
ships from Reactome and WikiPathways, four KEGG re-
lationships (i.e., hidden compound, state change,
dissociation, and missing interaction) could not be trans-
lated into BEL due to the lack of correspondingly
equivalent edges in the BEL syntax. However, these four
relationships represent non-causal interactions between
biological entities and are also minimally utilized by
KEGG curators. Mappings between edges from the
Fig. 1 Design of the PathMe framework. The PathMe software package facilitates the transformation of pathway content into BEL. The initial step consists
of extracting, parsing, and/or querying content from each pathway database to retrieve entities, concepts, interactions and reactions, and their associated
metadata. Subsequently, database specific identifiers for all entities are unified to stable and consistent ones, where possible. Data are then directly
mapped into equivalent BEL nodes and edges, translating all human pathways from the databases into BEL. Finally, an interactive pathway viewer is
implemented such that any combination of pathways, represented as BEL networks, can be explored and the consensus surrounding pathway knowledge
can be directly compared
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source databases to BEL are reported in Additional file
1: Tables S3, S5 and, S7.
Implementation details
PathMe relies on the individual parsers that convert the
original formats from the databases to BEL. Each parser is
implemented using libraries that enable the manipulation
and transformation of its corresponding schemata (i.e.,
RDFLib for Resource Description Framework (RDF) and
the xml Python package for Extensible Markup Language
(XML)). Moreover, the parsers are structured into their
own packages inside the main Python module to facilitate
the inclusion of additional database parsers in the future.
During the entity normalization process, mappings across
identifiers are facilitated through the numerous packages
included in the Bio2BEL framework (https://github.com/
bio2bel) (Additional file 1: Table S9). After the
normalization, entities and their relationships in each
pathway are translated to BEL using the internal domain
specific language (DSL) and the BELGraph class of the
PyBEL Python software package [22]. PathMe benefits
from the numerous modules implemented in the PyBEL
ecosystem since it offers a variety of functionalities and al-
gorithms that enable querying, transforming, and analyz-
ing biological networks, as well as an export module that
can output multiple formats. Finally, PathMe is distributed
as a Python package through Python Package Index (PyPI)
and its source code is available in GitHub at https://
github.com/PathwayMerger/PathMe.
PathMe viewer
A web application to explore pathway knowledge
As discussed in the introduction, several visualization tools
have focused on the exploration of biological networks, but
have never attempted to study or evaluate the coverage,
consensus, and crosstalks across heterogeneous networks.
Since the particular use case of this work called for custom-
ized solutions (e.g., delineating boundaries or highlighting
agreements when multiple pathways are being visualized),
we also implemented a novel tool called PathMe Viewer to
fulfill these unmet needs and complement the PathMe
package. Since the target audience for this application are
pathway curators and researchers, we opted to implement
the viewer in the form of a user-friendly web application
compatible with any device. The front-end extends the vi-
sualizations from BEL Commons [23] and provides an in-
tuitive and interactive interface for visualizing and
exploring the knowledge comprised in the pathway land-
scape. Moreover, the web application is complemented with
analysis modules and network algorithms to query path-
ways or calculate their similarity as well as exporting
options to multiple standard formats such as BEL,
GraphML, or JSON so networks can be used in other soft-
ware designed for visualization purposes such as Cytoscape
[17] or advanced algorithmic analyses such as SPIA [40]. Fi-
nally, the network visualization is a stand-alone component
within the web application and it remains agnostic to BEL
by rendering the graphics using the Node-Link JSON data
format, a standard format used by popular visualization li-
braries; thus, facilitating the reusability of the component
out of the BEL community.
Implementation details
PathMe Viewer follows a model-view-controller (MVC)
software architecture. While the back-end is implemented
in Python using the Flask microframework, the front-end is
implemented in JavaScript using libraries such as jQuery
(https://jquery.com), D3.js (https://d3js.org), and Bootstrap
(https://getbootstrap.com). The source code is available at
https://github.com/PathwayMerger/PathMe-Viewer so that
all visualizations and components can be reused or ex-
tended by future applications. Furthermore, the web appli-
cation is distributed through PyPI and can also be deployed
with Docker which facilitates the reproducibility of this
work since Docker’s automated deployment process en-
sures that every single instance runs with the exact same
settings, regardless of the host machine. Documentation is
included in the GitHub repository and it is also accessible
through Read the Docs (https://pathme-viewer.readthe-
docs.io/en/latest/). Finally, we provide access to a public de-
ployment of the PathMe Viewer at https://pathme.scai.
fraunhofer.de.
Calculating pathway similarity
As an application of the software, we conducted the follow-
ing protocol to evaluate the degree of overlap between the
three representations of each equivalent pathway (Case sce-
nario II). We used a variation of the Szymkiewicz–Simp-
son/Overlap coefficient (Eq. 1), calculated for common
molecular nodes shared between the networks. To calculate
a pathway similarity index, we summed the three coeffi-
cients obtained for each individual pairwise comparison
and divided this number by three to normalize to a
zero-to-one scale. In other words, each pathway similarity
index corresponds to a normalized sum of the individual
overlaps between: i) the KEGG and Reactome representa-
tion, ii) the KEGG and WikiPathways representations, and
iii) the Reactome and WikiPathways representations.
Therefore, the pathway similarity index (S) lies between 0 ≤
S ≤ 1 (with 0 corresponding to no overlap between any of
the three sets, and 1 corresponding to three fully overlap-
ping sets).
S X;Yð Þ ¼ j X∩Y j
min jXj; jY jð Þ ð1Þ
Equation 1 The Szymkiewicz-Simpson coefficient cal-
culates the similarity between two sets (X and Y) where
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0 ≤ S ≤ 1. The similarity is the size of the intersection of
the two sets divided by the size of the smaller set. In this
case, the sets correspond to the number of individual
molecular entities excluding group nodes in the BEL
graph, this is discussed in detail in the Additional file 1.
Results
In the first two sections, we present the main functional-
ities of the PathMe software and web application re-
spectively, while the following section outlines the
architecture and design of the framework. Next, three
case scenarios applied at increasingly granular scales of
pathway knowledge are presented to illustrate the usabil-
ity of the framework in database integration from a glo-
bal, database-wide perspective to a detailed, path way
level one.
PathMe functions
The PathMe package offers a set of functionalities for the
set of databases incorporated thus far: i) download the raw
pathway files, ii) generate BEL networks and export them
as binary data, iii) summarize the transformed content,
and iv) calculate detailed network statistics (e.g., number
of nodes, edges and their types) (Table 1). Moreover, data-
base specific features include functionalities to flatten all
group nodes (e.g., protein complexes, gene families, etc.)
in KEGG and exclusively parse canonical pathways from
WikiPathways and Reactome. In conclusion, these func-
tionalities combined with the ones already offered by the
PyBEL ecosystem assist bioinformaticians in transforming,
exploring, and analyzing the generated pathway networks.
PathMe viewer
Beyond the software concerned with the integration of
pathway knowledge, a novel web application (i.e. PathMe
Viewer) was implemented for intuitive querying, brows-
ing, and navigating of the normalized BEL networks.
Queries can be submitted for a single or a set of pathways
on the main page of the viewer, as illustrated in Fig. 2a.
The result of the query leads to a visualization, as seen in
Fig. 2b, that renders the corresponding network.
The PathMe Viewer is powered by multiple, built-in
functionalities enabling users to navigate through the
pathway(s). Although the initial network layout is de-
fined by the D3 force algorithm which enables users to
get a comprehensive overview of the relevant parts of
the network, the network arrangement can also be cus-
tomized by dragging and moving nodes around the
viewer. Furthermore, node and edge meta-information
can be accessed via double click. For nodes, this includes
specifications on their name, function and namespace,
while for edges, the pathway name, identifier and source
database are provided. When multiple pathways are
queried, marked boundaries delineate the topological
landscape of each of the networks which synergistically
contribute to the consolidated one to facilitate the ex-
ploration of pathway crosstalks (i.e. the interaction of
pathways through their sharing of common entities)
(Fig. 2b). Furthermore, search and mining tools enable
navigation of the resulting network such as selecting and
filtering nodes/edges or calculating paths. Another novel
feature of the viewer is the automatic identification of
contradictory and consensus relationships across path-
ways (i.e., edges between identical nodes with equivalent
or opposite relationship), which are highlighted in blue/
red in the network. The viewer also incorporates a func-
tionality which collapses all BEL proteins, RNA species
and genes into gene nodes. This function was included
in the viewer because of the interchangeable usage of
these entities by the various databases which would both
preclude the ability to fairly establish if there is overlap
in the network topology and to conduct fair compari-
sons. Finally, network algorithms such as betweenness
centrality can be used to quickly identify central nodes
in the network or to calculate pathway similarity as we
will present in the case scenario.
Software development techniques
Successful contributions to the bioinformatics domain
are predicated by their ability to be replicated and
reused. In line with community standards designed to
foster these attributes, the PathMe and PathMe-Viewer
packages use git (https://git-scm.com) for version con-
trol on GitHub (https://github.com), flake8 (https://
github.com/PyCQA/flake8) to enforce code quality,
setuptools (https://github.com/pypa/setuptools) to build
distributions, pyroma (https://github.com/regebro/pyr-
oma) to enforce package metadata standards, sphinx
(https://github.com/sphinx-doc/sphinx) to build docu-
mentation, Read the Docs (https://readthedocs.org) to
Table 1 Core functions of the PathMe Python package
Function Description
Download Downloads the pathway files from the original source
BEL Converts the original pathway files to BEL
Summarize Presents global statistics of the total number of nodes and edges converted to BEL
Statistics Creates an excel sheet that summarizes the results of the BEL conversion for every pathway
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host documentation, pytest (https://github.com/pytest-
dev/pytest) as a unit and integration testing harness, and
Travis-CI as a continuous integration server to run each
of these with each commit (https://travis-ci.com/
PathwayMerger/PathMe and https://travis-ci.com/
PathwayMerger/PathMe-Viewer). Each package is dis-
tributed publicly through PyPI such that they can be in-
cluded in other Python projects with requirements.txt or
included in the setup.py using the install_requires setting
without the need for complicated build steps or any
other user configuration.
Because PathMe works on frequently updated external
pathway data from multiple sources, it must be re-run
frequently to incorporate those updates. Following the
recommendation from Kim et al. [28] for building repro-
ducible environments for bioinformatics, we have encap-
sulated the entire PathMe workflow of acquiring,
parsing, mapping, and normalizing the pathway re-
sources within a Docker container such that it can be
run on a cron job (i.e. a task scheduled to be re-run
periodically). After, these changes are incorporated into
the publicly available instance of the PathMe-Viewer.
The cron job has the additional benefit that it reports
when the formats of the underlying data change (which
happens with moderate frequency) so the relevant
PathMe components can be adapted. Also following the
recommendation from Kim et al. for the scientific aspect
of reproducibility, the three application scenarios pre-
sented in the next sections were conducted in IPython
notebooks that are available and documented on GitHub
(https://github.com/PathwayMerger/PathMe-Resources)
that illustrate useful commands that might serve to as-
sist similar future analyses.
Case scenario I: global entity comparison across pathway
databases
As a first application, we conducted a global comparison
of biological entities across major modalities (Fig. 3). We
would like to note that in order to ensure the quality of
the comparison presented in this case scenario, this ana-
lysis exclusively uses a highly cited and peer-reviewed
pathway set provided by WikiPathways (approximately
510) that has been approved and tagged for usability in
data analysis. While we attempted to maximize the re-
tention of biological entities, we found severe differences
in the level of overlap across resources which demon-
strates the importance of database integration to gain a
holistic picture of pathway knowledge.
The degree of consensus of biological entities across all
three databases was found to be relatively low, albeit vari-
able across the assessed modalities (Fig. 3). The propor-
tion of genes present in all databases was lower than the
results obtained by Stobbe et al. (15%), though they exclu-
sively focused their work on a set of metabolic pathways
present in five major databases which included KEGG and
Reactome. Total consensus of miRNAs in all three
databases was unsurprisingly low due to a disproportion-
ate representation of miRNA species across the databases.
Specifically, as few as 13 miRNAs were derived from Reac-
tome while 149 were present in KEGG. Similarly, the total
consensus for metabolites was grossly deficient at less
than 2%.
For partial overlap, we found that results varied across
the three modalities, with a higher degree of overlap be-
tween miRNA species at approximately 30%, followed by
genes with nearly 20%, and metabolites with approxi-
mately 11%. Accordingly, we found the proportion of
Fig. 2 a PathMe Viewer main page. b The merged mTOR signaling network from KEGG, Reactome, and WikiPathways visualized in the PathMe Viewer.
The highlighted regions mark the boundaries of each of the networks to definitively identify pathway landscapes, as defined by each of the
network sources
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distinct entities to be substantially higher than those
present in any two or all three databases. The particu-
larly low levels of overlap observed in all modalities can
be largely attributed to several factors:
1. The number of entities per modality across
databases is highly variable (Table 2). Per
definition, sets with significant variations in
cardinality (i.e., set size) limit the likelihood of
consensus since only a portion of the larger sets
can intersect with the smaller ones. For instance,
KEGG contains 4048 metabolites while
WikiPathways only contains 655. Accordingly,
the maximum number of metabolites that can
be common among them is limited to the number
of metabolites contained in WikiPathways
(i.e., 655). In this case, the maximum overlap
would be the total number of metabolites
contained in WikiPathways divided by the total
number contained in KEGG, or 16.18%. Thus,
the maximum degree of consensus between
databases can be constrained by databases
which contain fewer entities.
2. The scope of the pathways comprised in each
database varies. Each database places a distinct
emphasis on discrete aspects or regions of
biological pathways which tend to be defined
subjectively in the absence of standard
nomenclatures, as outlined by [14] who reported
only 21 equivalent pathways between the three
databases. Therefore, despite the presence of key
biological players in all three databases, the
majority of biological entities are particular to
a single database. For example, over 200 glycan
molecules are present in KEGG since this
resource contains multiple pathways related to
glycan metabolism (i.e., ‘Glycan biosynthesis and
metabolism’) while they are absent in the others.
3. Highly specific entity identifiers impede entity
mappings with major standard nomenclatures.
Some entity identifiers have no discernible mapping
Fig. 3 Overlapping entities across modalities in the three databases studied (i.e., KEGG, Reactome, and WikiPathways). The comparison analysis studied
the degree of overlap for three different biological entities (i.e., genes, metabolites, and miRNAs) to evaluate whether entities are shared across databases
(i.e., the ratio of the number of nodes present in all three databases to the number of nodes in the union of all databases for that modality), partially
overlap (i.e., the ratio of the number of nodes present in only two databases to the number of nodes in the union of all databases for that modality) or are
exclusive (i.e., the ratio of the number of nodes unique in one database to the number of nodes in the union of all databases for that modality). The
classification of entities by their corresponding modalities are described in Table 2. We would like to remark that the analysis accounted for every entity
present in the full set of pathways from the studied databases
Table 2 Pathway database content statistics. Each cell reflects the
unique number of entities for a given modality in its corresponding
database. The genes modality comprises genes, mRNAs, and gene
products as well as any modifications on those. The metabolites
modality comprises biological entities from small molecules to
cellular components. The miRNAs modality contains microRNA
molecules. Finally, nodes that correspond to other pathways,
molecular events, or biological processes (e.g., Gene Ontology (GO;
[8]) terms) are included in the biological processes modality. The
statistics reflect the status of the content available from KEGG and
WikiPathways from the 13th of March, 2019 and the latest
Reactome release (version 67) from the 13th of December, 2018
Modality KEGG Reactome WikiPathways
Genes 7289 8653 3361
Metabolites 4048 2712 655
miRNAs 149 13 91
Biological processes 418 2219 138
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to major standard nomenclatures because they
exhibit a high degree of specificity. This is
particularly evident for genes where curators have
also captured entities such as specific protein
events (e.g., “p-y641-stat6”), protein mutations
(e.g., “activated fgfr1 mutants”), protein families
(e.g., “lim kinases”), protein fragments (e.g., “ub
c-terminal hh fragments”), or splicing events
(e.g., “xbp1 mrna (spliced)”). A way to account for
these high granular cases would be to standardize
protein family names with resources such as Pfam
[16] or FamPlex [3]. For cases such as protein
fragments or events, BEL enables their
harmonization as they can be incorporated into
its syntax (e.g., BEL proteinModification(),
fragment(), variant(), etc.).
4. Biological modalities can be broadly defined.
We characterize modalities to correspond to
BEL node classes (Table 2). For instance, the
genes modality comprises gene, protein, and RNA
BEL nodes. While this modality is clearly defined,
there is a higher degree of variability in the entity
types that can be that can be classified with the
metabolites modality since the latter comprises a
broad range of abundance BEL nodes (i.e., small
molecules, cellular components, clinical
measurements, or categories that do not fit in
other BEL node classes; [34]). Without the use
of standard nomenclatures by the source databases,
an extensive manual effort would be required to
partition these modalities into more granular
classifications. For example, the usage of GO as
opposed to internally-defined terminologies to
define cellular components would enable the
categorization of cellular components into their
own distinct modality. Similarly, the biological
processes modality exhibits minimal overlap due
to a lack of usage of standardized ontologies
such as GO (Additional file 1).
Case scenario II: comparing equivalent pathways in the
three databases
Merging pathway knowledge enables analyzing the
crosstalks for any set of pathways through the PathMe
Viewer. As a case scenario, we used PathMe in con-
junction with the viewer to explore the knowledge
consolidated from 21 equivalent pathways across the
three databases previously curated by Domingo-Fer-
nández et al. (Table 3). While conducting a cross-data-
base pathway comparison previously required either
extensive manual curation or harmonization of both
entity identifiers and data formats on a case by case
basis, this example illustrates how PathMe can be
exploited to enable a systematic comparison of equiva-
lent pathways.
To evaluate the degree of overlap between the three
representations of each equivalent pathway, we used a
variation of the Szymkiewicz–Simpson coefficient calcu-
lated for the common molecular nodes between the net-
works (Eq. 1).
Each of the 21 equivalent pathways showed partial
overlap, except ‘Non-homologous end-joining’ which did
not contain the pathway information required to convert
the pathway into BEL in two of its original files. Among
the equivalent pathways with the highest degree of simi-
larity, we found well-studied pathways such as ‘Cell cycle’,
‘Toll-like receptor signaling’, ‘mTOR signaling’, Hedgehog
signaling’, and ‘Apoptosis’. Although the three databases
represent the most widely studied molecular players in
each of these pathways, merging their knowledge assists
in filling the gaps between the complex interactions occur-
ring in these pathways. Pathways with low similarity, such
as ‘TCA Cycle’ and ‘Sphingolipid Metabolism’, indicate the
resources captured distinct aspects of the biology within
the pathway. Unsurprisingly, this is in concordance with
the findings reported by Stobbe et al. who conducted a
comparison of the ‘TCA Cycle’ across five metabolic path-
way databases. We would like to note that while previous
approaches to characterize pathway similarity were purely
gene-centric, our approach includes not only gene sets,
but a range of modalities represented in pathways. Finally,
beyond harmonizing entities and concepts, PathMe also
harmonizes relationships, thus facilitating further analyses
where pathway topology is included, as shown in the next
case scenario.
Case scenario III: in-depth pathway analysis of mTOR
signaling after superimposing its multiple representations
As a further application of the framework, we used the
PathMe Viewer to conduct a detailed investigation of
the mammalian target of rapamycin (mTOR) signaling
pathway to demonstrate its utility in enriching pathway
knowledge. In Fig. 4, the consensus in terms of entity
overlap across equivalent mTOR signaling pathways
from each of the databases is depicted. All three data-
bases are complementary to the others, but also pos-
sess some degree of overlap and thus are neither
entirely identical nor distinct. Variability in the size of
the mTOR signaling pathway, as measured by the
number of nodes in each database, is also clearly dis-
cernible with KEGG contributing the largest propor-
tion of distinct nodes to the heterogeneous, merged
network (Fig. 4a).
A key functionality of PathMe Viewer is in the
visualization and interactive exploration of pathways. In
Fig. 5a and b, using the viewer, an in-depth analysis of
mTOR signaling reveals novel sets of interactions in
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the integrated network that are absent in individual
mTOR signaling networks. The role of AKT signaling
in modulating mTOR, as illustrated in 5a and sourced
from KEGG, has already been well-described in the lit-
erature [1, 33]. More notably, by superimposing the
mTOR signaling pathway as defined in KEGG with its
equivalent pathway from WikiPathways (Fig. 5b), an as-
sociation between AKT1 and insulin related-processes
becomes apparent in the merged network, though nei-
ther of the individual pathway sources connect the
downstream effects of mTOR on insulin signaling.
Nevertheless, the association between mTOR and insu-
lin signaling through AKT modulation has been previ-
ously described in the literature [30]. Additionally,
bidirectional effects of mTOR have been demonstrated
on AKT activity; these effects can vary both by the type
of mTOR complex involved in the pathway and by
negative feedback loops on insulin signaling, leading to
altered states of AKT activity [1, 30]. As such, both
pathways serve to complement each other in the inte-
grated network, unraveling a connection which was
hidden in disparate databases, though has been
well-studied in the literature. Recent studies have also
demonstrated that mTOR receives input from multiple
pathways [33]; a principal feature of the PathMe Viewer
is in its capacity to directly visualize pathway crosstalk.
While in the previous case scenario, crosstalk analyses
were performed across equivalent pathways, in this
case, using the viewer it would be possible to simultan-
eously visualize and explore different pathways which
are evidenced to, or are possibly involved in, crosstalk
with the mTOR signaling one.
Similarly, by superimposing the mTOR signaling
pathways from KEGG and WikiPathways, downstream
interactions between mTOR and mRNA translation via
EIF4EBP1 are evident (Fig. 5a and b). The inhibition of
mTOR has been noted to be a potent repressor of pro-
tein translation while mTOR activation can stimulate
mRNA translation through EIF4EBP1 [10, 19]. Though
only the inhibition relationship is captured in the
viewer, in the presence of an activation relationship, the
viewer also offers a feature to detect contradictory
Table 3 Consolidated pathway representations, their similarity indexes, and links to visualize the merged networks in the PathMe Viewer. A
detailed analysis with the scripts to replicate the results and comments on the identified overlaps for each of the 21 equivalent pathways is
available at https://nbviewer.jupyter.org/github/PathwayMerger/PathMe-Resources/blob/master/notebooks/case_scenarios/evaluating_
similarity_equivalent_pathways.ipynb
KEGG Reactome WikiPathways Pathway Similarity
Index
Cell cycle Cell Cycle Cell Cycle 0.70
Toll-like receptor signaling pathway Toll-Like Receptors Cascades Toll-like Receptor Signaling Pathway 0.62
mTOR signaling pathway mTOR signalling Target Of Rapamycin (TOR) Signaling 0.58
Hedgehog signaling pathway Signaling by Hedgehog Hedgehog Signaling Pathway 0.56
Apoptosis Apoptosis Apoptosis 0.43
IL-17 signaling pathway Interleukin-17 signaling IL17 signaling pathway 0.42
PI3K-Akt signaling pathway PI3K/AKT activation PI3K-Akt Signaling Pathway 0.42
Wnt signaling pathway Signaling by WNT Wnt Signaling Pathway 0.41
MAPK signaling pathway MAPK family signaling cascades MAPK Signaling Pathway 0.40
B cell receptor signaling pathway B Cell Receptor Signaling Pathway Signaling by the B Cell Receptor (BCR) 0.37
Pentose phosphate pathway Pentose phosphate pathway
(hexose monophosphate shunt)
Pentose Phosphate Pathway 0.33
Citrate cycle (TCA cycle) Citric acid cycle (TCA cycle) TCA Cycle 0.33
Synthesis and degradation of
ketone bodies
Ketone body metabolism Synthesis and Degradation of
Ketone Bodies
0.33
Notch signaling pathway Signaling by NOTCH Notch Signaling Pathway 0.29
DNA replication DNA Replication DNA Replication 0.28
Prolactin signaling pathway Prolactin receptor signaling Prolactin receptor signaling 0.28
TGF-beta signaling pathway Signaling by TGF-beta family members TGF-beta Signaling Pathway 0.26
Thyroid hormone synthesis Thyroxine biosynthesis Thyroxine (Thyroid Hormone) Production 0.20
Sphingolipid metabolism Sphingolipid metabolism Sphingolipid Metabolism 0.16
Mismatch repair Mismatch Repair Mismatch repair 0.08
Non-homologous end-joining Nonhomologous End-Joining (NHEJ) Non-homologous end joining 0
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edges (e.g., node A increases node B in one pathway
and decreases B in another) between identical nodes
across two databases.
Conclusions
Parallel developments of pathway databases during re-
cent decades have resulted in different formalization
schemas, hampering the interoperability between these
resources and creating data silos. Overcoming this obs-
tacle is instrumental to better understand the mecha-
nisms underlying pathway knowledge. Additionally,
while our approach can accommodate multi-scale path-
way information from divergent database formats into a
singular and standardized schema, a minority of entities
and interactions have no discernible equivalencies in
BEL and, as such, had to be omitted. For instance, so far
Fig. 4 Node overlap between the three pathway representations of mTOR signaling. Note that this analysis includes all modalities harmonized by PathMe
(e.g., genes, metabolites, miRNAs, biological processes). Particularly for mTOR signaling, while there are overlapping nodes between each pair of databases
and between all three, each database also contributes unique nodes to the consolidated mTOR signaling network, providing a more comprehensive
overview of mTOR signaling. In a), a more detailed analysis conducted on IPython notebooks shows the proportion of shared nodes across the three
equivalent representations. Equivalent interactive Venn diagrams can also be generated directly from the PathMe Viewer for any set of pathways, as
visualized in b)
Fig. 5 Superimposing mTOR signaling subgraphs from KEGG and WikiPathways. A deeper analysis performed using PathMe Viewer to visualize mTOR
signaling subgraphs can be seen highlighting interactions present in a KEGG only and b KEGG and WikiPathways. The contribution of WikiPathways onto
the pathway found in KEGG is highlighted in orange. Neither agreements nor discrepancies in topology are noted between these subgraphs though there
are overlapping genes (e.g., mTOR, RICTOR, EIF4EBP1, etc.). Instead, subgraph a) is complemented by additional interactions superimposed onto the
network, as visualized in subgraph b)
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PathMe parsers can extract information from both
humans and other species; however, despite the capacity
of PathMe to harmonize human identifiers, additional
work is required for the harmonization of identifiers be-
longing to other species as integration can help in iden-
tifying evolutionarily conserved genes and processes.
Here, we have presented a framework through which
content across multiple pathway databases can be inte-
grated and transformed into a unified schema. Although
PathMe currently only incorporates content from three
major pathway databases, its flexibility allows for future
inclusion of additional pathway databases. Moreover, it
holds the capacity to update its content and track devel-
opments in pathway knowledge, an issue earlier outlined
by Wadi et al.. Finally, the three case scenarios presented
illustrate how the framework can be used to assist re-
searchers in addressing biological questions at varying
degrees of specificity such as: i) integrating the pathway
landscape at the database level, ii) comparing the degree
of consensus at the pathway level, and iii) exploring
pathway crosstalk and studying consensus at the mo-
lecular level.
Ultimately, we have shown how integrating pathway da-
tabases and making them interoperable enables global
pathway representations that can contribute to a more
holistic overview of pathway knowledge than the know-
ledge contained in any single one of the databases. In the
future, these global representations could be used to
conduct more comprehensive pathway-centric analyses.
Furthermore, the reproducibility of previous pathway en-
richment analyses could also be evaluated by replicating
them using any database combination. In other words,
what would happen if, instead of KEGG, an identical ana-
lysis were to be performed using the Reactome or Wiki-
pathways databases, or any combination of the three?
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Conclusions
We have presented PathMe [120], the first tool that successfully harmonizes path-
way networks from major databases. We also implemented PathMe Viewer [121],
a complementary web application that provides comprehensive network visual-
ization of the consensus pathway knowledge. This entire framework adheres to
the same principles of flexibility and reproducibility as ComPath (chapter 2).
In the paper, we demonstrate that consolidating pathway knowledge from
multiple resources results in more comprehensive pathway representations. By
overlaying equivalent pathways across databases with the help of the mappings cu-
rated with ComPath, we were able to derive their consensus networks. From there,
we uncovered novel relationships and contradictory evidences within equivalent
pathways. Furthermore, using PathMe, we carried out a systematic evaluation of
the similarity across the pathway landscape. Previously, this entire process process
would have been done manually [61].
In the future, additional databases can be incorporated into the framework
thanks to its flexible design. Since the results of pathway-based analyses are
heavily influenced by the dynamic changes in pathway knowledge, we have also
implemented PathMe to automatically update its content [122]. Finally, this work
leaves two open questions. First, if the results of a pathway-driven analysis are
influenced by pathway choice, and second, whether the results improve by using
integrative resources versus individual databases.
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4 The impact of pathway database
choice on statistical enrichment
analysis and predictive modeling
Introduction
The abundance of pathway databases has resulted in an unintended segmentation
of knowledge. Researchers can only gain close familiarity with a small number of
these databases. As a result, they limit their attention to a popular few, and the
knowledge contained in the many other databases remains out of sight. In fact,
despite this plethora of resources, most pathway analyses are still conducted using
a single database. The choice of this database is the result of the researcher’s own
biases, preferences, and experience.
However, as illustrated in the last two chapters, not only is the overlap of
pathways across databases low, but even representations of the same biological
pathway can notably differ. Building on the success of the tools discussed in the
two previous chapters, we present the first benchmarking study evaluating the
choice of pathway database on a broad spectrum of pathway enrichment methods
and predictive modeling applications. This study demonstrates the significant
influence of database selection in the downstream results of enrichment methods
as well as in the performance of predictive models.
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The Impact of Pathway Database 
Choice on Statistical Enrichment 
Analysis and Predictive Modeling
Sarah Mubeen 1,2, Charles Tapley Hoyt 1,2†, André Gemünd 1, Martin Hofmann-Apitius 1,2, 
Holger Fröhlich 2 and Daniel Domingo-Fernández 1,2*
1 Department of Bioinformatics, Fraunhofer Institute for Algorithms and Scientific Computing (SCAI), Sankt Augustin, 
Germany, 2 Bonn-Aachen International Center for IT, Rheinische Friedrich-Wilhelms-Universität Bonn, Bonn, Germany
Pathway-centric approaches are widely used to interpret and contextualize -omics data. 
However, databases contain different representations of the same biological pathway, 
which may lead to different results of statistical enrichment analysis and predictive models 
in the context of precision medicine. We have performed an in-depth benchmarking of 
the impact of pathway database choice on statistical enrichment analysis and predictive 
modeling. We analyzed five cancer datasets using three major pathway databases and 
developed an approach to merge several databases into a single integrative one: MPath. 
Our results show that equivalent pathways from different databases yield disparate results 
in statistical enrichment analysis. Moreover, we observed a significant dataset-dependent 
impact on the performance of machine learning models on different prediction tasks. 
In some cases, MPath significantly improved prediction performance and also reduced 
the variance of prediction performances. Furthermore, MPath yielded more consistent 
and biologically plausible results in statistical enrichment analyses. In summary, this 
benchmarking study demonstrates that pathway database choice can influence the results 
of statistical enrichment analysis and predictive modeling. Therefore, we recommend the 
use of multiple pathway databases or integrative ones.
Keywords: pathway enrichment, benchmarking, databases, machine learning, statistical hypothesis testing
INTRODUCTION
As fundamental interactions within complex biological systems have been discovered in experimental 
biology labs, they have often been assembled into computable pathway representations. Because 
they have proven immensely useful in the analysis and interpretation of -omics data when coupled 
with algorithmic approaches (e.g., gene set enrichment analysis, GSEA), academic and commercial 
groups have generated and maintained a comprehensive set of databases during the last 15 years 
(Bader et al., 2006). Examples include KEGG, Reactome, WikiPathways, NCIPathways, and 
Pathway Commons (Schaefer et al., 2008; Cerami et al., 2011; Kanehisa et al., 2016; Slenter et al., 
2017; Fabregat et al., 2018).
However, these databases tend to differ in the average number of pathways they contain, the 
average number of proteins per pathway, the types of biochemical interactions they incorporate, and 
the subcategories of pathways that they provide (e.g., signal transduction, genetic interaction, and 
metabolic) (Kirouac et al., 2012; Türei et al., 2016). Pathways are often also described at varying levels 
of detail, with diverse data types and with loosely defined boundaries (Domingo-Fernández et al., 
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2018). Nonetheless, most pathway analyses are still conducted 
exclusively by employing a single database, often chosen in part 
by researchers' preferences or previous experiences (e.g., bias 
towards a database previously yielding good results and ease of 
use of a particular database) (Table 1). Notably, the selection of a 
suitable pathway database depends on the actual biological context 
that is investigated, yet KEGG remains severely overrepresented 
in published -omics studies. This raises concerns and motivates 
the consideration of multiple pathway databases or, preferably, an 
integration over several pathways resources.
Several integrative resources have been developed, including 
meta-databases [e.g., Pathway Commons (Cerami et al., 
2011), MSigDB (Liberzon et al., 2015), and ConsensusPathDB 
(Kamburov et al., 2008)] that enable pathway exploration in their 
corresponding web applications and integrative software tools 
[e.g., graphite (Sales et al., 2018), PathMe (Domingo-Fernandez 
et al., 2019), and OmniPath (Türei et al., 2016)] designed to 
enable bioinformatics analyses. By consolidating pathway 
databases, these resources have attempted to summarize major 
reference points in the existing knowledge and demonstrate how 
data contained in one resource can be complemented by data 
contained in others. Thus, through their usage, the biomedical 
community has benefitted from comprehensive overviews of 
pathway landscapes which can then make for more robust 
resources highly suited for analytic usage.
The typical approach to combine pathway information with 
-omics data is via statistical enrichment analysis, also known 
as pathway enrichment. The task of navigating through the 
continuously developing variants of enrichment methods has 
been undertaken by several recent studies which benchmarked 
the performance of these techniques (Bayerlová et al., 2015; 
Ihnatova et al., 2018; Lim et al., 2018) and guide users on the 
choice for their analyses (Fabris et al., 2019; Reimand et al., 2019). 
While Bateman et al. (2014) examined the impact of choice of 
different subsets of MSigDB on GSEA, it remains unclear what 
broader impact an integrative pathway meta-database would have 
for statistical enrichment analysis. Additionally, the overlap of 
pathways within the same integrative database can induce biases 
(Liberzon et al., 2015), specifically when conducting multiple 
testing correction via the popular Benjamini–Hochberg method 
(Benjamini and Hochberg, 1995) that supposes independence of 
statistical tests. This issue is of particular concern for large-scale 
meta-databases such as MSigDB.
The aim of this work is to systematically investigate the influence 
of alternative representations of the same biological pathway 
(e.g., in KEGG, Reactome, and WikiPathways) on the results of 
statistical enrichment analysis via three common methods: the 
hypergeometric test, GSEA, and signaling pathway impact analysis 
(SPIA) (Fisher, 1992; Subramanian et al., 2005; Tarca et al., 2008) 
using five The Cancer Genome Atlas (TCGA) datasets (Weinstein 
et al., 2013). In addition, we also show that pathway activity-
based patient classification and survival analysis via single-sample 
GSEA (ssGSEA; Barbie et al., 2009) can be impacted by the choice 
of pathway resource in some cases. As a solution, we propose 
to integrate different pathway resources via a method where 
semantically analogous pathways across databases (e.g., "Notch 
signaling pathway" in KEGG and "Signaling by NOTCH" pathway 
in Reactome) are combined. This approach exploits the pathway 
mappings and harmonized pathway representations described in 
our previous work (Domingo-Fernández et al., 2018; Domingo-
Fernandez et al., 2019). We demonstrate that when aided by our 
integrative pathway database, it is possible to better capture expected 
disease biology than with individual resources, and to sometimes 
obtain better predictions of clinical endpoints. Our entire analytic 
pipeline is implemented in a reusable Python package (pathway_
forte; see Materials and Methods) to facilitate reproducing the results 
with other databases or datasets in the future.
MATERIAlS AND METhODS
In the first two subsections, we describe the pathway resources 
and the clinical and genomic datasets we used in benchmarking. 
The following sections then outline the statistical enrichment 
analysis and predictive modeling conducted in this study. Finally, 
in the last two subsections, we describe the statistical methods 
and the software implemented to conduct the benchmarking.
Pathway Databases
Selection Criteria
Numerous viable pathway databases have been made available to 
infer biologically relevant pathway activity (Bader et al., 2006). 
In this work, we systematically compared three major ones (i.e., 
KEGG, Reactome, and WikiPathways) as the subset of databases 
to benchmark. The rationale for the inclusion of these databases 
was twofold: firstly, these databases are open-sourced, well-
established, and highly cited in studies investigating pathways 
associated with variable gene expression patterns in different 
sets of conditions (Table 1). Secondly, we expected distinctions 
between these databases to be strong enough to observe variable 
results of enrichment analysis and patient classification, yet 
these databases also contain a reasonable number of equivalent 
pathways such that objective comparisons could be made, as 
outlined in our previous work (Domingo-Fernández et al., 2018).
Data Retrieval and Processing
In order to systematically compare results yielded by different 
databases, we retrieved the contents of KEGG, Reactome, and 
WikiPathways using ComPath (Domingo-Fernández et al., 2018) 
TABlE 1 | Number of publications citing major pathway resources for pathway 
enrichment in PubMed Central (PMC), 2019. To develop an estimate on 
the number of publications using several pathway databases for pathway 
enrichment, SCAIView (http://academia.scaiview.com/academia; indexed on 
01/03/2019) was used to conduct the following query using the PMC corpus: 
“<pathway resource>” AND “pathway enrichment”.
Type Pathway resource Publications
Primary KEgg 27,713
Reactome 3,765
WikiPathways 651
Integrative MSigDB 2,892
ConsensusPathDB 339
Pathway Commons 1,640
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and converted it into the Gene Matrix Transposed (GMT) file 
format. Generated networks encoded in Biological Expression 
Language (BEL; Slater, 2014) were retrieved using PathMe 
(Domingo-Fernández et al., 2019).
To test the potential utility of an integrative pathway resource, 
we used equivalent pathways across the three databases that were 
manually curated in our previous work (Domingo-Fernández 
et al., 2018; see our earlier publication for further details). In 
the following, we call these “pathways analogs” or “equivalent 
pathways” (Figure 1A), while we call a pathway found as 
analogous across all KEGG, Reactome, as well as WikiPathways 
a “super pathway”.
In a second step, we merged equivalent pathways by 
taking the graph union with respect to contained genes and 
interactions (Figures 1B, C). We have also described this 
step in more detail in our earlier work (Domingo-Fernandez 
et al., 2019).
The set union of KEGG, Reactome, and WikiPathways, 
while taking into account pathway equivalence, gave rise to an 
integrative resource to which we refer as MPath (Figure 1D). By 
merging equivalent pathways, MPath contains a fewer number 
of pathways than the sum of all pathways from all primary 
resources. In total, MPath contains 2,896 pathways, of which 238 
are derived from KEGG, 2,119 from Reactome, and 409 from 
FIgURE 1 | Schema illustrating the generation of MPath. The curated pathway mapping catalog is depicted in (A), which links equivalent pathways from different 
resources. Pathways that are shared across two resources are referred to as pathway analogs (i.e., Pathway A in Reactome and Pathway A′ in KEGG) and pathways 
that are shared across all three resources are referred to as "super pathways" (i.e., Pathway A in KEGG, Pathway A′ in Reactome, and Pathway A″ in WikiPathways). 
(B) Using these mappings, gene sets of equivalent pathways from different resources can be combined, ensuring key molecular players from the different resources are 
included. (C) Similarly, network representations of the pathways can be overlaid to generate more comprehensive pathways. (D) Finally, both the combined gene sets 
and networks representations are included in MPath. Note that pathways that are exclusive to a single database are included in MPath unchanged.
Frontiers in Genetics | www.frontiersin.org November 2019 | Volume 10 | Article 1203
Benchmarking Pathway DatabasesMubeen et al.
4
WikiPathways, while another 129 pathways are pathway analogs 
and 26 are super pathways.
We next compared the latest versions of pathway gene 
sets from KEGG, Reactome, WikiPathways, and MPath with 
pathway gene sets from MSigDB, a highly cited integrative 
pathway database containing older versions of the KEGG and 
Reactome gene sets (Liberzon et al., 2015). We downloaded 
KEGG and Reactome gene sets from the curated gene set (C2) 
collection of MSigDB (http://software.broadinstitute.org/gsea/
msigdb/collections.jsp #C2; version6.2; July 2018). Detailed 
statistics on the number of pathways from each resource are 
presented in Table S1.
Clinical and genomic Data
We used five widely used datasets acquired from TCGA 
(Weinstein et al., 2013), a cancer genomics project that has 
catalogued molecular and clinical information for normal and 
tumor samples (Table 2). TCGA data were retrieved through 
the Genomic Data Commons (GDC; https://gdc.cancer.gov) 
portal and cBioportal (https://www.cbioportal.org) on 14-03-
2019. RNA-seq gene expression data subjected to an mRNA 
quantification analysis pipeline for BRCA, KIRC, LIHC, OV, 
and PRAD TCGA datasets were queried, downloaded, and 
prepared from the GDC through the R/Bioconductor package, 
TCGAbiolinks (R version: 3.5.2; TCGAbiolinks version: 2.10.3) 
(Colaprico et al., 2015). The data were preprocessed as follows: 
gene expression was quantified by the number of reads aligned 
to each gene and read counts were measured using HTSeq 
and normalized using fragments per kilobase of transcript per 
million mapped reads upper quartile (FPKM-UQ). HTSeq raw 
read counts also subject to the GDC pipeline were similarly 
queried, downloaded, and prepared with TCGAbiolinks. Read 
count data downloaded for the BRCA, KIRC, LIHC, and PRAD 
datasets were processed to remove identical entries, while 
unique measurements of identical genes were averaged. The 
differential gene expression analysis of cancer versus normal 
samples was performed using the R/Bioconductor package, 
DESeq2 (version 1.22.2). Genes with adjusted p value < 5% were 
considered significantly dysregulated. For all downloaded data, 
gene identifiers were mapped to HGNC gene symbols (Povey 
et al., 2001), where possible. To obtain additional information 
on the survival status and time to death, or censored survival 
times of patients, patient identifiers in the TCGA datasets 
were mapped to their equivalent identifiers in cBioPortal. 
Additionally, cancer subtype classifications or the PRAD and 
BRCA datasets were retrieved from the GDC. We would like to 
note that although there are other cohorts available (e.g., COAD 
and STAD) containing all of these modalities, we did not include 
them in this analysis because of the limited number of samples 
they contain (i.e., less than 300 patients). Detailed statistics of all 
five datasets are presented in Table 2.
Pathway Enrichment Methods
In this subsection, we describe three different classes of 
pathway enrichment methods that we tested: 1) statistical 
overrepresentation analysis (ORA); 2) functional class scoring 
(FCS); and 3) pathway topology (PT)-based enrichment 
(Figure 2) (Khatri et al., 2012; García-Campos et al., 2015; 
Fabris et al., 2019).
Overrepresentation Analysis
We conducted pathway enrichment using genes that exhibited a 
q value <0.05 using a one-sided Fisher's exact test (Fisher, 1992) 
for each of the pathways in all pathway databases. We consider a 
pathway to be significantly enriched if its q value is smaller than 
0.05 after applying multiple hypothesis testing correction with 
the Benjamini–Yekutieli method under dependency (Benjamini 
and Yekutieli, 2001).
Functional Class Scoring Methods
We selected GSEA, one of the most commonly used FCS 
methods (Subramanian et al., 2005). We performed GSEA with 
the Python package, GSEApy (version 0.9.12; https://github.
com/zqfang/gseapy), using normalized RNA-seq expression 
quantifications (FPKM-UQ) obtained for the BRCA, KIRC, 
LIHC, and PRAD datasets containing both normal and tumor 
samples (Table 2). All genes were ranked by their differential 
expression based on their log2 fold changes. Query gene 
sets for GSEA included pathways from KEGG, Reactome, 
WikiPathways, and MPath. GSEA results were filtered to 
include pathway gene sets with p values below 0.05 and a 
minimum gene set size of 10 or a maximum gene size of 3,000. 
Similarly, GSEApy was used to perform ssGSEA (Barbie et al., 
2009) (Table S2) to acquire sample-wise pathway scores using 
FPKM-UQ for BRCA, KIRC, LIHC, OV, and PRAD datasets, 
irrespective of phenotype labels (Barbie et al., 2009). Datasets 
were filtered to only include normalized expression data for 
genes found in the pathway gene sets of KEGG, Reactome, 
WikiPathways, and MPath and then used for ssGSEA. 
Expression data were ranked and sample-wise normalized 
enrichment scores were obtained.
TABlE 2 | Statistics of the five TCGA cancer datasets used in this work.
Cancer type TCgA abbreviation Tumor samples Normal samples Surviving patients Deceased patients
Breast invasive carcinoma BRCA 1,102 113 946 153
Kidney renal clear cell carcinoma KIRC 538 72 365 173
liver hepatocellular carcinoma LIHC 371 50 240 130
Prostate adenocarcinoma PRAD 498 52 498 10
Ovarian cancer OV 374 0 143 229
The statistics correspond to those retrieved from the GDC portal and cBioportal on 14-03-2019. Longitudinal statistics of survival data are presented in Figure S1.
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Pathway Topology-Based Enrichment
To evaluate PT-based methods, we selected the well-known 
and highly cited SPIA method (Tarca et al., 2008) for two main 
reasons: firstly, the guidelines outlined by a comparative study 
on topology-based methods (Ihnatova et al., 2018) recommend 
the use of SPIA for datasets with properties similar to TCGA 
(i.e., possessing two well-defined classes, full expression profiles, 
many samples, and numerous differentially expressed genes). 
Secondly, SPIA has been reported to have a high specificity while 
preserving dependency on topological information (Ihnatova 
et al., 2018). Because the R/Bioconductor's SPIA package only 
contains KEGG pathways, we converted the pathway topologies 
from the three databases used in this work to a custom format in 
a similar fashion as graphite (Sales et al., 2018) (Supplementary 
Text). We declared significance for SPIA-based pathway 
enrichment, if the Bonferroni corrected p value was <5%.
Evaluation Based on Enrichment of Pathway Analogs
To better understand the impact of database choice, we compared 
the raw p value rankings (i.e., before multiple testing correction) 
of pathway analogs across each possible pair of databases (i.e., 
in KEGG and Reactome, Reactome and WikiPathways, and 
WikiPathways and KEGG) and in each statistical enrichment 
analysis (i.e., hypergeometric test, GSEA, and SPIA) with 
the Wilcoxon signed-rank test. It assessed the average rank 
difference of the pathway analogs and reported how significantly 
different the results were for each database pair. Importantly, we 
only tested statistical enrichment of the analogous pathways in 
order to avoid statistical biases due to differences in the size of 
pathway databases.
Machine learning
ssGSEA was conducted to summarize the gene expression profile 
mapping to a particular pathway of interest within a given patient 
sample, hence resulting in a pathway activity profile for each 
patient. We then evaluated the different pathway resources with 
respect to three machine learning tasks:
 1. Prediction of tumor vs. normal
 2. Prediction of known tumor subtype
 3. Prediction of overall survival
Prediction of Tumor vs. Normal
The first task was to train and evaluate binary classifiers to predict 
normal versus tumor sample labels. This task was conducted for 
four of the five TCGA datasets (i.e., BRCA, KIRC, LIHC, and 
PRAD), while OV, which only contains tumor samples, was 
omitted. We performed this classification using a commonly used 
elastic net penalized logistic regression model (Zou and Trevor, 
2005). Prediction performance was evaluated via a 10 times 
repeated 10-fold stratified cross-validation. Importantly, tuning 
of elastic net hyper-parameters (l1, l2 regularization parameters) 
was conducted within the cross-validation loop to avoid over-
optimism (Molinaro et al., 2005).
Prediction of Tumor Subtype
The second task was to train and evaluate multi-label classifiers 
to predict tumor subtypes using sample-wise pathway activity 
scores generated from ssGSEA. This task was only conducted 
for the BRCA and PRAD datasets, similar to the work done by 
Lim et al. (2018), because the remaining three datasets included 
FIgURE 2 | Design of the benchmarking schema. The influence of alternative pathway databases on the results of statistical pathway enrichment (left) and machine 
learning classification tasks (right) are compared.
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in this work lacked subtype information. From the five breast 
cancer subtypes present in the BRCA dataset by the PAM50 
classification method (Sorlie et al., 2001), we included four 
subtypes (i.e., 194 Basal samples, 82 Her2 samples, 567 LumA 
samples, and 207 LumB samples). These four were selected as 
they constitute the agreed-upon intrinsic breast cancer subtypes 
according to the 2015 St. Gallen Consensus Conference (Coates 
et al., 2015) and are also recommended by the ESMO Clinical 
Practice Guidelines (Senkus et al., 2015). For the PRAD 
dataset, evaluated subtypes included 151 ERG samples, 27 
ETV1 samples, 14 ETV4 samples, 38 SPOP samples, and 87 
samples classified as other (Cancer Genome Atlas Research 
Network, 2014). Similar to the approach by Graudenzi et al. 
(2017), support vector machines (SVMs) (Cortes and Vapnik, 
1995) were used for subtype classification by implementing 
a one-versus-one strategy in which a single classifier is fit for 
each pair of class labels. This strategy transforms a multi-
class classification problem into a set of binary classification 
problems. We again used a 10 times repeated 10-fold cross-
validation scheme, and the soft margin parameter of the linear 
SVM was tuned within the cross-validation loop via a grid 
search. We assessed the multi-class classifier performance in 
terms of accuracy, precision, and recall.
Prediction of Overall Survival
The third task was to train and evaluate machine learning models 
to predict overall survival of cancer patients. For this purpose, a 
Cox proportional hazards model with elastic net penalty was used 
(Tibshirani, 1997; Friedman et al., 2010). Prediction performance 
was evaluated on the basis of five TCGA datasets (i.e., BRCA, 
LIHC, KIRC, OV, and PRAD) (Table 2) using the same 10 times 
repeated 10-fold nested cross-validation procedure as described 
before. The performance of the model was assessed by Harrell's 
concordance index (c-index; Harrell et al., 1982), which is an 
extension of the well-known area under receiver operating 
characteristic (ROC) curve for right censored time-to-event 
(here: death) data.
Statistical Assessment of Database Impact on 
Prediction Performance
To understand the degree to which the observed variability of area 
under the ROC curve (AUC) values, accuracies, and c-indices 
could be explained by the actually used pathway resource, 
we conducted a two-way analysis of variance (ANOVA). The 
ANOVA model had the following form:
 performance database dataset database data + + × set  
We then tested the significance of the database factor via 
an F test. In addition, we performed Wilcoxon tests analysis to 
understand specific differences between databases in a dataset-
dependent manner.
Software Implementation
The workflow presented in this article consists of three major 
components: 1) the acquisition and preprocessing of gene set 
and pathway databases; 2) the acquisition and preprocessing 
of experimental datasets; and 3) the re-implementation or 
adaptation of existing analytical pipelines for benchmarking. 
We implemented these components in the pathway_forte 
Python package to facilitate the reproducibility of this work, the 
inclusion of additional gene set and pathway databases, and to 
include additional experimental datasets.
The acquisition of KEGG, MSigDB, Reactome, and 
WikiPathways was mediated by their corresponding Bio2BEL 
Python packages (Hoyt et al., 2019; https://github.com/
bio2bel) in order to provide uniform access to the underlying 
databases and to enable the reproduction of this work as they 
are updated. Each Bio2BEL package uses Python's entry points 
to integrate in the previously mentioned ComPath framework 
in order to support uniform preprocessing and enable the 
integration of further pathway databases in the future, without 
changing any underlying code in the pathway_forte package. 
The network preprocessing defers to PathMe (Domingo-
Fernandez et al., 2019; https://github.com/pathwaymerger). 
Because it is based on PyBEL (Hoyt et al., 2018; https://github.
com/pybel), it is extensible to the growing ecosystem of BEL-
aware software.
While the acquisition and preprocessing of experimental 
datasets is currently limited to a subset of TCGA, it is extensible 
to further cancer-specific and other condition-specific datasets. 
We implemented independent preprocessing pipelines for several 
previously mentioned datasets using extensive manual curation, 
preparation, and processing with the pandas Python package 
(McKinney, 2010; https://github.com/pandas-dev/pandas). Unlike 
the pathway databases, which were amenable to standardization, 
the preprocessing of each new dataset must be bespoke.
The re-implementation and adaptation of existing analytical 
methods for functional enrichment and prediction involved 
wrapping several existing analytical packages (Table S3) in order 
to make their application programming interfaces more user-
friendly and to make the business logic of the benchmarking 
more elegantly reflected in the source code of pathway_forte. 
Each is independent and can be used with any combination of 
pathway database and dataset. Finally, all figures presented in 
this paper and complementary analyses can be generated and 
reproduced with the Jupyter notebooks located at https://github.
com/pathwayforte/results/.
Ultimately, we wrapped each of these components in a 
command line interface (CLI) such that the results presented in 
each section of this work can be generated with a corresponding 
command following the guidelines described by Grüning et al. 
(2019). The scripts for generating the figures in this manuscript 
are not included in the main pathway_forte, but rather in their 
own repository within Jupyter notebooks at https://github.com/
PathwayForte/results.
The source code of the pathway_forte Python package is 
available at https://github.com/PathwayForte/pathway-forte, 
its latest documentation can be found at https://pathwayforte.
readthedocs.io, and its distributions can be found on PyPI at 
https://pypi.org/project/pathway-forte.
The pathway_forte Python package has a tool chain consisting 
of pytest (https://github.com/pytest-dev/pytest) as a testing 
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framework, coverage (https://github.com/nedbat/coveragepy) 
to assess testing coverage, sphinx (https://github.com/sphinx-
doc/sphinx) to build documentation, flake8 (https://github.
com/PyCQA/flake8) to enforce code and documentation 
quality, setuptools (https://github.com/pypa/setuptools) to build 
distributions, pyroma (https://github.com/regebro/pyroma) to 
enforce package metadata standards, and tox (https://github.com/
tox-dev/tox) as a build tool to facilitate the usage of each of these 
tools in a reproducible way. It leverages community and open-
source resources to improve its usability by using Travis-CI (https://
travis-ci.com) as a continuous integration service, monitoring 
testing coverage with Codecov (https://codecov.io), and hosting its 
documentation on Read the Docs (https://readthedocs.org).
hardware
Computations for each of the tasks were performed on a 
symmetric multiprocessing (SMP) node with four Intel Xeon 
Platinum 8160 processors per node with 24 cores/48 threads each 
(96 cores/192 threads per node in total) and 2.1-GHz base/3.7-
GHz Turbo Frequency with 1,536-GB/1.5-TB RAM (DDR4 ECC 
Reg). The network was 100 GBit/s Intel OmniPath, storage was 
2× Intel P4600 1.6-TB U.2 PCIe NVMe for local intermediate 
data and BeeGFS parallel file system for Home directories. Table 
3 provides a qualitative description of the memory and time 
requirements for each task.
RESUlTS
The results of the benchmarking study have been divided into 
two subsections for each of the pathway methods described 
above. We first compared the effects of database selection on 
the results of functional pathway enrichment methods. In the 
following subsection, we benchmarked the performance of the 
pathway resources on the various machine learning classification 
tasks conducted.
Benchmarking the Impact on Enrichment 
Methods
Overrepresentation Analysis
As illustrated by our results, pathway analogs from different 
pathway databases in several cases showed clearly significant 
rank differences (Figure 3). These differences were most 
pronounced between Reactome and WikiPathways. For 
example, while the "Thyroxine Biosynthesis" pathway was 
highly statistically significant (q value <0.01) in the LIHC 
dataset for Reactome, its analogs in WikiPathways (i.e., 
"Thyroxine (Thyroid Hormone) Production") and KEGG 
(i.e., "Thyroid Hormone Synthesis") were not. However, the 
pathway was found to be significantly enriched in MPath. Such 
differences were similarly observed for the "Notch signaling" 
pathway in the PRAD dataset, in which the pathway was 
highly statistically significant (q value <0.01) for Reactome and 
MPath, but showed no statistical significance for KEGG and 
WikiPathways. Similar cases were systematically observed for 
additional pathway analogs and super pathways, demonstrating 
that marked differences in rankings can arise depending on the 
database used.
Gene Set Enrichment Analysis
Similar to ORA, GSEA showed significant differences between 
pathway analogs across databases in several cases (Figure 3). 
These differences were most pronounced between KEGG and 
WikiPathways in the KIRC and LIHC datasets and between 
KEGG and Reactome in the BRCA and PRAD datasets. Since 
GSEA calculates the observed direction of regulation (e.g., over/
underexpressed) of each pathway, we also examined whether 
super pathways or pathway analogs exhibited opposite signs in 
their normalized enrichment scores (NES) (e.g., one pathway 
is overexpressed while its equivalent pair is underexpressed). 
As an illustration, GSEA results of the LIHC dataset revealed 
the contradiction that the "DNA replication" pathway, one of 26 
super pathways, was overexpressed according to Reactome and 
underexpressed according to KEGG and WikiPathways, though 
the pathway was not statistically significant for any of these 
databases. However, the merged "DNA replication" pathway in 
MPath appeared as significantly underexpressed. Similarly, in 
the BRCA dataset, the WikiPathways definition of the "Notch 
signaling" and "Hedgehog signaling" pathways were significantly 
overexpressed, while the KEGG and Reactome definitions were 
insignificantly overexpressed. Interestingly, both the merged 
"Notch signaling" and merged "Hedgehog signaling" pathways 
appeared as significantly underexpressed (q < 0.05) in MPath.
Signaling Pathway Impact Analysis
The final of the three statistical enrichment analyses conducted 
revealed further differences between pathway analogs across 
databases. As expected, differences in the results of analogous 
pathways were exacerbated on topology-based methods 
compared with ORA and GSEA, as these latter methods do 
not consider pathway topology (i.e., incorporation of pathway 
topology introduces one extra level of complexity, leading to 
higher variability) (Figure 3). Beyond a cursory inspection 
of the statistical results, we also investigated the concordance 
of the direction of change of pathway activity (i.e., activation 
or inhibition) for equivalent pathways. We found that for two 
database (i.e., LIHC and KIRC), the direction of change was 
inconsistently reported for the "TGF beta signaling" pathway, 
depending on the database used (i.e., the KEGG representation 
TABlE 3 | A qualitative description of the computational costs of the analyses 
performed.
Task Relative memory 
usage
Timescale
ORA Low Seconds
GSEA Medium Minutes
ssGSEA Very high Hours
Prediction of tumor vs. normal Medium Minutes
Prediction of known tumor subtype Medium Minutes
Prediction of overall survival Medium Hours
Performing ssGSEA required on the scale of 100 GB of RAM for some dataset/database 
combinations, while the other tasks could be run on a modern laptop with no issues.
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was activated and the WikiPathways one inhibited). A similar 
effect was observed in the "Estrogen signaling pathway," 
found to be inhibited in KEGG and activated in WikiPathways 
in the LIHC dataset. The merging of equivalent pathway 
networks resulted in the observation of inhibition for both 
the "TGF beta signaling" and "Estrogen signaling" pathways in 
MPath results.
Benchmarking the Impact on Predictive 
Modeling
Prediction of Tumor vs. Normal
We compared the prediction performance of an elastic net 
penalized logistic regression classifier to discriminate normal 
from cancer samples based on their pathway activity profiles. 
The cross-validated prediction performance was measured 
FIgURE 3 | Left Distribution of raw p values of pathway analogs across databases [top to bottom: overrepresentation analysis (ORA), gene set enrichment analysis 
(GSEA), and signaling pathway impact analysis (SPIA)]. Right Significance of average rank differences of pathway analogs across pairwise database comparisons for 
the given method.
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via the AUC and precision-recall curve (see the corresponding 
Materials and Methods section). The AUC indicated no overall 
significant effect of the choice of pathway database on model 
prediction performance (p = 0.5, ANOVA F test; Figure 4). 
Similarly, the results of the precision-recall curve did not show a 
significant effect of the database selected on the model's predictive 
performance. Finally, these results were not surprising due to the 
relative ease of the classification task (i.e., all AUC values were 
close to 1).
Prediction of Tumor Subtype
We next compared the prediction performances of a multi-
class classifier predicting known tumor subtypes of BRCA 
and PRAD using ssGSEA-based pathway activity profiles. 
Figure 5 demonstrated no overall significant effect of the 
choice of pathway database (p = 0.16, ANOVA F test). We used 
Wilcoxon tests to investigate if each pair of distributions of 
the accuracies based on each database were different, but did 
not achieve statistical significance (q < 0.01) after Benjamini–
Hochberg correction for multiple hypothesis testing. While 
the lack of significance is probably due to the limited amount 
of datasets (only two contained subtype information) and 
measurements, we would like to note that MPath showed 
the best classification metrics (similar to the previous 
classification task).
Prediction of Overall Survival
As a next step, we compared the prediction performance of an 
elastic net penalized Cox regression model for overall survival 
using ssGSEA-based pathway activity profiles derived from 
different resources. As indicated in Figure 6, no overall significant 
effect of the actually used pathway database could be observed 
(p = 0.28, ANOVA F test). A limiting factor of this analysis is the 
fact that overall survival can generally only be predicted slightly 
above chance level (c-indices range between 55% and 60%) 
based on gene expression alone, which is in agreement with the 
FIgURE 4 | Comparison of prediction performance of an elastic net classifier (tumor vs. normal) using single-sample gene set enrichment analysis (ssGSEA)-based 
pathway activity profiles computed from different resources. Each box plot shows the distribution of the area under the ROC curves (AUCs) over 10 repeats of the 
10-fold cross-validation procedure.
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FIgURE 5 | Comparison of prediction performance of an elastic net classifier (BRCA and PRAD subtypes) using single-sample gene set enrichment analysis 
(ssGSEA)-based pathway activity profiles computed from different resources. Each box plot shows the distribution of the area under the ROC curves (AUCs) over 10 
repeats of the 10-fold cross-validation procedure.
FIgURE 6 | Comparison of prediction performance of an elastic net penalized Cox regression model (overall survival) using single-sample gene set enrichment 
analysis (ssGSEA)-based pathway activity profiles computed from different resources. Each box plot shows the distribution of the area under the ROC curves 
(AUCs) over 10 repeats of the 10-fold cross-validation procedure.
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literature (Van Wieringen et al., 2009; Fröhlich, 2014; Mayr and 
Schmid, 2014; Zhang et al., 2018).
DISCUSSION
In this work, we presented a comprehensive comparative study 
of pathway databases based on functional enrichment and 
predictive modeling. We have shown that the choice of pathway 
database can significantly influence the results of statistical 
enrichment, which raises concerns about the typical lack of 
consideration that is given to the choice of pathway resource 
in many gene expression studies. This finding was specifically 
pronounced for SPIA because this method is a topology-based 
enrichment approach and therefore expected to be most sensitive 
to the actual definition of a pathway. At the same time, we 
observed that an integrative pathway resource (MPath) led to 
more biologically consistent results and, in some cases, improved 
prediction performance.
Generating a merged dataset such as MPath is non-trivial. We 
purposely restricted this study to three major pathway databases 
because of the availability of inter-database pathway mappings 
and pathway networks from our previous work which enabled 
conducting objective database comparisons. The incorporation 
of additional pathway databases into MPath would first require 
the curation of pathway mappings prior to conducting the 
benchmarking study, which can be labor-intensive. Furthermore, 
performing the tasks described in this work comes with a high 
computational cost (Table 1).
Our strategy to build MPath is one of many possible 
approaches to integrate pathway knowledge from multiple 
databases. Although alternative meta-databases such as 
Pathway Commons and MSigDB do exist, the novelty of this 
work lies in the usage of mappings and harmonized pathway 
representations for generating a merged dataset. While we 
have presented MPath as one possible integrative approach, 
alternative meta-databases may be used, but would require 
that researchers ensure that the meta-databases' contents are 
continuously updated (Wadi et al., 2016).
Our developed mapping strategy between different 
graph representations of analogous pathways enabled us 
to objectively compare pathway enrichment results that 
otherwise would have been conducted manually and 
subjectively. Furthermore, they allowed us to generate super 
pathways inspired by previous approaches that have shown 
the benefit of merging similar pathway representations 
(Doderer et al., 2012; Vivar et al., 2013; Belinky et al., 2015; 
Stoney et al., 2018; Miller et al., 2019). In this case, this was 
made possible by the fully harmonized gene sets and networks 
generated by our previous work, ComPath and PathMe. A 
detailed description of the ComPath and PathMe publications, 
source code, and extensions to existing analyses (i.e., SPIA) to 
better suit the methods used in this work can be found in the 
Supplementary Text.
One of the limitations of this work is that we restricted 
the analysis to five cancer datasets from TCGA and we did 
not expand it to other conditions besides cancer. The use of 
this disease area was mainly driven by the availability of data 
and the corresponding possibilities to draw statistically valid 
conclusions. However, we acknowledge the fact that data from 
other disease areas may result in different findings. More 
specifically, we believe that a similar benchmarking study 
based on data from disease conditions with an unknown 
pathophysiology (e.g., neurological disorders) may yield even 
more pronounced differences between pathway resources. 
Additionally, further techniques for gene expression-based 
pathway activity scoring could be incorporated, such as 
Pathifier or SAS (Drier et al., 2013; Lim et al., 2016).
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Conclusions
This work is the first benchmarking study that highlights the significant impact
of database selection on statistical pathway enrichment and predictive modeling.
There are three major messages to be drawn from this work. First, we have con-
firmed that results of pathway-driven approaches can be heavily influenced by
database selection. These findings suggest that future pathway-driven analyses
should be further validated with a complementary database (e.g., replicating the
results with a second database). Second, it has also demonstrated that the observed
differences at database level can be mitigated by using integrative approaches
such as MPath. We have demonstrated how our unifying approach outperforms
the predictive power of models that use individual databases. This point is highly
relevant to the machine and deep learning field, where a vast amount of data is
required. Third, we have shown a possible and practical solution (i.e., MPath’s
construction workflow) for future integration of pathway resources by leveraging
the work presented in the previous chapters (i.e., ComPath and PathMe). While
centralizing approaches are essential to break down data silos, they are also fun-
damental to drive research by exploiting the explanatory power derived from
pathway knowledge.
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5 Multimodal Mechanistic
Signatures for Neurodegenerative
Diseases (NeuroMMSig): a web server
for mechanism enrichment
Introduction
After decades of research, many clinical trials, and billions invested, there is still no
treatment for the major neurological disorders such as AD or PD. This suggests that
it could be time to take a step back and analyze the potential mistakes made, before
launching yet another study (doomed to fail?). In the AD area, for instance, the
pharmaceutical industry still tries to target two of the main mechanisms implicated
in AD (i.e., amyloid beta and tau protein), despite decades of continuous failures
[87]. Instead of focusing on single mechanisms, we could try to understand how all
the numerous mechanisms that are in the aetiology of these disorders could lead
to the disease state. Following this direction, we present Multimodal Mechanistic
Signatures for Neurodegenerative Diseases (NeuroMMSig), the largest inventory
of knowledge-based mechanisms for AD and PD. In NeuroMMSig, each of the
mechanisms is formalized as a computable network and exposed through a web
application that enables the interpretation of multi-scale and multimodal clinical
data by adopting the novel paradigm of mechanism enrichment.
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Abstract
Motivation: The concept of a ‘mechanism-based taxonomy of human disease’ is currently replac-
ing the outdated paradigm of diseases classified by clinical appearance. We have tackled the para-
digm of mechanism-based patient subgroup identification in the challenging area of research on
neurodegenerative diseases.
Results: We have developed a knowledge base representing essential pathophysiology mechan-
isms of neurodegenerative diseases. Together with dedicated algorithms, this knowledge base
forms the basis for a ‘mechanism-enrichment server’ that supports the mechanistic interpretation
of multiscale, multimodal clinical data.
Availability and implementation: NeuroMMSig is available at http://neurommsig.scai.fraunhofer.
de/
Contact:martin.hofmann-apitius@scai.fraunhofer.de
Supplementary information: Supplementary data are available at Bioinformatics online.
1 Introduction
The development of novel high throughput ‘omic’ technologies in
the last decade has revealed new insight and progresses in areas of
cancer, cardiovascular and metabolic disorders. The datasets coming
from these technologies have led to the discovery of candidate bio-
markers and potential drug targets. However, in other areas such as
neurodegenerative diseases, this mechanistic understanding is either
rather limited or almost absent.
Readouts in translational biomedicine are going beyond molecu-
lar level: they can span from genes and genetic variation information
to imaging and organ-level (or even organism-level) data and
markers. The definition of a disease as ‘dysregulated pathways’ may
hold true for cancer, but is inappropriate for neurodegenerative dis-
eases as pathways refer typically to rapid molecular processes and
the alterations in neurodegenerative diseases are slow and multi-
facetted. There is simply no such thing as a ‘degeno-gene’ (in ana-
logy to the ‘onco-gene’). Supporting that, there have not been any
described ‘cause-effect’ relationships that would explain the differ-
ent pathological changes observed in patients with these disorders.
When the effects of dysregulation can be easily observed—like in
monogenic diseases—it is generally not so difficult to link the pheno-
type with the event that lead to it. This is likely to be attributed to a
short and direct chain of causality (Hofmann-Apitius et al., 2015a).
Hence, because the complexity of neurodegenerative diseases is
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enormous; it is crucial to integrate a wider spectrum of causal asser-
tions into models that represent and organize the available mechan-
istic knowledge.
MSigDB (Subramanian et al., 2015) is the prototypic implemen-
tation of a system that allows for the identification of perturbed
pathways. However, the output of ranking algorithms like GSEA is
usually a list of associated canonical pathways that do not contain
disease-specific information and multimodal data. In addition,
canonical pathways are also biased towards cancer biology
(Hofmann-Apitius et al., 2015b).
Adopting the fundamental principle of ‘running patterns in data
against a knowledge base of established patterns’ (‘pathways’; ‘sig-
natures’), we have developed a mechanism enrichment server and
extended it towards multiscale and multimodal data. This is where
the two ‘M’ of NeuroMMSig come from: Multimodal and
Mechanistic. It is noteworthy that the difference between
NeuroMMSig and other, conventional methods for pathway enrich-
ment or functional gene annotation lies in the specificity of the dis-
ease context. Pathway enrichment is based upon canonical
pathways, which are not disease specific. The multimodal mechan-
isms behind NeuroMMSig, however, are manually curated and con-
tain detailed representations of multimodal pathophysiology in a
well-defined disease context.
Here, we present NeuroMMSig, a web server for mechanism en-
richment that allows submission of multiscale data from molecular
to clinical level to return mechanisms that fit best the data. We have
focused on neurodegenerative diseases, as we try to establish a
‘mechanism-based taxonomy of Alzheimer’s Disease (AD) and
Parkinson’s Disease (PD)’. This is the core of the AETIONOMY
project (www.aetionomy.eu) and in fact, NeuroMMSig (DB and
Server) form the backbone of attempts at stratifying patient sub-
groups based on disease mechanisms.
2 Systems and methods
2.1 Categorization of NDD pathways frommechanism
based models
Disease knowledge assembly models were built using Biological
Expression Language (BEL) which integrate literature-derived ‘cause
and effect’ relationships in the form of triples (Kodamullil et al.,
2015). We have captured a representative subsample of the scientific
knowledge on existing canonical pathways in AD and PD (Iyappan
et al., 2016) which have been grouped into subgraphs.
2.2 Multimodal data integration, data sources and
software
NeuroMMSig’s subgraphs have been enriched with multimodal data
(e.g. imaging features, variant information and drugs). The method-
ology describing how the linking across different data scales was
performed is provided in the Supplementary text. Moreover, we
have developed an enrichment algorithm to rank the subgraphs
based on the input.
3 Implementation
3.1 NeuroMMSig server
NeuroMMSig is available at http://neurommsig.scai.fraunhofer.de/.
A user interface offers a simple, yet comprehensive menu (Fig. 1A).
Input fields allow users to submit multimodal data (e.g. genes,
SNPs, imaging features). Users can also set the enrichment algorithm
parameters and define the operators of the query. After data
submission, a ranked list of subgraphs is displayed to the user
(Fig. 1B). Here, associated information to the submitted data is
shown as icons in a user friendly table: drug-gene interactions,
known regulating miRNA and co-expressed networks. Moreover,
when the user selects one or multiple subgraphs and clicks on
‘Visualize Network’, NeuroMMSig displays the graph representing
the selection where the user can investigate how the disruption of
the network occurs (Fig. 1C). For that reason, NeuroMMSig offers
multiple functionalities enabling graph mining and reasoning over
the graphs (e.g. graph algorithms, search and exporting options,
knowledge provenance and Sankey diagram representations for
pathway analysis).
3.2 Application scenario
The five most relevant genes associated with ‘Dopamine signaling
pathway’ in PD according to SCAIView [http://academia.scaiview.
com/academia/] (Supplementary text) were used as an input
(Fig. 1A). Two subgraphs were retrieved from NeuroMMSig
Fig. 1. The web interface for NeuroMMSig. (A) Home page. Users can select
the disease context and submit their data. In the navbar, links are provided to
‘Introduction’ and ‘How to use’ pages. (B) Example of the results provided by
ranking algorithm with the most enriched subgraphs. (C) By clicking
‘Visualize Network’, the users can access the interactive network visualization
with multiple functionalities. (D) Sankey diagram of causal relationships com-
prising the proposed mechanism
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(‘Dopaminergic subgraph’ and ‘Synuclein subgraph’) and they were
selected for further analysis (Fig. 1B). Using the query tools, the two
main hub nodes SNCA and Parkinson’s disease were removed from
the network in order to avoid most of the paths going through them,
which biases the retrieval of best candidate mechanisms. By choos-
ing a process of interest such as ‘alpha synuclein toxicity’, the server
proposes candidate mechanisms in which the data-mapped-nodes
may perturb normal physiology (Fig. 1C and D).
4 Discussion
Harmonization of heterogeneous and multiscale datasets is yet a tre-
mendous challenge in the field of neurodegeneration. The gap be-
tween molecular and clinical data is too wide to establish stable and
meaningful assertions between imaging features and genes, for in-
stance. Thus, integration of different data scales is a necessary step
to shed some light on the mechanisms underlying neurodegenerative
diseases.
The modeling approach chosen in NeuroMMSig is capable of
explaining causal and correlative relationships among different enti-
ties namely genes, proteins or biological processes in the context of
neurological disorders (Kodamullil et al., 2015). These relationships
reveal the upstream and downstream regulators of each node in the
network and how they are activating/inhibiting their neighboring
nodes. Thus, navigating through the network it is possible to iden-
tify the root or primarily cause of a dysfunctional gene or protein
which eventually contributes to the disorder.
The inventory of mechanisms specific for neurodegenerative dis-
eases, which forms the basis of NeuroMMSig, is composed of small
cause-and-effect models encoded in OpenBEL. Evidences for the
BEL-encoded mechanisms come from the scientific literature, from
experimental data analysis and from clinical readouts such as imag-
ing biomarkers. Furthermore, both AD and PD models incorporate
genetic and epigenetic information, which might, for instance, indi-
cate and partially explain the effect of a particular SNP in a mechan-
ism (Khanam et al., 2015; Naz et al., 2016). The presented work
also serves as a comparison tool between different diseases. Thus, it
allows to systematically identify shared-mechanisms between them.
Combining all together, the BEL-encoded mechanisms contain
pathophysiology information at highest resolution, with highly cura-
ted evidences spanning from the genetics and epigenetics layer via
cell-type specific information to clinical phenotypes and biomarkers.
Hence, NeuroMMSig overcomes some of challenges that pathway
analysis methods currently have, as indicated by Khatri et al.
(2012).
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Conclusions
This work presents a paradigm shift in the neurodegenerative field by offering to
the scientific community over 200 networks that represent the knowledge around
well-established disease-specific mechanisms involved in these disorders. The
value of this resource has already been demonstrated in numerous applications
spanning from drug discovery [123] to precision medicine (see chapter 7). One of
the visions of precision medicine has been to re-define disease taxonomies based
on molecular characteristics rather than on phenotypic evidence. This is precisely
the most promising application of NeuroMMSig. Supported by its mechanistic
backbone, we aim to build a mechanism-based taxonomy for AD and PD that
can classify patient populations into different strata based on the mechanisms
involved. Finally, the success and generalizability of this approach has prompted
us to translate the concept of mechanism enrichment to other domains such as the
psychiatric field.
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6 PTSD Biomarker Database: deep
dive meta-database for PTSD
biomarkers, visualizations, and
analysis tools
Introduction
Although hundreds of biomarkers have been associated with PTSD, very few have
been replicated, and none have yet been validated and qualified for deployment in
clinical care. Additionally, biomarker-focused meta-analyses have systematically
shown conflicting and inconsistent results [124–126]. Therefore, organizing and
contextualizing published information and data is critical to understanding the
level of confirmatory and contradictory evidence for single biomarkers. Moreover,
there are no diagnostic biomarkers for this condition. Therefore, PTSD diagnosis
is currently based solely on symptom presentation which often lead to late diag-
nosis. For these reasons, identifying diagnostic biomarkers is essential to an early
intervention that can enable the evaluation and follow-up of disease progression.
In this work, we present PTSD Biomarker Database (PTSDDB), the first resource
aiming to capture and organize biomarker knowledge in this PTSD.
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Abstract
The PTSD Biomarker Database (PTSDDB) is a database that provides a landscape view
of physiological markers being studied as putative biomarkers in the current post-
traumatic stress disorder (PTSD) literature to enable researchers to explore and compare
findings quickly. The PTSDDB currently contains over 900 biomarkers and their relevant
information from 109 original articles published from 1997 to 2017. Further, the curated
content stored in this database is complemented by a web application consisting of
multiple interactive visualizations that enable the investigation of biomarker knowledge
in PTSD (e.g. clinical study metadata, biomarker findings, experimental methods, etc.)
by compiling results from biomarker studies to visualize the level of evidence for single
biomarkers and across functional categories. This resource is the first attempt, to the
best of our knowledge, to capture and organize biomarker and metadata in the area of
PTSD for storage in a comprehensive database that may, in turn, facilitate future analysis
and research in the field.
Database URL: https://ptsd.scai.fraunhofer.de
Introduction
Post-traumatic stress disorder (PTSD) is a common psy-
chiatric disorder that occurs in some individuals after a
traumatic event (13) and is diagnosed by mental health pro-
fessionals based on the presentation of four symptom clus-
ters—intrusions, avoidance, negative cognitions/mood and
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hyperarousal (1). PTSD pathophysiology is complex and
affects multiple interconnected biological systems that regu-
late mental and physical health functions and are associated
with PTSD’s clinical heterogeneity and diverse comorbidity
profiles (2,5,9,11,14,15).
An extensive amount of research in PTSD has explored
the utility of physiological markers as being discrete
biomarkers of this disorder; however, no such putative
biomarkers of PTSD have been identified to date based
on the regulatory approval process for qualifying and
validating biomarkers around specific clinical contexts of
use (hereafter the term ‘biomarker’ will be used to refer to
‘physiological markers of disease’). In the PTSD literature,
the types of physiological markers most commonly
studied include neuroimaging and psychophysiological
measures, behavioral and neurocognitive readouts and
analytes measured in peripheral biofluids, such as blood
and saliva at baseline or after psychological challenge
(4,6,8,12,20). Fluid-based peripheral biomarkers may
include inflammation indicators, hypothalamic pituitary
adrenal axis mediators, neurosteroids and neurotransmit-
ters, which have functional roles both in the peripheral and
central nervous system, potentially enabling biologically
meaningful inference with clinical utility (4).
The increasing amount of biomarker studies in all dis-
ease areas is paralleled by the growing number of meta-
analyses that combine data from multiple studies to sys-
tematically derive common conclusions. However, the lack
of disease-specific biomarker registries impedes the harmo-
nization and integration of results from these studies, which
often remain in the form of non-structured text, figures,
tables or supplementary files. Organizing and storing this
knowledge is essential to provide a comprehensive view of
the biomarker landscape and to foster the discovery and
development of diagnostics and treatments.
Along these lines, several biomarker databases have
been recently developed that focus on specific disease
domains, such as colorectal cancer (19), Alzheimer’s disease
(10), tuberculosis (18) and liver cancer (3) to name a few.
Furthermore, there are multiple resources that store and
catalog biomarker information from multiple indications,
such as the Online Mendelian Inheritance in Man (OMIM)
(7), the cancer biomarker database (16) and the infectious
disease database (17). These resources illustrate how
biomarker information can be curated and harmonized
and currently serve as hubs for biomarker research in
their respective areas. Although biomarkers of PTSD—once
identified—have the potential to improve patient outcomes,
groups have yet to embark on similar efforts for a PTSD-
specific database.
To address this, we are developing the comprehensive
PTSD Biomarkers Database (PTSDDB), focusing on fluid-
based biomarkers as a resource for bringing together
published findings within the context of study design and
related results. Organizing and contextualizing published
information and data are critical to understand the
level of confirmatory and contradictory evidence for
single biomarkers. Overall, this work represents one first
step to crossing the translational divide between basic
science discovery and clinical implementation. Considering
findings for single biomarkers in tandem with details
around study design may offer insights into the robustness
and replicability of studies. Here, we present the first
version of the PTSDDB biomarker database that provides
a comprehensive and interactive view of results from an
extensive, systematic curation effort in over 100 PTSD-
focused articles. We aim to continually build on this
resource in the future to enable a better interpretation of
the state of the field in biomarker research that supports
formal meta-analyses around single biomarkers in PTSD.
Materials and Methods
Curation procedure and database content
Corpus selection Articles included in the PTSDDB were
compiled via two routes: recommendations and referrals
from experts in the field and mining cited references
from PTSD review publications. In general, publications
included in this deep-dive database were original articles
published from 1997 to 2017 that evaluated fluid-based
biomarkers in humans, with a focus on PTSD patients vs
control populations (e.g. healthy controls, trauma-exposed
controls and/or patients with psychiatric disorders or other
comorbidities). Exclusion criterion included publications
that did not include a PTSD population, those that included
PTSD patients but in the absence of fluid-based biomarkers,
or that were preclinical studies.
Data extraction and quality assessment The biomarker metadata
information contained in the resulting 109 publications
was manually extracted independently by five independent
trained curators and added to a data model template. The
spectrum of curated metadata covers many fields, including
study design, demographics, study findings, assay infor-
mation and statistical methods. Ultimately, three rounds
of quality control (QC) were conducted to ensure the
fidelity of the metadata. In each round of QC, the metadata
was reviewed by a distinct curator; if inconsistencies were
found, curators worked together to reach a consensus.
While there exist other QC procedures ensuring the quality
of the curated data such as inter-curator agreement, these
involve significant time constraints as they require two
distinct curators working in parallel to extract the same
Database, Vol. 2019, Article ID baz081 Page 3 of 8
Table 1. Types of information extracted from each manuscript and stored as entries in the PTSDDB. For each data category,
extensive informationwas curated and stored as separate entries in the PTSDDB. For example, the Data Category “Biomarker”
includes information on Biomarker name, HUGO ID or another acronym, gene symbol/identifier, and biomarker application
(e.g., biomarkers for disease risk, patient stratification, diagnostic marker, predictive markers of disease severity or treatment
response, and safety/toxicity biomarkers).
Model/data category Fields
Publication PubMed identifier, authors information (e.g. names, year of publication and geographical information)
Biomarker Biomarker name, HUGO ID or other acronym, gene symbol, biomarker application. Protein, gene or
miRNA biomarkers are coded using the HGNC nomenclature if possible. Small molecules
nomenclatures are prioritized in the following order: ChEBI, PubChem and InChIKeys.
Time point Study time point (e.g. 6 weeks post-trauma, 2 years post-trauma)
Approach panel details Name, statistical method, cutoff used (e.g. P-value, False Discovery Rate, etc.), whether the biomarker
was part of a panel, other analytes included, risk SNP, allele risk and additional notes on risk SNP
Numerical summary Statistics (i.e. mean and standard deviation [SD]) about the biomarker measurements for primary
indication, trauma-exposed controls, other central nervous system and healthy controls
Clinical instrument Clinical instrument for primary indication, trauma in adult, childhood and lifetime (e.g.
Clinician-Administered PTSD SCALE [CAPS], PTSD Checklist [PCL], Structured Clinical Interview for
DSM-5 [SCID], etc.)
Clinical study Type of study (e.g. cross-sectional, longitudinal), timeline, challenge type, treatment response study,
number of subjects per indication (e.g. trauma-exposed PTSD, trauma-exposed controls, healthy
controls, other indications)
Indication Name and specifics of the condition (e.g. PTSD, childhood trauma, maternal PTSD)
Comorbidity Name, comorbidity measurements (e.g. mean and SD)
Numerical readouts Statistical details of each different group included in the study (e.g. mean, SD of the biomarker for
primary indication or control)
Inclusion/exclusion criteria The description of inclusion and exclusion criteria provided by each publication
Cohort name and demographic
details
Details about the cohort (e.g. percent female plus the overall mean and SD in trauma-exposed PTSD vs
trauma-exposed and healthy controls, mean age and SD age of subjects)
Ancestry Ancestry details for Caucasian, African American and other ancestry of the cohort (e.g. percentage of
each group included in the study)
Study findings Direction of change of the biomarker in cases vs controls as specified by the study authors (e.g.
increased, no change, decreased), specific circuit changes, notes and descriptions
Assay Assay details: assay brand, probe, fluid, biological substrate, assay brand, assay limit detection and
measurement units
Assay calculations Mean and SD concentration (in primary indication, trauma-exposed controls, healthy controls and
CNS controls), sigma combined and effect size
Statistical info Mean, SD and variance, methylation change, t and P-value
information.On the other hand, our QC procedure allowed
us to include a larger amount of biomarker metadata while
maintaining the quality of data curation. The data model
template for metadata extraction was predefined based on
the initial set of 10 articles. However, new metadata fields
were added as necessary to accommodate new types of
information being extracted from additional manuscripts.
Database design and web application
implementation
Database model One challenge in data integration when
curating disparate sources of information is organizing this
knowledge according to a common schema, which greatly
influences subsequent steps of data management and
analysis. In order to structure the information comprised
in the 193 columns of the curation template/worksheet,
we designed a data model storing this information into 17
different models (e.g. publication, biomarker, clinical study,
cohort metadata, etc.), which are represented as tables in
the database (Table 1). Next, we implemented a parser of
the curation template that populates the MySQL database
and controls the quality of the worksheet by identifying
duplicates, checking the syntax and normalizing terms.
Finally, a web application integrated the database enabling
users to query, visualize and analyze the curated content as
illustrated in this manuscript.
PTSDDB implementation The application was implemented
following a model-view-controller (MVC) software archi-
tecture. The back-end is written in Python using the Django
web framework technology (https://www.djangoproject.
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Figure 1. PTSDDM - Biomarker Data and Integrated Metadata: a) Frequency plot of biomarkers captured in the current version of the PTSDDB , b)
Geographical map displaying locations of institutions in the curated literature, and c) Heatmap visualization showing the frequency of individual
biomarkers studied together in the same articles curated in the PTSDDB. Descriptions of these visualizations are outlined in the Supplementary
Information, and these figures can be dynamically explored at https://ptsd.scai.fraunhofer.de/frequencies and https://ptsd.scai.fraunhofer.de/literature.
com/). Django embraces the MVC paradigm by storing the
data into a MySQL relational database controlled by views
that are responsible for querying the database and rendering
its content to the users. The front-end renders interactive
visualizations using a collection of powerful Javascript
libraries: D3.js (https://d3js.org/), C3.js (http://c3js.org/),
DataTables (https://datatables.net/) and DataMaps (https://
datamaps.github.io/). Because the main goal of the web
application is data exploration and visualization, the
front-end is powered by Bootstrap, thereby retaining
full compatibility with a broad range of devices (e.g.
smartphones, tablets, laptops, etc.). Finally, PTSDDB is
complemented with a RESTful API documented with an
OpenAPI specification (https://www.openapis.org).
Results and discussion
The PTSDDB is an interactive database that catalogs infor-
mation on more than 900 physiological markers, extracting
data from over 100 manuscripts. The current PTSDDB
demonstrates our ability to successfully capture and orga-
nize large amounts of knowledge around PTSD physiologi-
cal markers reported in the literature, using this information
to support the creation of interactive data visualizations. By
Database, Vol. 2019, Article ID baz081 Page 5 of 8
Figure 2. a) Biological substrates of the five most frequently reported biomarkers in PTSDDB when they are studied as a metabolite, protein, or RNA.
The source code to reproduce this figure is available at https://github.com/ddomingof/PTSDDB-Resources. b) Relative changes in the ten most common
biomarkers captured in the database. This figure can be explored interactively at https://ptsd.scai.fraunhofer.de/relative_changes.
expanding on the PTSDDB in the future, we aim to enable
the broad investigation of biomarkers implicated in PTSD
pathogenesis.
Biomarkers overview
The first page, ‘biomarkers overview’, presents an overview
of the biomarker knowledge available in the database,
depicted by the frequency of captured biomarkers across
studies (Figure 1a), the biofluids in which they were
measured, the relative changes reported and the biolog-
ical substrates captured (e.g. DNA, RNA and protein;
Figure 2a).
Direction of change by biomarker
Also, the second page of the PTSDDB provides information
on ‘direction of change by biomarker’ with visualiza-
tions that summarize the directionality of biomarker
findings (i.e. whether a biomarker was observed to be
increased, decreased or unchanged in cases vs controls).
For example, Figure 2b summarizes the reported changes
in 10 of the most common biomarkers captured in this
database. To better contextualize the direction of change,
the functionality of this page allows users to assess
changes based on the biological substrate, where the
biomarker was measured, as well as a dedicated page to
explore metadata information, which will subsequently be
described.
The current version of the PTSDDB provides a ‘proof-of-
concept’ that such visualizations can be successfully created
and enable users to interact with articles and data curated
in the PTSDDB. The next iteration of the PTSDDB will
include a comprehensive landscape analysis of the PTSD
biomarker literature so that these visualizations will facili-
tate researchers’ ability to investigate and critically evaluate
the metadata information. For instance, users may glean
important information by evaluating and comparing studies
Page 6 of 8 Database, Vol. 2019, Article ID baz081
around factors that may impact reported findings, such
as study type (cross-sectional vs longitudinal), sample size
(e.g. number of subjects, controls, etc.), study population
(military vs civilian, men vs women) and experimental
methods (e.g. how was the biomarker measured).
Study metadata
While abstracts and results sections summarize the essential
findings in biomarker publications, capturing the level of
evidence supporting single biomarkers requires information
such as sample size or statistical measurements (e.g.
mean, standard deviation, etc.), and these data are often
unstructured in the form of figures or supplementary files.
By storing and cataloging biomarker-related metadata, and
then exposing it to the user via the ‘study metadata’ page,
the PTSDDB enables users to easily access and query this
type of information. In contrast to the previously described
information, this page focuses on the sparse world of
clinical metadata, which is crucial to compare various
study designs that are often complex and heterogeneous in
nature. Here, users can first search for studies containing a
particular biomarker and then inspect associated metadata
(e.g. type of study, duration, challenge, trauma, sample
size, assay, diagnostic criteria, etc.) for further analysis.
Additionally, users can filter the studies by the specific
application of the putative biomarker (i.e. diagnostic,
prognostic, risk and stratification), allowing for more
precise inquiries. Finally, a quick search box lists the
biomarkers analyzed in a given study in order to facilitate
the linkage between the meta information displayed in this
page with the rest of the pages in PTSDDB (e.g. ‘biomarkers
overview’ or ‘direction of change by biomarker’), which
are focused on providing a comprehensive overview of the
results reported in the studies.
Literature analysis
Biomarker research is often driven by current trends, tech-
nologies and specific hypotheses related to domain exper-
tise. Currently, the increasing quantity of data, informa-
tion and knowledge makes it incredibly complicated for
researchers to stay abreast of all new studies published
in a given area of interest. Thus, it is essential to provide
researchers with an overview of what biomarkers have
already been investigated as well as how the study was
conducted. This information not only allows scientists to
be aware of what has been studied but also may encourage
collaboration among those working on similar hypotheses.
To provide an overview of the literature included in the
database and foster new research, PTSDDB includes a
page with novel visualizations, ‘literature analysis’, illus-
Figure 3. Content of the current version of PTSDDB (May 2019): the
database contains 109 articles, 924 biomarkers, 23 indications or distinct
manifestations of PTSD, 11 biological fluids, and 9 substrates in which
the biomarkers were tested.
trating which biomarkers are frequently studied together;
where, how, and when were the studies were conducted;
or in which biological substrates the biomarkers were mea-
sured. First, a table displays the main article information:
PubMed-ID, title, journal, authors and year of publication.
Second, map-based visualizations represent the geograph-
ical distribution of the analyzed articles to help identify
PTSD-focused research hubs in the USA and across the
globe, which may help identify collaborative opportuni-
ties for biomarker replication and validation (Figure 1b).
Third, a histogram of the years when the articles included
were published (Supplementary Information). Finally, two
different heatmaps depict which biomarkers are frequently
reported together in publications (Figure 1c) and which are
studied in the same bio-fluid (Supplementary Information).
By exploring this, we can investigate which combinations
of biomarkers are most frequently studied in concert (e.g.
cortisol and dehydroepiandrosterone sulfate cortisol and
NR3C1 were measured together in five of the studies that
we have included so far in the database) or which biological
substrates have been used together in clinical studies.
Database content
Since PTSDDB contains a large number of variables and
metadata (Figure 3), it is an arduous task to implement
interactive visualizations for every possible database query.
Therefore, the last page, ‘database content’, contains a
RESTful API (https://ptsd.scai.fraunhofer.de/swagger-ui)
that exposes the database as well as a summary table of
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the database, providing both interactive and programmatic
interfaces to query, browse and navigate its content. The
API is the gateway for researchers who are interested
in data models that cannot be accessed through the
interactive visualizations presented before (i.e. ancestry
information, assay details and calculations, statistical
information and inclusion/exclusion criteria). This enables
researchers to access specific information extracted from
the study, ranging from inclusion/exclusion criteria (e.g.
type of medication excluded, comorbidities excluded, etc.)
to details about the equipment used in the study (e.g.
machine, brand, limits of detection, etc.). Furthermore,
users can access associated statistics (e.g. means, standard
deviations, P-values and fold changes calculated when
comparing the biomarker in cases vs controls) in order
to conduct or complement future meta-analyses. Finally,
the API handles advanced database queries for extracting
biomarker information that can be used to conduct
complementary bioinformatics analyses as outlined by
Zhang et al. in the context of colorectal cancer.
Conclusion
The PTSDDB organizes knowledge in the field of PTSD
to provide a review of the literature, bringing together
results from different studies so that researchers can eval-
uate results of single biomarkers, understand how they
were measured, in what population and in what clini-
cal contexts of use. This first version of the PTSDDB
involved significant curation and harmonization of infor-
mation from disparate biomarker studies and related lit-
erature and storing this information in a database. In the
future, we plan to integrate PTSDDB into Brain Commons
(https://www.braincommons.org), a big data cloud-based
platform for computational discovery designed with user-
friendly tools so that the PTSDDB can be regularly updated
and openly shared with the research community. In sum-
mary, to the best of our knowledge, the PTSDDB is the
first resource designed to catalog biomarker knowledge and
metadata in PTSD and is complemented with a compre-
hensive web application that provides interactive visualiza-
tions and tools to query the cataloged knowledge. As this
resource expands to capture all known knowledge around
PTSD biomarkers, we aim to facilitate more formal meta-
analyses so that robust conclusions may be drawn around
the state of the field, in turn leading to new hypotheses for
future studies.
Supplementary data
Supplementary data are available at Database Online.
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Conclusions
This work crosses the translational divide between basic science discovery and
clinical implementation by providing the first database in PTSD biomarker re-
search. PTSDDB provides a comprehensive overview of results from an extensive
curation effort in over one hundred articles reporting findings on fluid-based
biomarkers. Additionally, this resource is not presented as a static database, but
complemented with visualizations and a sophisticated API designed to assist
researchers in analyzing and elucidating the results of the biomarker studies
incorporated. In summary, the presented work paves the way not only for the
harmonization and unification of biomarker knowledge in the PTSD area, but also
for conducting meta-analyses with each of the biomarkers in the database. This, in
turn, could provide insights that explain the conflicting and inconsistent evidences
reported in the scientific literature until now.
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7 Using multi-scale genetic,
neuroimaging and clinical data for
predicting Alzheimer’s disease and
reconstruction of relevant biological
mechanisms
Introduction
The question "can we detect Alzheimer’s disease early enough to treat it in its early
stages?" has prompted the development of numerous predictive models using
large clinical datasets [127–129]. Although the prognostic power of such models
could be higher than any clinician, they are presented as black boxes due to the lack
of biological insights into how the underlying predictions are derived. However,
bridging the gap between patient-level data and the mechanistic knowledge
necessary to interpret the predictions of a model is still a challenging task. We
propose a novel methodology to closes this gap. Namely, we linked the features
derived from a predictive model trained on the largest AD clinical study with
NeuroMMSig, the knowledge-driven mechanistic inventory presented in chapter 5.
This crosstalk between both approaches uncovered potential mechanisms driving
the transition from normal and Mild Cognitive Impairment (MCI) cases to AD
patients.
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Using Multi-Scale Genetic, 
Neuroimaging and Clinical Data 
for Predicting Alzheimer’s Disease 
and Reconstruction of Relevant 
Biological Mechanisms
Shashank Khanna1,2, Daniel Domingo-Fernández  1,2, Anandhi Iyappan1,2, 
Mohammad Asif Emon1,2, Martin Hofmann-Apitius  1,2 & Holger Fröhlich  2,3
Alzheimer’s Disease (AD) is among the most frequent neuro-degenerative diseases. Early diagnosis is 
essential for successful disease management and chance to attenuate symptoms by disease modifying 
drugs. In the past, a number of cerebrospinal fluid (CSF), plasma and neuro-imaging based biomarkers 
have been proposed. Still, in current clinical practice, AD diagnosis cannot be made until the patient 
shows clear signs of cognitive decline, which can partially be attributed to the multi-factorial nature of 
AD. In this work, we integrated genotype information, neuro-imaging as well as clinical data (including 
neuro-psychological measures) from ~900 normal and mild cognitively impaired (MCI) individuals and 
developed a highly accurate machine learning model to predict the time until AD is diagnosed. We 
performed an in-depth investigation of the relevant baseline characteristics that contributed to the AD 
risk prediction. More specifically, we used Bayesian Networks to uncover the interplay across biological 
scales between neuro-psychological assessment scores, single genetic variants, pathways and neuro-
imaging related features. Together with information extracted from the literature, this allowed us to 
partially reconstruct biological mechanisms that could play a role in the conversion of normal/MCI into 
AD pathology. This in turn may open the door to novel therapeutic options in the future.
Alzheimer’s Disease (AD) is among the most frequent neuro-degenerative diseases in people above 65 and affects 
more than 45 Million people worldwide1. It is a chronic disease that usually starts slowly with a pre-symptomatic 
phase and worsens over time2. Early diagnosis is essential for successful disease management and chance to 
attenuate symptoms by disease modifying drugs. In the past, a number of cerebrospinal fluid (CSF), plasma and 
neuro-imaging based biomarkers have been proposed for that purpose3. Still, in current clinical practice, AD 
diagnosis cannot be made until the patient shows clear signs of cognitive decline, which can partially be attrib-
uted to the multi-factorial nature of AD4. AD pathology covers multiple biological scales, ranging from disease 
risk increasing genomic variants over altered intra-cellular signaling events and regional brain atrophy up to 
neuro-psychological behavior5. Hence, there is a need for establishing robust biomarker signatures covering mul-
tiple biological scales, which allow for early AD diagnosis. Several authors proposed models, which discriminate 
between AD and mild cognitively impaired (MCI) patients using subsets of markers from different data modal-
ities5–9. A model to predict the time to conversion from 346 MCI into AD based on clinical data, neuro-imaging 
features and highly restricted genotype information (only 2 SNPs) was developed by Lee et al.10. The authors 
developed a Bayesian functional linear Cox model, which they evaluated based on simulation studies. Based on 
these simulations they reported an integrated area under ROC curve of 84%. In addition to the general limitation 
of such a purely simulation based validation the actually utility for clinical practice would have to be validated in 
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a follow-up study first. Moreover, the biological mechanisms driving the MCI to AD conversion remain entirely 
unclear.
More recently, Li et al.11 individually investigated different baseline cognitive, neuro-psychological and 
neuro-imaging scores to predict MCI to AD conversion. The authors employed univariate Cox models with 
covariate adjustments for age, gender, APOE4 status and education level. Using 6-fold cross-validation they 
reported a time dependent area under ROC curves of 68–81% for the respective scores. Once again, the biological 
mechanisms driving the MCI to AD conversion remain unclear.
The goal of this work was two-fold: First, our aim was to establish a multivariate, multi-modal predictive 
model for the time to AD conversion of normal/MCI patients and to identify most relevant prognostic features. 
Our model integrated rich genotype information (including newly developed SNP functional pathway impact 
scores), neuro-imaging (volume measurements of brain regions, PET scan results) as well as clinical data from 
900 normal and MCI individuals extracted from the Alzheimer’ s Disease Neuroimaging Initiative (ADNI) 
(http://adni.loni.usc.edu/), a large scale observational study started in 2004 to evaluate the use of diverse types 
of biomarkers in clinical practice. A second aim of this work was to better understand the biological mecha-
nisms driving the conversion of normal/MCI into AD pathology, which may ultimately open the door to novel 
therapeutic options. To this end, we employed a combination of data driven probabilistic and knowledge driven 
mechanistic approaches. More specifically, we used Bayesian Networks to uncover the interplay across biological 
scales between genetic variants, pathways, PET scan results and neuro-imaging related features. Together with 
manually curated cause-effect chains extracted from the literature, this allowed us to partially reconstruct biolog-
ical mechanisms that could play a role in the conversion of normal/MCI into AD pathology.
Results
Overview about Approach. We extracted multi-modal baseline data from 315 normal and 609 mild cog-
nitively impaired (MCI) patients from the ADNI database. 14 (4.4%) of the normal and 238 (39%) of the MCI 
patients developed AD during the 96 months of the study. We cannot exclude that patients without transition 
to AD pathology during study time developed AD later. Hence, their disease outcome has to be viewed as right 
censored.
The clinical baseline data of the altogether 924 patients used in this work comprised 73 variables with diagno-
sis, demographic information, age, gender, education level, neuro-psychological test, MRI and PET scan results, 
volume measurements of different brain regions as well as 300,000 single nucleotide polymorphisms (SNPs), 
which are commonly available from both ADNI1 and ADNI2/GO studies. Our overall approach to analyze these 
data and reduce their complexity contained six steps that are outlined in Fig. 1:
 1. Literature mining of known disease associated SNPs (see Methods for details).
 2. Further genomic feature extraction based on global population structure (principal components) plus a 
newly developed score to measure putative pathway impact of SNPs on individual patient level.
 3. Development and evaluation of a predictive time-to-event model for normal/MCI to AD transition.
 4. Estimation of (partially causal) dependencies between relevant features in the predictive model via Bayesi-
an Network (BN) structure learning.
 5. Validation of the BN with literature derived cause-effect relationships.
Steps 1. and 2. resulted into 313 pathway impact scores, 363 SNPs and 32 principal components that were 
added to the above mentioned 73 clinical baseline variables.
Predicting the Time Dependent Alzheimer’s Disease Risk and Identification of Associated Relevant 
Baseline Characteristics. AD Can Be Predicted Accurately. We developed an approach to appropriately 
integrate the multi-modal data used in this work within a machine learning framework to predict the AD risk 
for MCI and pre-symptomatic patients (see Methods for details). Our approach uses a weighted ensemble of 
Figure 1. Overall approach to analyze ADNI data.
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constraint decision trees - a Gradient Boosting Machine (GBM12) - to combine most relevant pathways, SNPs, 
principal components and clinical baseline variables into a final patient specific prediction score. GBM is an 
established machine learning method that is – due to its nature as an ensemble of decision trees – well suited to 
integrate heterogeneous data types (e.g. clinical features plus SNPs) on rather different numerical scales, as in our 
application13. Moreover, GBM allow for an embedded subset selection of most relevant features and appropriately 
deal with missing values in clinical data.
The prediction performance of our developed GBM based algorithm was assessed via a 10 times repeated 
10-fold cross-validation procedure: Cross-validation randomly splits the overall data into k (here 10) folds, while 
successively one of these folds is left out for model validation and the rest for model training. The ability to predict 
the time to first AD diagnosis for patients in the validation set of each of the 10 GBM models was assessed via 
Harrell’s concordance/C-index14, which is a generalization of the area under ROC curve measure used in binary 
classification. The C-index ranges from 0 to 1, where 0.5 indicates chance level.
As indicated in Fig. 2A our algorithm achieved a high prediction performance with a cross-validated C-index 
of 0.86. Figure 2B depicts the time dependent prediction error (in terms of Brier score) of the GBM model on 
held out test data during the repeated cross-validation procedure in comparison to a Kaplan-Meier estimator, 
showing clearly superior performance with low prediction error. We thus conclude that our employed multi-scale 
data allows for an accurate prediction of the time dependent risk to convert from normal/MCI to AD pathology. 
Notably, our developed GBM model achieved a significantly higher cross-validated C-index than another and 
popular ensemble based decision tree technique, Random Survival Forest15, elastic net penalized Cox regres-
sion16,17 and two different Canonical Correlation Analysis (CCA) based methods18,19 followed by conventional 
Cox regression, see Methods.
Most Relevant Features are Interpretable. To better understand the contribution of individual features for the 
AD risk prediction we ranked variables according to their relative importance in a final GBM model that was 
trained on all available data (Fig. 2C). The top 25 most relevant variables comprised, besides baseline diagno-
sis (DX), results of different neuro-psychological/cognitive assessments (Alzheimer’s Disease Assessment Scale 
Cognitive Plus - ADAS13, ADAS11, Functional Assessment Questionnaire - FAQ, Clinical Dementia Rating - 
CDRSB, Rey Auditory Verbal Learning Test - RAVLT, Everyday Cognition Study Partner Report - EcogSPMem), 
neuro-imaging features (Region_Hippocampus, Region_Enthorhinal, Region_MidTemp, Region_WholeBrain8), 
PET and FDG PET imaging diagnosis (AV45, FDG), APOE4 status as well as patient age. Furthermore, different 
features describing the genetic population sub-structure (EV1, EV2,…) as well as the SNP functional impact on 
cell cycle were contained. It has been suggested that dysfunction in neuronal cell cycle reentry plays a fundamen-
tal role in AD pathology20. More specifically, the hypothesis has been stated that the disease is caused by aberrant 
re-entry of different neuronal populations into the cell division cycle21.
Notably, most of the top 25 were selected highly stable during the 10 times repeated 10-fold cross-validation 
procedure (Fig. 2D). That means the vast majority of GBM models trained during the cross-validation procedure 
contained the same most relevant features. This finding specifically includes the above mentioned cell cycle. 
Figure 2. (A) Boxplot of cross-validated concordance index. (B) Prediction error (Brier score) as a function 
of time for GBM vs. Kaplan-Meier estimator. The prediction error curve is calculated on held out test data 
during the 10 times repeated 10-fold cross-validation procedure. The solid curve corresponds to the mean and 
the shaded area to the standard deviation. (C) 25 most relevant features according to GBM model trained on 
the whole tuning dataset. (D) Selection frequency of these features during the 10 times repeated 10-fold cross-
validation procedure. (E) cumulative relative influence of feature groups in final model.
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Altogether there were 170 featues that were selected at least in 50 out of 100 times (see full list in Supplementary 
material). These features contained the neuro-psychological assessments (ADAS, Ecog, RAVLT, CDRSB, MMSE, 
FAQ), PET scanning results (AV45, FDG), APOE4 status, age, baseline diagnosis, educational status as well as 
different brain regions and pathways (including cell cycle). The most stably selected SNP rs10509663 (selected 
70/100 times) has been associated with CSF levels of amyloid-β. Misfolding of this peptide is a well known hall-
mark of AD that results into the characteristic plaques in the brain of AD patients22. Interestingly, immune system 
and ribosome were found as most stably selected pathways (84/100 times). It has recently been indicated that 
activation of the innate immune system plays a crucial role in disease progression23. Ribosome dysfunction has 
been observed as an early event in AD development24.
The most influential SNP in the final GBM model was rs9871760 (selected 36/100 times), which has been 
associated to the whole brain volume25. The TT or CT genotypes of the second most relevant SNP rs3756577 
(CAMK2A, selected 32/100) have been associated with a nearly 8 times risk reduction for AD26. Two other exam-
ples include rs4263408 (selected 32/100 times) and rs6859 (selected 60/100 times). The SNP rs4263408 (UBE2K) 
has been found to affect amyloid-β concentrations27. The SNP rs6859 (NECTIN2) has been associated with late 
AD onset28.
Altogether the cumulative relative influence of all genomically derived features (including APOE4 status) 
was ~22% in our model, and 109/170 features that were selected at least 50/100 times during the repeated 
cross-validation procedure were genomically derived. Figure 2E systematically visualizes the cumulative relative 
influence of different feature groups, such as SNPs, neuro-psychological/cognitive tests, features describing the 
genomic population sub-structure (principal components), SNP impact on pathways and neuro-imaging features. 
This demonstrates an equal contribution of neuro-imaging and genomic features, whereas neuro-psychological/
cognitive test results have an almost twice has high cumulative influence.
The Model Allows for Patient Stratification. Figure 3 exemplifies the possibility to stratify patients by the pre-
dictions made by our model into “high risk” and “low risk” groups. More specifically the Figure compares the 
cumulative risk curves of 93 patients in the upper 10% quantile of the risk score produced by our model with 
93 patients in the lower 10% quantile of the risk score. Both curves show a clear difference (p ≈ 0, log rank test). 
We performed univariate statistical tests (Wilcoxon for continuous and χ2-test for discrete variables) for each 
individual feature used in our GBM model to better understand differences between the high risk and low risk 
group. P-values were corrected for multiple testing using the Benjamin-Yekutieli false discovery rate (FDR) 
control under dependency29. Accordingly, we found clear differences in the APOE4 status (FDR < 1e−9), in all 
neuro-psychological assessment scores, PET imaging diagnosis (FDR < 1e−4), rs405509 (FDR < 0.05), ErbB sig-
naling and olfactory transduction (both FDR < 0.05). In the low risk group 63% of the patients were diagnosed as 
healthy at baseline, whereas in the high risk group all patients were already late phase mild cognitively impaired. 
According to dbSNP30, rs405509 is located in the APOE4 gene region and synergizes with the APOE4 ε4 allele 
in the impairment of cognition. The T allele has been identified as a risk factor for AD31. ErbB signaling and 
olfactory transduction both showed a significant difference in SNP pathway scores. However, the difference in 
the impact score was in both cases less than 1%. Hence, any further interpretation should be taken with care. 
However, we like to mention that olfactory dysfunction and insufficient ErbB signaling have both been associated 
with AD32,33.
Bayesian Network Modeling Reveals Dependencies Between Relevant Features. Our predic-
tive GBM model altogether contained a set of 335 features. To gain a better understanding of the complex and 
multiple interactions between these features we developed a Bayesian Network (BN) model34. BNs belong to the 
family of probabilistic graphical models and enable the description of a complex multivariate distribution with 
many variables (here all relevant features in our predictive model). BNs can be visualized as graphs, where nodes 
Figure 3. Cumulative hazard as a function of time for the 10% patients with highest AD risk scores (red) and 
10% patients with lowest AD risk scores (green). Depicted are the average risk curves plus standard errors as 
confidence bands.
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correspond to random variables and edges reflect conditional statistical dependencies. BNs have a long tradition 
in systems biology for learning and describing biological pathways35–37, because they - at least partially - allow for 
discovery of causal relationships from observed data (see Methods).
We developed a BN for the same 924 patients used in our final predictive GBM model. Importantly, we 
included the time until AD diagnosis together with a censoring indicator as variables. Six different BN learning 
algorithms were compared via a 10-fold cross-validation procedure (see Methods) and the best performing one 
(tabu search38) selected. Subsequently, we applied a non-parametric bootstrap to network learning, resulting 
into 257 edges appearing in more than 50% of 1000 network reconstructions based on random sub-samples of 
the data (see details in Methods section). Figure 4 shows two zooms into the network of these stable edges high-
lighting the direct dependency of the clinical outcome (Event_Time, AD_Flag) on baseline diagnosis (DX) and 
PET scan (AV45). PET scanning results manifest in the entorhinal region, which is known to be affected by AD 
pathology39. Baseline diagnosis is dependent on age and APOE4 mutation status. APOE polymorphic alleles are 
one of the major AD risk factors40. Baseline diagnosis influences neuro-psychological assessments (ADAS13, 
ADAS11, MMSE) and manifests in the entorhinal region and hippocampus, which is vulnerable specifically in 
early AD stages41.
Figure 4B further highlights the dependency of APOE4 status on sub-population structure (EV1), which is 
reflected by differences in cell cycle, hence supporting the above cited neuronal cell cycle hypothesis as one of the 
possible disease causes. Cell cycle includes DNA replication and repair, which is mirrored by a corresponding 
edge in our BN. DNA damaging by oxidative stress has been reported as one of the earliest detectable events in 
the progression to dementia42. More specifically, altered DNA repair has been observed in GABAergic neurons43 
and let to the idea of a therapeutic modulation of the GABAergic system in early AD stages44. GABAergic neurons 
distinctly express CB1 receptors, thus explaining the subsequent link to the endocannabinoid system45. Targeting 
this system has been discussed as a therapeutic option45.
To specifically validate some of the less obvious dependencies between pathways that were reflected via sta-
ble edges in our BN we checked the overlap of genes that could be mapped to the respective pathways based on 
KEGG46 and Reactome47 databases. The statistical significance of overlaps was assessed via a hyper-geometric 
test, and p-values corrected for multiple testing via the Benjamini-Yekutieli false discovery rate (FDR) under 
dependency29. Accordingly we obtained significant results (FDR < 5%) for 63/76 (83%) pathway pairs in our BN 
(see results in Supplements).
Pathway Dependencies are Interpretable via Biological Mechanisms. Mapping of Stable Edges to 
Causal Biological Mechanisms. To further validate pathway dependencies found by our BN methodology and 
to gain additional insights into underlying molecular mechanisms we employed a literature derived mechanis-
tic AD disease model encoded in the OpenBEL language48. Briefly, this model describes cause-effect relation-
ships between different biological entities, such as genes, SNPs and biological processes (e.g. neuronal death) in a 
purely qualitative manner. We developed an algorithmic approach to map nodes and edges in our network to the 
Figure 4. Edges appearing in more than 50% of 1000 Bayesian Network reconstructions based on random sub-
samples of the data. Line thickness is proportional to the relative frequency of observing an edge in the 1000 
network reconstrucions, and the corresponding number is shown as edge label. The node size is proportional 
to the relative influence of the variable in the final GBM model, and the color reflects the selection frequency 
in the repeated cross-validation procedure (more black = higher stability). Sub-figures (A) and (B) depict two 
examples zooms into the overall network.
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OpenBEL AD disease model. In conclusion, we could identify 12 cause-effect-relationship networks that could 
be linked to specific stable pathway-pathway edges in our BN (see Figures in Supplements). We have developed 
a software tool to explore our BN and associated mechanism mappings in a fully interactive manner. The tool is 
accessible under http://neurommsig.scai.fraunhofer.de/bayesian. In the following we discuss two selected mech-
anism mappings in greater detail.
Example 1: Adherens Junction and Autophagy. As a first example, our Bayesian Network predicts an 
association between adherens junction and autophagy, which has recently also been proposed in Nighot et al.49 
(Fig. 5A). Adherens junctions, also known as tight junctions, are comprised of epithelial cells that are present in 
all tissues, particularly in junction between cerebral epithelial cells of the blood-brain barrier (BBB)50,51. The BBB 
is a biochemical barrier which regulates the entry of blood based molecules into the brain and helps in maintain-
ing ionic homeostasis within the brain. These barriers further inhibit diffusion of cellular components thereby 
protecting the central nervous system52,53. However, during pathological conditions such as AD, the BBB are 
disrupted increasing the cell permeability as well as accumulation of amyloid-β resulting in autophagy.
Mapping of the edge between adherens junction and autophagy in the BN to OpenBEL encoded mecha-
nisms allowed us to identify molecular players, which may play a role in the normal/MCI to AD transition: 
Proteolytic processing of amyloid precursor protein (APP) is one of the hallmarks of AD pathophysiology22. 
The processing of APP to amyloid-β is greatly affected by the sub-cellular localization of β and γ secretases due 
to trans-membrane receptors as well as adapter proteins54,55. Internalization of APP via adapter proteins such as 
DAB2 triggers clathrin mediated endocytosis by binding to the YXNPXY motif region of APP triggering endo-
cytosis56,57. Apart from DAB2, there are other adapter proteins that trigger the production of amyloid-β namely 
APBA2 and APBA1. These two proteins are enriched in neurons and contain a phosphotyrosine binding site 
(PTB) domain58,59. These proteins are involved in cellular activities pertaining to neuronal transport and synaptic 
function. Unlike DAB2, APBA1 and APBA2 interact with the YENPTY motif region of APP and thereby affect-
ing APP trafficking. During AD pathology, APBA1 protein modulates the secretory and endocytic trafficking 
of APP whereas APBA2 accelerates APP endocytosis which leads to autophagosomes that enhances amyloid-β 
internalization60,61.
Autophagosomes are structures that facilitate the break down of accumulated amyloid-β peptides by fusion 
with lysosomes. Lyosomes contain enzymes that break down accumulated peptides62,63. However, during AD 
progression, autophagosomes accumulate within neurons of AD patients. The scaffolding protein MAPK8IP1 
is a regulator of autophagosomal motility by activating the c-Jun-N-terminal kinase (JNK), which mediates the 
JNK signaling cascade. JNK signaling formulates the formation of neurofibrillary tangles through direct phos-
phorylation of tau proteins further resulting in stress induced apoptosis in neuronal cells64,65. Furthermore, the 
activation of JNK signaling induces phosphorylation of Bcl-2 releasing beclin-1 protein which further aggravates 
autophagosome formation, resulting in cognitive decline66,67.
Figure 5. Two examples of mapping stable BN edges to biological mechanisms via the OpenBEL AD graph by 
Kodamullil et al.48: (A) adjherens junction and autophagy; (B) insulin signaling and natural killer cell mediated 
cytotoxicity. Biological entities mapping to the source of the edge marked by an arrow on the left hand side of 
the Figure are drawn in yellow in the OpenBEL graph on the right hand side. Biological entities mapping to the 
sink of the edge are shown in red. Red edges highlight the shortest among all possible paths connecting yellow 
and red nodes.
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Example 2: Insulin Signaling and Natural Killer (NK) Cell Mediated Cytotoxicity. Another exam-
ple is the BN predicted link between insulin signaling and natural killer (NK) cell mediated cytotoxicity (Fig. 5B), 
which has again been proposed in the literature68. Our extracted mechanism shows, how the axonal transport 
and APP trafficking may influence AD development: APP proteins are transported to distinct nerve cells through 
axons via anterograde pathways for maintaining homeostasis and neuronal function69. The fast anterograde trans-
port is mediated through APP and Kinesin 1 (KLC1) and Fe65, adapter protein. The proteolytic processing of 
amyloid-β occurs within the axons and through this process amyloid-β is generated releasing the complex KLC1 
from APP. During AD progression, the excessive production of amyloid-β prevents the release of Kinesin and 
thereby restricts the axonal transport. The arrested axonal transport also triggers the phosphorylation of APP 
through the amyloidogenic pathway concomitantly releases the Fe65 and translocates into the nucleus to regulate 
the expression of stress-related genes including glycogen synthase kinase 3 beta (GSK3B)70,71.
Apart from APP and KLC1, insulin and IGF regulate neuronal stem cell activation, synaptic maintenance and 
neuroprotection72,73. Insulin regulates the glucose and lipid metabolism in the brain and thereby contributes to 
learning and memory74. It is known that insulin is locally produced in the brain and can be easily transported 
through the BBB75–77. The glucose metabolism is mediated by binding of the IGF to its receptor promoting the 
phosphorylation of the tyrosine residue and further phosphorylating the insulin receptor substrate (IRS) at the 
tyrosine residue. The two receptors, IRS-1 and IRS-2 are mediators of insulin-dependent mitogenesis and regu-
lation of glucose metabolism, which is a part of the insulin-signaling pathway78,79. The phosphorylation of IRS1 
results in the downstream activation of AKT, mammalian target of rapamycin (mTOR), growth receptor binding 
protein 2 (GRB2), mitogen-activated protein kinase (MAPK) and GSK3B, thereby promoting the APP trans-
port and clearance of amyloid-β from the BBB80,81. During AD progression, the insulin signaling pathway shows 
aberrant activity, resulting in increased accumulation of amyloid-β, tau phosphorylation and decreased cerebral 
blood flow. Furthermore, the binding of IRS to its receptor is inhibited, resulting in decreased glucose metabolism 
and cognition82. Brain insulin resistance thus contributes to AD, a complex phenomenon accompanied by IGF-1 
resistance and dysfunction of IRS-1 triggered by amyloid-β oligomers, stimulating cognitive decline independent 
of AD pathology83.
Discussion
Determining the risk of an individual to develop AD is an important aspect to start treatment with disease mod-
ifying drugs as early as possible and to better manage the disease. To better address this need we developed a 
highly predictive time-to-event model for normal/MCI to AD transition based on multi-modal data from ADNI. 
For this purpose we proposed a novel approach to capture the functional impact of SNPs on pathway level for 
each individual patient. Analysis of our model confirmed the significant impact of the baseline diagnosis (cogni-
tively normal, early or late stage mild impaired) for predictions and demonstrated the crucial role for stratifying 
patients into high and low risk groups. Further relevant features of our model include neuro-psychological assess-
ment scores, neuro-imaging features (including PET scan results), age as well as genetic predisposition, which 
altogether contributed 22% cumulative influence. In addition to well known risk factors such as APOE4 status we 
specifically identified SNP functional impact on cell cycle as a relevant feature in our model, which agrees well 
with the hypothesis of AD being caused by dysfunction of the neuronal cell cycle reentry20.
As a further contribution of our work we tried to better understand dependencies of relevant features via a 
Bayesian Network model. Thanks to our proposed pathway functional impact score and with the help of a spe-
cifically developed algorithm we were able to relate several non-obvious links to detailed biological mechanisms, 
which constitutes a partial literature based validation. As two examples we discussed the mechanisms linking 
tight junction and autophagy as well as insulin signaling and NK cell mediated cytotoxicity in more detail and 
provided literature based evidence for the involvement into AD pathology. Altogether stable edges found in our 
BN provide a broad overview about the complex interplay of different AD risk factors and provide insights into 
their underlying biological mechanisms. Such insights could potentially help in developing novel and more mech-
anistic therapies in the future, which are critically needed in the field.
Of course, there are limitations of our work that we would like to mention: The whole work presented here 
was based on the ADNI cohort. Since this patient group primarily represents an amnestic rather than an epide-
miologically selected population we cannot exclude population biases. Hence, a confirmation of our findings 
based on a different study cohort has to be conducted in the future. Furthermore, it is believed that AD pathology 
starts decades before actual diagnosis84. The age range of ADNI subjects is thus probably too late to find very early 
disease indications, and the follow-up time of 96 months is likely too short for many patients that were initially 
cognitively normal to allow for a definite AD diagnosis till end of study. Taking these aspects into consideration 
we therefore see the need for long lasting studies in a more epidemic population in the future. Key findings from 
our work could help designing such a study by identifying relevant factors to measure.
Methods
Clinical and Genomic Feature Extraction from ADNI. Data Preprocessing. Clinical variables (includ-
ing age, gender, education level, neuro-psychological assessments, pre-computed volume measurements of dif-
ferent brain regions and PET scan results) from all ADNI studies (ADNI1, ADNI2, ADNI-GO) were retrieved 
via the ADNImerge R-package (https://adni.bitbucket.io/), altogether comprising 73 features at study baseline 
after dropping variables with more than 65% missing values. For the 818 subjects in the ADNI1 study popula-
tion 620,901 SNP calls were available via the Illumina Human610-Quad BeadChip platform. Further genomic 
data (730,525 SNPs, Illumina HumanOmniExpress BeadChip) was available for 432 subjects in ADNI2/GO. 979 
patients were diagnosed as either normal or MCI at baseline, and 314,134 SNPs were found in common between 
both ADNI phases. Following common convention we encoded SNPs by the occurrence of a minor allele (0, 1, 2) 
while taking dbSNP as ref.85.
www.nature.com/scientificreports/
8SCIENTIFIC REPORTS |  (2018) 8:11173  | DOI:10.1038/s41598-018-29433-3
The initial set of 979 patients was reduced to 926 by filtering out individuals with kinship coefficient <0.1 
and inbreeding coefficient >0.1. Kinship coefficient was calculated by the PLINK method of moment for 
identity-by-descent analysis86. Inbreeding coefficient estimation was based on the method described in Yang 
et al.87. For both analyses we employed the SNPRelate software88. SNPs with MAF <1% or missing rate >5% were 
filtered out.
Literature Derived SNPs. We used the text mining software SCAIView89, the DisGeNET database90 and GWAS 
catalogue91 with a similar search query (“Alzheimer’ s Disease” and “Homo sapiens”) to retrieve 1,866 putatively 
disease associated SNPs, of which 363 intersected with the 314,134 SNPs measured in both ADNI phases (Fig. 6). 
Application of LD pruning (r2 < 0.2) using SNPRelate reduced this number further to ∼300. Notably, this step 
was done as part of predictive model training and more specifically also within the repeated cross-validation 
procedure.
Principal Components. In addition to knowledge derived, LD pruned SNPs, we considered the global genetic 
population structure by retrieving the top principal components (based on all 314,134 SNPs) via a Bayesian 
principal component analysis (PCA)92 after LD pruning. We favored Bayesian PCA over conventional maximum 
likelihood based PCA here due to the high dimensionality of SNPs compared to the number of patients. Bayesian 
PCA effectively regularizes PCA and thus results into more stable and robust estimates. Again, Bayesian PCA was 
done as part of model training and thus within the repeated cross-validation procedure. Note that the extremely 
high dimensionality of SNP data prevents us from extracting all principal components due to prohibitive compu-
tational costs. However, extraction of the top k (here: 32, the default in SNPRelate) principal components can be 
done efficiently using Lanczo’s method93. We relied on the implementation provided in the SNPRelate software88. 
The proportion of explained variance by the top principal components was typically around 5–6%, depending 
on the actual set of patients in the training set. This fact highlights that the top principal components for sure 
do not describe the global population structure entirely. However, they may still capture useful signals for our 
predictive model. The fact that several eigenvectors were among the most relevant features (Fig. 2) in our final 
model supports this thought.
SNP Based Pathway Impact Scores. We performed a gene mapping of SNPs. This was done by
 1. Considering all 363 putatively disease associated SNPs taken from the literature and all those in strong LD 
(r2 > 0.8). Each SNP in an LD block was then mapped to its closest genes via dbSNP30.
 2. Considering significant (false discovery rate <5%) cis- and trans-eQTLs in different brain regions from 
GTex94. For this step the same SNPs as in the previous one where used.
Note that both steps can result into a mapping of one SNP to several genes. The The entire set of genes was 
then extended to a pathway mapping, where pathways were taken from KEGG46 and Reactome47. Around 30,000 
SNPs were map-able to pathways altogether. For these ∼30,000 SNPs we used functional impact predictions from 
SIFT95 and Polyphen296. We then developed an experimental score to capture the overall functional impact on 
each pathway per patient: This score was defined as the fraction of at least possibly damaging/deleterious SNPs 
relative to all pathway map-able SNPs. This score is a number between 0 and 1 for each individual patient and 
pathway.
Multi-Modal Time-to-AD-Diagnosis Prediction. Intermediate Data Fusion with Gradient Boosting 
Machines. The employed data is characterized by a high heterogeneity with respect to different statistical distri-
butions and numerical scales (e.g. SNPs vs. neuro-imaging features). Gradient Boosting Machines (GBM) have 
Figure 6. Approach to genomic feature extraction.
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been introduced as a decision tree based ensemble learning technique that enables non-linear and non-parametric 
time-to-event prediction based on such heterogeneous data12. A GBM constitutes a weighted ensemble of weak 
decision tree classifiers (base learners) with restricted maximal depth (here 3). A higher maximal tree depth 
results into more complex base learners. that capture higher order interactions between variables (here: up to 
3-way interactions). On the other hand, a tree depth of 1 corresponds to simple decision stumps and can require 
longer boosting, depending on the overall optimal complexity of the GBM model. The reason is that the actual 
number of trees in the ensemble (and thus overall complexity of the GBM model) critically depends on the num-
ber of boosting steps, which is a tunable hyper-parameter. Depending on the maximal depth and number of deci-
sion trees GBMs do not necessarily employ all existing features in the data, but possibly only a subset. We found 
the optimal number of boosting steps found via an inner 10-fold cross-validation. Importantly, this was done 
within the outer 10 times repeated 10-fold cross-validation procedure used to evaluate prediction performance.
GBM can deal with censored time-to-event (here: time to AD diagnosis) data, as in our application: We like 
to predict the time until AD is diagnosed. For some AD converters such a diagnosis will be observed within 
the study time. However, there are also patients for which the diagnosis cannot be established within the study 
time, but potentially after the end of study. Their observed times to event are thus right censored. Our employed 
GBM implementation (R-package gbm) allows for dealing with time-to-event data by using the negative partial 
log-likelihood of the Cox proportional hazards model as a loss function.
As typical in clinical studies ADNI data contains missing values. GBM rely on a surrogate split approach for 
this purpose97. GBM allow for a ranking of variables according to their relevance for the model. This is done by 
recording the relative reduction of the error loss function as a measure of variable importance. Accordingly, fea-
tures with zero importance can be filtered out. Hence, GBM can be used for feature selection.
In our data there is a difference in the number of features from SNPs, pathways, principal components and 
clinical data. In order to avoid any potential selection bias towards one of these feature types due to differing 
number of features we decided to implement a two-step strategy:
 1. Training of a separate GBM model for each data modality and selection of most relevant features.
 2. Joining of these features and training of a final GBM model.
Note that the first step ignores feature dependencies from different modalities while the second one takes 
them into account.
Multi-modal data fusion is a field of active research, and there is not a universal best performing approach. In 
the data science literature classically three general strategies for multi-modal data fusion are distinguished98,99, 
see Ahmad and Fröhlich100 for a more extensive review100. Early data fusion methods focus on extraction of 
common features from several data modalities, resulting into one integrated data matrix. In a second step con-
ventional machine learning methods can then be applied. Late integration algorithms first learn separate models 
for each data modality and then only combine predictions made by these models, for example with the help of 
a meta-model trained on the outputs of data source specific sub-models. These methods hence ignore feature 
dependencies between different data modalities. Intermediate integration algorithms are the youngest branch 
of data fusion approaches. The idea is to join data sources while building the predictive model. Our proposed 
approach can be seen as an instance of an intermediate data fusion approach.
No significant difference in prediction performance (C-index) compared to a conventional approach using 
a GBM model with all features was observed (p = 0.35, Wilcoxon test). However, the final GBM model with the 
two-step strategy contained fewer features (335 vs. 435).
Comparison to Other Prediction Methods. We compared our proposed approach to a Random Survival Forest15, 
resulting into a significantly higher C-index with our GBM modeling strategy (p = 1.1e−5, Wilcoxon test, 
Figure S4). The GBM model also outperformed an elastic net penalized Cox regression16,17 (p = 0.0002, Wilcoxon 
test, Figure S4). Importantly, application of elastic net penalized Cox regression requires to impute missing values. 
This was done via the missForest algorithm101 in a pre-processing step prior to running the cross-validation. Note 
that this step may result into slightly over-optimistic results for the elastic net.
In addition, we compared our approach against supervised sparse Generalized Canonical Correlation Analysis 
(ssGCCA)18,19 in conjunction with a conventional Cox regression as predictive model. Sparse GCCA is an early 
data fusion approach that extracts latent variables (canonical variates) from different data modalities (here: clin-
ical, SNPs, pathways, principal components). Each canonical variate describes a sparse linear combination of 
existing features within a specific data modality and is chosen to maximize the sum of correlations with canonical 
variates from other data modalities. We used a sparse GCCA version here, because we expect only a subset of 
original features to be relevant for the predicted outcome. In addition, we performed a supervised pre-filtering 
of features in each data modality. For this purpose and in agreement to Witten et al. we performed univariate 
Cox regressions and selected the 20% features with lowest p-value according to the log-likelihood ratio test. 
Afterwards we conducted feature extraction via sparse GCCA, as described before, and projected data of each 
modality into the low-dimensional space spanned by first canonical variates, and in that space a predictive Cox 
regression was trained. We here tested two different sparse GCCA implementations, one provided in R-package 
“mixOmics”102 and the other one provided in R-package “PMA”18. Sparse GCCA involves tuning of regulariza-
tion/sparsity parameters for each data modality. The sparse GCCA implementation in R-package “PMA” provides 
a permutation test for this purpose, while the sparse GCCA implementation in R-package “mixOmics” requires to 
run an inner cross-validation over a grid of regularization parameters (see details in Supplements). Both ssGCCA 
methods performed similar and resulted into significantly lower C-indices than our GBM approach (median 80% 
with PMA, 82% with mixOmics vs. 86% with our method; p < 1e−4 for PMA and mixOmics vs. our method with 
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Wilcoxon test, see Figure S4). Omitting the supervised pre-filtering step suggested by Witten et al. resulted into a 
clear drop of the C-index by around 5% (p = 1.8e−5 with Wilcoxon test, see Figure S4).
Bayesian Network Learning. General. Let G = (V, E) be a directed acyclic graph (DAG) and X = (Xv)v∈V 
a set of random variables indexed by nodes in V. X is called a Bayesian Network (BN) with respect to G, if the joint 
distribution p(X1, X2, ..., Xn) factorizes according to:
( )p X x X x X x p X x X x( , , , ) (1)n n v V v v pa v pa v1 1 2 2 ( ) ( )∏= = … = = = =∈
where pa(v) denotes the parents of node v and xpa(v) their joint configuration34.
The Markov Blanket (MB) of node v, MB(v), is defined as the set of nodes consisting of v’s parents, children, 
and any other parents of v’s children. If X is a BN with respect to G, then every node is conditionally independent 
of all other nodes in the network, given its Markov Blanket, i.e.
⊥ ∈ ∈ − −X X X i V j V i MB ifor all , { } ( ) (2)i j MB i( )
Learning the Structure of a Bayesian Network from Data. In the simplest case the DAG G is defined by an expert, 
but in many real life applications (as our present one) this is not the case and thus G should be learned from 
data. In general there exists two existing strategies for that purpose: search-and-score and constraint-based 
algorithms34. Search-and-score based approaches walk through the space of all possible DAG structures and 
score each candidate by its fit to the data. Typically such methods are thus computationally not scale-able to 
large BNs. In contrast, constrained-based approaches are significantly faster and scale-able to BNs with hun-
dreds of variables. They typically rely on conditional independence tests between variables103. In this work we 
used and compared six different algorithms implemented in the R-package bnlearn104: greedy hill climbing (50 
random restarts), tabu search38, Max-Min Hill Climbing (MMHC)105, Max-Min Parent Child (MMPC)105 and 
semi-interleaved Hiton Parent Child (SI-HITON-PC)106. Greedy hill climbing and tabu search are heuristic score 
based optimization approaches, whereas MMPC and SI-HITON-PC are constrained-based structure learning 
methods that try to identify the Markov Blanket of each node in the Bayesian Network. MMHC is a hybrid 
approach, which uses ideas from both, search-and-score as well as constrained-based techniques: MMHC first 
learns the skeleton of the BN using the MMPC constrained-based algorithm. In a second phase edges are then 
oriented via a greedy hill climbing search.
Selection between different BN structure learning algorithms can be done via k-fold cross-validation akin 
to conventional supervised learning34. That means the overall data is randomly split into k folds, and the BN 
structure together with its parameters successively learned from k−1 folds. If the fitted BN correctly models the 
overall population (and not just the training data), the data in the left out fold should with high probability fall 
into the same statistical distribution that is described by the BN. This can be quantified via the negated expected 
log-likelihood of the test data. Accordingly, cross-validation can be used to assess the generalization ability of 
a BN model and to compare different structure learning algorithms on that basis (see results in Supplements).
An important question in BN structure learning is, in how far the learned structure reflects causal relation-
ships in the data. Indeed, if the BN is faithful to the underlying statistical distribution (i.e. models it correctly), 
then the true causal network is known to be part of a class of equivalent graph structures, called class partially 
directed acyclic graph (CPDAG)34,103. Under the above mentioned assumptions the CPDAG has the same skeleton 
as the true causal graph, but may leave some edges undirected. Hence, in practical applications it is important to 
restrict the CPDAG equivalence class as much as possible by prior knowledge to allow correct orientation of as 
many edges as possible. In our case we specifically imposed the following constraints for BN structures:
t No genomic feature can be influenced by a non-genomic feature. However, genomic features are allowed to 
have interactions among themselves (e.g. pathway-pathway dependencies).
t Neuro-psychological test results cannot be influenced by neuro-imaging features, but the other way around 
is possible.
t Age does not depend on any other variable.
t The baseline diagnosis cannot be influenced by any clinical variable, except for age and education level.
t The education level does not depend on any other clinical variable.
t The time-to-AD diagnosis is always dependent on a censoring indicator, and it does not influence any other 
variable.
Despite of these constraints identifying the true (CP)DAG structure from limited data still remains a challenge 
and thus raises the question, how confident one can be about the existence of an individual edge. One possible 
way of addressing this question is via a non-parametric bootstrap107. Briefly, given data from N patients we sample 
N patient records with replacement for a number of times (here: 1000). For each of these 1000 bootstrap samples 
a BN structure is learned. Afterwards the relative frequency of observing a particular edge is recorded, resulting 
into a confidence measure, which reflects the robustness of an edge against perturbations of the data.
Prior to BN structure learning we imputed missing values on the whole dataset of 900 patients using the miss-
Forest algorithm for mixed categorical and continuous data types101. Furthermore, all variables were discretized 
into three bins using equal interval width.
Comparison Against Literature Derived Cause-Effect-Relationships. We refer to48 for details about 
the construction of the literature derived, cause-and-effect relationship model for AD. One of the main challenges 
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with this model is that it contains many variables that have no direct correspondence in our data and vice versa. 
In our case only SNP rs405509 (in APOE4 gene) could be mapped directly to the OpenBEL model. To address 
this challenge we employed NeuroMMSig108. NeuroMMSig categorizes biological entities according to their role 
in disease specific pathways based on support from the literature. Corresponding references are stored in the 
NeuroMMSig database. This gene set view allowed us to relate OpenBEL sub-graphs to KEGG and Reactome 
pathways. For this purpose each KEGG and Reactome pathway was viewed as a gene set, using GeneCards109 
for gene to pathway mapping. For each pathway we then searched for the gene sets in the OpenBEL model with 
largest overlap. The statistical significance of this overlap was assessed via a hyper-geometric test and corrected for 
multiple testing using the Benjamini-Yekutieli method under dependency29. In conclusion 24 KEGG/Reactome 
pathways could be mapped at a significance cutoff of 5% (see complete list in Supplements).
Given two mapped gene sets A, B we then calculated shortest paths between all a ∈ A and b ∈ B. The union of 
these shortest paths was depicted as an OpenBEL sub-graph.
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Conclusions
The work presents a novel strategy to bridge the gap between clinical data and
mechanistic knowledge that not only improves the robustness of a predictive
model but also its interpretability. We demonstrate that the most predictive multi-
scale features from our model can be used to reconstruct the biological mechanisms
that are known to play a role in AD pathophysiology. As future work, the pin-
pointed mechanisms could be targeted and further validated in a clinical study.
Further, the generalizability and success of this approach has made it de facto a
state-of-the-art methodology as it is currently employed on other domains such as
PD, more specifically on the PPMI dataset.
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8 Conclusion and outlook
This new age of information, where data and computational power are constantly
increasing [130], has shifted numerous paradigms in the biomedical field. While
in the past, the challenge was to find patterns in data, the present asks for novel
methods devised to assist in interpreting patterns emerging from the vast amount
of data. One of the reasons explaining this phenomena is the increasing mismatch
between the amount of signals coming from -omics experiments and the lack
of means to filter and decode these signals. Therefore, enhancing interpretation
power is crucial, especially in interdisciplinary fields such as bioinformatics.
This dissertation has presented a repertoire of both knowledge- and data-
driven computational methods designed to model complex biological systems.
First, this work has shown novel knowledge-based methods that leverage pathway
and mechanistic knowledge to drive interpretation and analysis of biomedical data.
Additionally, this thesis has presented sophisticated machine learning methods
that illustrate how both approaches (i.e., knowledge- and data-driven) can syner-
gically complement each other, in particular, in the challenging area of neurology.
Besides the methodological aspect of this work, the integrative efforts conducted
provide a more comprehensive view of the canonical pathway landscape. Further,
this work has presented the world’s largest mechanistic inventory in the neurode-
generation area containing over two hundred highly-curated and context specific
networks modeling disease mechanisms. This immense knowledge template can
be used for patient stratification based on disease mechanisms; thereby, improving
diagnosis and personalizing treatments. In summary, the mechanistic knowledge
contained in the pathway networks and disease maps presented in this thesis have
the potential to widen the knowledge space by revealing novel interactions and
crosstalks that could uncover the pathophysiology underlying human conditions,
particularly in the neurodegeneration and psychiatric arena.
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This thesis has added to the bioinformatics field by establishing the first path-
way mappings and harmonizing pathway representations across major databases.
By overcoming the two major obstacles in pathway knowledge integration (i.e.,
linking pathway concepts and unifying formats), this work has described a method
to integrate knowledge from multiple resources. To conduct this endeavor, two
ecosystems (i.e., ComPath and PathMe) were implemented using state of the art
technologies and following a modular design to facilitate their re-usability. There-
fore, both open source tools can be used to keep track of rapid changes in the
pathway landscape as well as to incorporate additional resources in the future.
Finally, another important aspect of the work part of this thesis is its strong focus
on reproducibility. All the resources, software, analytical scripts or pipelines pre-
sented here have been packaged and tested following strict software development
standards by the scientific community [131, 132] and are all publicly available in
major repositories such as GitHub or PyPi.
Beyond the direct link with pathway analyses, both resources are part of the
Bio2BEL framework [41], so they can be used for other applications such as the
enrichment of BEL networks. As an illustration, the ComPath mapping dataset
has been used to demonstrate the promising application of network represen-
tation learning approaches in the biomedical domain [133]. Furthermore, the
integration and consolidation of three major pathway resources is instrumental in
generating novel datasets that exploit the benefits of multiple resources and facili-
tate the dissemination of pathway knowledge. This is strongly evidenced by the
benchmarking study presented in this thesis which also introduces an integrative
approach that paves the way for a future consolidated pathway landscape.
Our benchmarking study not only shows how instrumental integrative ap-
proaches are in order to reach consensus conclusions, but also raises awareness
about the negative impact of restricting analysis to individual databases. This,
in turn, opens debate about the reproducibility of pathway-driven analyses and
strongly encourages the scientific community to adopt integrative approaches
aimed at unifying pathway knowledge in order to mitigate this bias. Further-
more, the software implemented during the course of the study, PathwayForte,
enables a re-evaluation of the presented results as well as the incorporation of
novel databases and methods in the future. Finally, high-impact scientific publica-
tions employing pathway-centric methods could be critically evaluated based on
database selection. Such analysis would illustrate the potential issue of resource
cherry picking in our field (i.e., running analyses on different databases until you
are satisfied with results).
In principle, the pathway-centric approaches presented in this dissertation can
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be applied to any disease domain with little or no further adaptations. Pathway
databases drive mechanistic interpretation of disease aetiology in areas where
both data and prior knowledge are abundant. However, complex and poorly-
understood indications require tailored approaches where knowledge is contextu-
alized and is exclusively derived from the particular disease or molecular process
of interest. As an example, after decades of research in AD and PD, little is known
about the molecular basis underlying these disorders. Therefore, one of the goals
of this thesis has been to organize mechanistic knowledge in the neurodegenera-
tive arena by curating and modeling disease-specific mechanisms by leveraging
previous work [134].
In developing NeuroMMSig, we have established the first draft of a mechanism-
based taxonomy for AD and PD, constituting a central part of the AETIONOMY
project1. On-going work in this project focuses on using the definitions of path-
ways for clustering dementia patients. We have also demonstrated how researchers
are able to investigate shared mechanisms across diseases thanks to the common
schemata and semantic alignment followed through the mechanism inventory
[123]. The context of NeuroMMSig has been extended with new diseases such
as epilepsy [123]. Further, NeuroMMSig was extended during the Human Brain
Pharmacome project2 with chemogenomic information to support computational
prediction of drug repositioning candidates. This work has also been used to sup-
port data-driven analysis of differential gene expression profiles of AD using heat
diffusion algorithms [136]. Thus, future efforts could be directed towards enabling
the submission of multimodal clinical data as outlined by [135], or using novel
algorithms on the mechanism enrichment server. Ultimately, NeuroMMSig has
been a teaching tool that lead clinicians, wet-lab scientists, and bioinformaticians
to their first steps into the world of systems and networks biology. In the future,
further work can be conducted to transfer the paradigm of NeuroMMSig to other
disease domains such as the psychiatric arena. In summary, the vast collection of
mechanistic networks is not only instrumental for identifying the mechanisms
underlying disparate subtypes of these conditions, but it is also a technology en-
abler that can have future implications in designing targets for other mechanisms
rather than the ones the pharmaceutical industry have been focused on in the last
decades [87].
Another endeavor of this thesis focused on cataloging biomarker knowledge
in the area of PTSD by developing the first biomarker database for this disorder:
PTSDDB. This functional resource includes a wide spectrum of biomarkers an-
1https://www.aetionomy.eu
2https://www.pharmacome.scai.fraunhofer.de
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alyzed for this indication from over a hundred different studies and provides a
suite of visualizations that enable the exploration of its highly-curated content.
Further, this work demonstrates how displaying biomarker knowledge through
user-friendly and interactive tools not only reveals new insights by examining
what has already been achieved in the biomarker landscape, but also guides the
design of future clinical, statistical, and bioinformatics studies. As an example of
one of its multiple applications, we showed how this database can easily identify
conflicting literature in the field. Ultimately, the highly-curated content incorpo-
rated in PTSDDB can be used to conduct a meta-analysis study around certain
biomarkers of interest.
Apart from pathway enrichment methods, few approaches that synergically
leverage data- and knowledge-driven approaches for data interpretation exist.
However, validating hypotheses derived from either approach is essential to pri-
oritize candidates in the first steps of the drug development process. The final
publication of this thesis has demonstrated how it is possible to enhance the
interpretation in translational clinical research. Our approach first reveals the de-
pendencies across the most predictive features via Bayesian modeling and linking
them to knowledge-derived networks (i.e., NeuroMMSig mechanisms). Since this
methodology was applied in the AD ADNI clinical cohort, the promising mech-
anistic links that were pinpointed could be further validated in an independent
study. Looking forward, this novel approach also paves the way to include time
dimension and thus disease progression into pathway and mechanistic networks.
By doing so, we would be able to link mechanistic hypotheses to progression
models and reveal how mechanisms dynamically change over time.
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